

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
26 April 2001 (26.04.2001)

PCT

(10) International Publication Number  
**WO 01/29247 A1**

(51) International Patent Classification<sup>7</sup>: C12P 21/06, C12N 9/00, 15/00, C07H 21/02, 21/04

(74) Agents: **ANTLER, Adriane, M.** et al.; Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036 (US).

(21) International Application Number: PCT/US00/28595

(22) International Filing Date: 16 October 2000 (16.10.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/159,763 15 October 1999 (15.10.1999) US

(71) Applicant (for all designated States except US): **AVATAR MEDICAL, LLC** [US/US]; 240 Dr. Martin Luther King Jr. Blvd., Newark, NJ 07102 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— With international search report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MARSHALL, Christopher, P.** [US/US]; 256 Dekalb Avenue, Brooklyn, NY 11205 (US). **HOFFMAN, Alexander** [DE/US]; 870 Hyperion Avenue, Los Angeles, CA 90029 (US). **ERRICO, Joseph, P.** [US/US]; 736 Morena Avenue, Palo Alto, CA 94303 (US). **MARSHALL, Paul, B.** [US/DE]; Isabellastrasse 8, 80798 Munich (DE).



**WO 01/29247 A1**

(54) Title: STABILIZED PROTEINS

(57) Abstract: The invention described herein comprises methods for stabilizing polypeptides and polypeptide complexes. The stabilization methods include controlled cross-link reaction such that polypeptides and polypeptide complexes maintain their original functionality. Embodiments of the invention outlining methods for identification of amino acid residues which when cross-linked are least disruptive to the structure and function of the polypeptides or polypeptide complex; as well as methods for mutagenesis for identifying residues to further control the cross-link reaction; and statistical analysis of the data base for the identification suitable residue pairs which are least likely to be disruptive of structure and function when cross-linked. Detailed cross-linked procedures and reaction conditions are exemplified and discussed.

ATTORNEY DOCKET NUMBER: 9725-0005

SERIAL NUMBER: 09/837,235

REFERENCE: AV

## **STABILIZED PROTEINS**

### **1. FIELD OF THE INVENTION**

The present invention relates to cross-linking methods to stabilize

- 5 polypeptides and polypeptide complexes for commercial uses (pharmaceutical, therapeutic, and industrial), and to polypeptides and polypeptide complexes so cross linked.

### **2. BACKGROUND OF THE INVENTION**

10

#### **2.1. STRUCTURE AND FUNCTION OF**

##### **POLYPEPTIDES AND POLYPEPTIDE COMPLEXES**

A protein molecule consists of a linear polypeptide chain of amino acids that is intricately folded in three dimensions to form, e.g., interaction surfaces, binding pockets and active sites. A specific three-dimensional fold is generally required for protein  
15 function, wherein the fold itself is specified by the linear sequence of amino acids (i.e., the primary structure of the protein). It is notable, however, that dissimilar primary structures can have nearly identical three-dimensional folds. Evolution has conserved specific folds to a greater extent than specific primary structures. The protein folding process remains an active field of study. It is known, however, that secondary structure elements such as alpha  
20 helices, beta sheets and beta turns contribute to assembly of the tertiary structure of a polypeptide. A biological protein entity made up of several polypeptides is said to have quaternary structure.

Protein folding ultimately results from the interaction of intra- and inter-molecular forces. As such, a folded protein has a finite stability that translates into a finite  
25 structural and functional "half-life" in a given solvent environment. For example, in an aqueous environment, proteins attain stability in part by clustering hydrophobic residues in the protein core and hydrophilic residues at the protein-solvent interface. Accordingly, the activity half-life for a given protein is in part a function of solvent properties. Additionally, chemical bonds such as disulfides occur in nature to fix the co-ordination of  
30 non-neighboring side chains in close proximity in a folded protein, thereby stabilizing its structure and function.

In many biological systems, proteins associate with each other to form dimers or higher order multimers (i.e. quaternary structures), and only as such carry out their specific functions. The formation of such complexes is often an important event in  
35 regulating the activity of proteins. Various mechanisms have been found to regulate protein complex formation, such as ligand binding, or post-translational modification. The

functions of protein complexes can range from providing structure to the intra-cellular matrix, where, for instance, actin forms a structural lattice, to transcription factors.

Proteins consist of discrete functional domains. Domains of similar or analogous function in different proteins usually show amino acid sequence similarities and are related in evolution. "Domain shuffling" has played a major role in the evolution (as well as in the gene engineering) of proteins with highly diverse functionalities. Interaction domains, for example, can be found in proteins of many different functions; however, sequence similarities reveal their presence. Crystallographic studies have shown that related domains are even more conserved in secondary, tertiary and quaternary structure than in primary amino acid sequence, such that structural inferences can be made about a particular domain if structural data is available on one or preferably multiple related domains (see e.g., Hofmann K., *Cell Mol. Life Sci.* vol. 55(8-9): pp. 1113-28, 1999; Chou J.J. *et al.*, *Cell* vol. 94(2): pp. 171-80, 1998).

## 2.2. BIOCATALYTIC ENZYMES

There are numerous conceivable commercial applications of stabilized proteins, protein complexes and protein-protein interactions. As an example of a class of proteins for which stabilization is desirable, enzymes and other proteins that have been used as biocatalysts in industrial applications are considered in this section. Valuation of the biocatalytic enzyme market is also considered.

Industrial biocatalytic processes have use in many industrial sectors, including the chemical, detergent, pharmaceutical, agricultural, food, cosmetics, textile, materials-processing, and paper industries. Within these industries, biocatalysts have many applications, ranging from product synthesis (e.g., amino acid manufacturing), use as active agents in certain products (e.g., biological washing powders), use in diagnostic testing equipment, and use as therapeutic agents. Total sales of industrial biocatalysts in 1999 were roughly \$1.4 billion. This figure is expected to grow significantly over the next decade as biocatalyst applications are enabled by novel technologies such as the invention described herein.

Market sectors believed to have potential for growth and technological innovation include engineered enzymes (e.g., for providing faster throughput, cheaper production, and/or the capability to produce novel products), pollution-control systems (e.g., for bioremediation), and non-aqueous biocatalytic systems (e.g., for oil and fat bioprocessing and drug manufacture) (*see* Business Intelligence Center, Explorer: "BIC Explorer"; Business Opportunities in Technology Commercialization).

Historically, only a handful of fine chemical companies such as DSM, Lonza and Avecia Ltd., have embraced and invested in biocatalytic processes. More recently, however, there have been several significant corporate investments in the field of biocatalysis. One example of such an investment is Bayer's recent announcement that it  
5 will use 6-7% of fine chemical sales to develop enzyme-based processes for certain molecules.

Major customers of fine chemical companies tend to favor suppliers with a broad range of process development. This consideration suggests that those with biocatalytic expertise stand to gain a further competitive edge in the marketplace. Some  
10 firms have recognized this and are trying quickly to close the gap via acquisitions (e.g. Great Lakes's acquisition of NSC Technologies and Cambrex's purchase of Celgene). Others acknowledge that they will lose out on further business opportunities if they don't do something to access the basic skills required for biocatalysis (Joe Blanchard, Altus Biologics Inc., 1999).

Major enzyme manufacturers (e.g. Novo, Genencor, Roche, etc.) tend to  
15 focus on large-scale enzyme production for the major industrial markets (such as detergents and textiles) and not on the application of enzymes for fine chemical development (Joe Blanchard, Altus Biologics Inc., 1999).

The continued growth in interest in the commercial use of biocatalysis and  
20 the fragmentation of the biocatalyst industry will allow both large and small companies to exploit innovative biocatalysts and the products and processes that utilize them (BIC Explorer: Business Opportunities in Technology Commercialization, 1999).

Bioremediation applications may, in the future, turn into one of the most economically important applications of biocatalytic enzymes. For example, approximately  
25 2.3 trillion gallons of municipal effluent and 4.9 billion gallons of industrial waste are passed into U.S. waters each year, and approximately 1 million gallons of hydrocarbons enter our environment per day. Hydrocarbon cleansing is a routine requirement for various commercial operations (e.g., oil tankers, marine bilges, storage, fuel and truck tanks).

Currently, there are several processes in development that utilize biocatalysts  
30 for decontamination/decomposition of both hydrocarbons and wastewater. Not only are these processes commercially the most promising systems due to efficiency and low costs, but they are also the cleanest.

Furthermore, biocatalytic desulfurization is an inexpensive and attractive technology to the crude oil production market, where low-sulfur crude oil commands a  
35 premium price over high-sulfur crude oil. There is a growing need for cost-effective sulfur management and desulfurization worldwide due to an increased level of sulfur in fossil



fuels and increasingly stringent regulations requiring lower sulfur emissions. Compliance with these regulations is expected to cost the European refining industry alone more than \$50 billion in capital and \$10 billion annually in operating expenditures.

All catalyst manufacturing in 1997 represented a \$10 billion-plus market in the U.S., a figure quoted by the American Chemical Society (*see also*, "Catalyst Industry Stresses Need for Partners as Key to Future Success," C&E News, July 11, 1994; CatCon '96 presentations by T. Ludermann of CONDEA Chemie GmbH, Paul Lamb of Englehard Corporation, and J. Ohmer and K. Herbert of Degussa Corporation). According to Maxigen, the total industrial enzymes market (a segment of the catalyst manufacturing market) is estimated at \$1.4 billion today, growing at roughly 10% annually.

### 2.3. STABILIZATION STRATEGIES

Several protein stabilization strategies are known in the art and have been previously described, as highlighted below.

#### 2.3.1. STABILIZATION OF BIOCATALYTIC ENZYMES

Several approaches have been taken to enhance the stability of biocatalysts. On the protein level, the most prominent approaches include discovery of stable biocatalysts from investigation of thermophilic organisms, directed evolution, and computational- and protein engineering, as described below.

Thermophilic organisms, or 'extremophiles', are sought in extreme environments such as deep-sea vents and Yellowstone geysers. Although enzymes of commercial relevance have been identified from them, this 'discovery' approach is limited by what can be found in nature. This approach has not yielded as many commercially-relevant, thermostable biocatalysts as was initially hoped for and/or projected.

'Directed evolution' techniques are powerful approaches capable of generating stabilized enzymes, often also with altered/improved functional specificities. However, the approach is limited by the feasibility of the selection procedure.

Algorithms that calculate intra-molecular forces within proteins are being used to design and/or evolve enzymes with greater thermostability *in silico*. This approach is still severely hampered by the limited understanding of the intra-molecular forces and the processes involved in protein folding.

Addition of chemical modifications that can hold proteins in their correct conformation is often referred to as protein engineering. Such protein engineering approaches include derivitization (e.g. PEGylation, addition of polymeric sucrose and/or dextran, methoxypolyethylene glycol, etc.) and old methods of protein cross-linking (e.g.

production of cross-linked enzyme crystals or CLEC's). Unfortunately, these approaches are often ineffectual or cause dramatic losses in activity.

Strategies for the operational stabilization of biocatalysts that have proven successful in some respects include (a) catalyst immobilization and (b) the use of organic solvents in the reaction medium (termed medium engineering). Thermal stability upon immobilization is the result of molecular rigidity and the creation of a protected microenvironment. Methods include multi-point covalent attachment and gel-entrapment. Immobilization of biocatalysts is the most used strategy as additional benefits are obtained, such as flexibility of reactor design, and facilitated product recovery without catalyst contamination. However, despite its great technological potential, few large-scale processes utilize immobilized enzymes. Severe restrictions often arise in scale-up because of additional costs, activity losses, and issues regarding diffusion.

The main purpose of medium engineering in biocatalysis was originally to utilize robust commercial hydrolytic enzymes in organic synthesis. However, enhanced thermostability in organic media has proven an additional and significant bonus. It is hypothesized that partial or almost total substitution of water is beneficial since water is involved in enzyme inactivation. Whatever the mechanism, numerous cases have recently been reported where remarkable enzyme stability has been obtained in organic media such as polyglycols and glymes. Despite this advance, medium engineering is unlikely to solve all biocatalysis stability problems.

Some of the most promising solutions to biocatalysis problems have combined evolutionary approaches with operational stabilization techniques, such as using directed evolution to generate enzymes with higher reaction rates in organic solvents. Such combined approaches may provide significant synergies which maximally improve upon and enable commercially-relevant biocatalytic processes. In principle, the invention described herein below can be applied in combination with any of the above-mentioned known stabilization approaches.

### **2.3.2. STABILIZATION OF OTHER PROTEINS**

Molecular biological techniques have made it possible to stabilize some proteins by, e.g., engineering fusion-proteins. Some fusion proteins have even displayed novel functionalities. To make a fusion-protein, a single nucleic acid construct is created that directs the expression of modular domains derived from at least two proteins as one protein. Due to fusion, two domains can be held in very close proximity to each other, thereby making the local concentration of each domain very high with respect to the other. In this way, a functional complex is stabilized. For example, homo- and heterodimers of

the interleukin 8 family have been stabilized in this way, maintaining functionality similar to wild type (Leong S.R. *et al.* Protein Sci.; vol. 6(3): pp: 609-17, 1997) Another example of protein complexes stabilized in this way is the method stabilizing immunoglobulin Fv fragments, consisting of the variable domains of immunoglobulin heavy and light chains, lacking the stabilizing effect of inter-chain disulfide bonds. It is necessary to stabilize the complex by another means to maintain the affinity of the immunoglobulin complex, and expression of both polypeptides as a single chain is one of the methods used (Pluckthun and P. Pack. Immunotechnology; vol. 3(2): pp. 83-105, 1997).

However, in the design of pharmacological reagents, it is often disadvantageous to create fusion proteins that require a linker sequence to stabilize them. For example, such linkers introduce non-self epitopes which are often recognized by the organism as foreign and elicit immune responses. This reduces the efficacy of such therapeutics and/or diagnostics because the reagents are then cleared by the immune system (see, for example, Raag R. and Whitlow M. FASEB; vol. 9: pp. 73-80, 1995). In the case of single chain Fv fragments, the linker, which is most frequently chosen to be a highly flexible structure, allows the complex to disassociate, since the affinity of the two polypeptides to each other is low. The single chain Fv fragments then aggregate, or clump, and thereby lose their functionality (Webber K.O. *et al.* Mol. Immunol.; vol. 32(4): pp. 249-258, 1995). More rigid linkers that lend the complex more stability, and would thereby decrease the level or speed of aggregation and loss of functionality, are associated with increased immunogenicity (Raag R. and Whitlow M. FASEB; vol. 9: pp. 73-80, 1995).

Cross-linking the domains at close contact sites would circumvent these problems, where it is possible to direct the cross-link between two proteins to such surfaces of the proteins where after the reaction the cross-link is buried. One such means is to stabilize complexes by introducing a disulfide bond between two polypeptides by introducing point mutations to cystine in both polypeptide chains. The mutations are introduced at positions that allow the formation of such bonds (see, for example, Reiter Y. *et al.* Nat Biotech.; vol. 14: pp. 1239-1245, 1996; Pastan *et al.* United States Patent No. 5,747,654, issued May 5, 1998).

Disulfide bonds are, however, unstable under many physiological conditions (Klinman J.P. (ed). Methods in Enzymology; vol. 258, 1995). Physiological conditions vary widely, for instance with respect to redox potential (oxidizing vs. reducing) and acidity (high vs. low pH) of the various, physiological milieus (intracellular, extracellular, pinocytosis vesicles, gastro-intestinal lumen, etc.). Di-sulfide bonds are found in nature only in extracellular proteins, and they are known to fall apart in reducing environments,

such as the intracellular milieu. But even in the extracellular milieu, many engineered disulfide bonds are unstable.

Several other chemical cross-link methodologies allow the formation of bonds that are stable under a broad range of physiological and non-physiological pH and redox conditions. However, in order to maintain the complex's activity and specificity, it is necessary that the cross-link is specifically directed and controlled such that, first, the overall structure of the protein is minimally disrupted, and second, that the cross-link is buried in the protein complex so as not to be immunogenic. But with most cross-link methodologies, the degree to which it is possible to direct the bond to a specific site is too limited to allow them to be used for most bio-pharmaceutical and/or diagnostic applications. Examples of such cross-link methodologies include UV-cross-linking, and treatment of protein with formamide or glutaraldehyde.

### 2.3.3. Fv FRAGMENTS

Immunoglobulin Fv fragments comprise another example of a class of proteins for which stabilization is desirable. Immunoglobulin Fv fragments are the smallest fragments of immunoglobulin complexes shown to bind antigen. Fv fragments consist of the variable regions of immunoglobulin heavy and light chains and have broad applicability in pharmaceutical and industrial settings.

#### 20 Value of Fv Fragment Market

A recent analysis estimated that 20 to 40 percent of all bio-technological therapeutics and diagnostics currently in development are based on immunoglobulin (Pharmaceutical Research and Manufacturers of America. New Medicines in Development, Survey. 1998). Furthermore, a significant portion, and the majority of current "state of the art" Ig-based therapeutics and diagnostics in development are Fv fragment-based (Price Waterhouse: Survey of Biopharmaceutical Industry, 1998). For reviews of the utility of immunoglobulin as a pharmacological agent, see Penichet M.L. et al., Hum Antibodies; vol. 8(3): pp. 106-18, 1997; Sensel M.G. et al. Chem. Immunol.; vol. 65: pp. 129-58, 1997; Reiter Y. and Pastan I. TIBTECH; vol. 16(12): pp. 513-520, 1998; Reiter Y. et al. Nat Biotech.; vol. 14: pp. 1239-1245, 1996; Pluckthun and P. Pack. Immunotechnology; vol. 3(2): pp. 83-105, 1997; Wright A. and Morrison S.L. Trends Biotechnol.; vol. 15(1): pp. 26-32, 1997; Schwartz M.A. et al. Cancer Chemother. Biol. Response Modif.; vol. 13: pp. 156-74, 1992; Houghton A.N. and Scheinberg D.A. Semin Oncol.; vol. 13(2): pp. 165-79, 1986; and Cao Y. and Suresh M.R. Bioconjugate Chemistry; vol. 9(6): pp. 635-644, 1998.

Following the successful introduction of the first Ig-based biotech drug, ReoPro by Centocor, in 1994, six more Ig-based drugs were approved in 1997 and 1998 and six more were in phase III clinical trials as of the end of 1998. Sales of a single, clinically successful, immunoglobulin-based product can result in annual revenues on the order of  
5 several hundreds of millions of dollars (Pharmaceutical Research and Manufacturers of America. New Medicines in Development, Survey, 1998). Together, these facts give evidence of the commercial and clinical value of these types of products.

The cost of developing, producing and clinically testing such products is, however, immense and the risk of failure is often great. Because of this, any technology  
10 that can either increase the product's effectiveness, broaden its range of applications or increase its chances of succeeding in clinical trials will add enormously to the Net Present Value of a product in development (Boston Consulting Group: The Contribution of Pharmaceutical Companies: What's at stake for America, 1993).

#### Fv Fragment Stabilization Methods

15 To date, a variety of methodologies have been employed to stabilize engineered antibodies. First, introduction of additional di-sulfide bonds has been performed through molecular biological manipulation of the antibody-expressing construct (Reiter Y. and Pastan I. TIBTECH; vol. 16(12): pp. 513-520, 1998). Second, introduction of a linker has been employed that allows both fragments to be expressed as a single chain (single  
20 chain Fv fragments) (Pluckthun and P. Pack. Immunotechnology; vol. 3(2): pp. 83-105, 1997; Cao Y. and Suresh M.R. Bioconjugate Chemistry; vol. 9(6): pp. 635-644, 1998). Finally, fusion of an exogenous di- or oligomerization domain to each of the Fv fragment chains has been performed (Pluckthun and P. Pack. Immunotechnology; vol. 3(2): pp. 83-105, 1997; Cao Y. and Suresh M.R. Bioconjugate Chemistry; vol. 9(6): pp. 635-644, 1998;  
25 see also Antibody Engineering Page, IMT, University of Marburg, FRG: [http://aximt1.imt.uni-marburg.de/\\_rek/indexfenster.html](http://aximt1.imt.uni-marburg.de/_rek/indexfenster.html)).

However, all of these technologies have significant drawbacks. Disulfide bonds are a suitable bond in the context of Fab fragments (see Figure 1D), and many other extra-cellular proteins, to stabilize protein complexes. Furthermore the introduction of  
30 disulfide bonds avoids the need to introduce foreign peptides, and the resultant stabilized complexes are minimally immunogenic. Nonetheless, the introduction of disulfide bonds in Fv fragments by molecular biological means results in complexes that are insufficiently stable under many commercially relevant, physiological conditions, such as the intracellular milieu and sometimes even serum. As such they have limited usefulness in the  
35 pharmaceutical context.

With single chain Fv fragments there is a trade-off between the stability of the complex and its immunogenicity in a therapeutic or *in vivo* diagnostic context. Linkers that result in stable conjugates that are more rigid structures, and elicit immune responses, which in turn results in decreased utility. Linkers that are not immunogenic are generally the more flexible linkers that provide insufficient stability (see above, Raag R. and Whitlow M. FASEB; vol. 9: pp. 73-80, 1995).

Fv fragments stabilized by fusion to multimerization domains are significantly immunogenic, and lack the most significant advantage of Fv fragments in the first place: reduced size and resultant increased tissue penetration.

Other currently available chemical cross-link methods, such as UV cross-linking (see above), are severely limited in the degree to which it is possible to direct the bond to a specific site. As bio-pharmaceutical and/or diagnostic applications require the maintenance of the polypeptide's function, specificity in the cross-link reaction is paramount.

#### 2.4. THE TYROSYL-TYROSYL OXIDATIVE CROSS-LINK

Oxidative cross-link reactions between tyrosyl side-chains have been demonstrated to occur naturally. For example, cytochrome c peroxidase compound I has been demonstrated to form di-tyrosine bonds during the endogenous reduction of its active site (Spangler B.D. and Erman J.E. Biochim. Biophys. Acta; vol. 872(1-2): pp. 155-7, 1986), and di-tyrosine-linked dimers of gammaB-crystallin are reportedly associated with cataractogenesis of the eye lens. *In vitro*, di-tyrosine protein-protein links are readily formed photodynamically in the presence of sensitizers (Kanwar R. and Balasubramanian D. Exp. Eye Res.; vol. 68(6): pp. 773-84, 1999). Furthermore, protein cross-linking through the formation of di-tyrosine bonds can be catalysed, for example, by peroxidase (Gmeiner B. and Seelos C. FEBS Lett ; vol. 255(2): pp. 395-7, 1989), or by metallo-ion complexes (Campbell *et al.* Bioorganic and Medicinal Chemistry, vol. 6: pp. 1301-1037, 1998; Brown K.C. *et al.* Biochem.; vol. 34(14): pp. 4733-4739, 1995), and by light-triggered oxidants (Fancy D.A. and Kodadek T. Proc. Natl. Acad. Sci., U.S.A.; vol. 96: pp. 6020-24, 1999).

As described by Campbell *et al.*, in the presence of an appropriate catalyst and an appropriate oxidizing reagent, an oxidative cross-link reaction can occur between tyrosyl side-chains of proteins that are properly spaced. In this reaction, the hydroxyl groups of the tyrosyl side-chains react with each other, an H<sub>2</sub>O molecule is released, and the side-chains are linked by a covalent bond. This reaction is thought to proceed through a high-valent metallo-oxo complex which abstracts an electron from an accessible tyrosyl

side-chain, followed by covalent coupling of the resultant tyrosyl radical with another tyrosyl side-chain that is in sufficient proximity.

This cross-link methodology was originally developed to cross-link proteins that interact in cell lysates, as a proxy to the *in vivo* situation, to enable the study of the functionality of proteins by identifying other proteins they interact with. The reaction only occurs with tyrosine side-chains that are in very close proximity to each other. Furthermore, the bond formed between the tyrosyl side-chains is irreversible and stable under a very wide range of physiological conditions.

None of the above-cited references disclose or suggest methods using di-tyrosyl cross-linking for formation of buried chemical cross-links for stabilizing a protein complex while maintaining the complex's activities and specificities. Accordingly, a need exists for such methods wherein the product is functional under a wide range of physiological and non-physiological conditions, and wherein the structure, function, and specificity of the cross-linked protein complex is maintained.

Citation or identification of any reference in Section 2 or any other section of this application shall not be construed as an admission that such reference is available as prior art to the present invention.

### 3. SUMMARY OF THE INVENTION

This invention provides a method for stabilization of a polypeptide or polypeptide complex, by the introduction of intra-polypeptide and/or inter-polypeptide di-tyrosine bonds, which simultaneously maintains the structure and function of the polypeptide or polypeptide complex. Further, this invention provides various methods for optimizing protein stabilization. Such methods include statistical analyses of the primary amino acid sequences of related proteins (two-dimensional data analysis) and statistical analyses of the three-dimensional coordinates of proteins believed to be related in three-dimensional structure (three-dimensional data analysis).

Further, this invention provides stabilized polypeptides and polypeptide complexes. To achieve stabilization, the cross-link reaction is carefully controlled such that polypeptides and polypeptide complexes maintain their original functionality. In one embodiment, the invention provides a method for the identification of amino acid residues which, when cross-linked, are least disruptive to the structure and function of the polypeptide or polypeptide complex. In another embodiment, the invention provides a method for mutagenesis of identified residues to further control the cross-link reaction. Polypeptides and polypeptide complexes so stabilized can be utilized under a wide variety of physiological and non-physiological conditions. Further, the cross-link methodology

disclosed herein may preclude the need for addition of exogenous structures to engineered proteins and complexes, such as peptide linkers. In another embodiment, the invention provides a method for statistical analysis of databases of structural and/or sequence information available for polypeptides and polypeptide complexes to be stabilized. The statistical analysis identifies suitable residue pairs which are least likely to be disruptive of structure and function when cross-linked. Further, in a polypeptide chain or chains to be cross-linked, potentially undesirable reactive side-chains may be altered using site-directed mutagenesis, *e.g.*, to introduce a maximally conservative point mutation that will not support the cross-link reaction. The cross-link reaction conditions may also be adjusted to prevent undesired cross-links. At residues identified as desirable positions for cross-linking, reactive side-chains may be introduced by site-directed mutagenesis, and the cross-link reaction is carried out using the conditions identified above.

#### 4. BRIEF DESCRIPTION OF THE FIGURES

The present invention may be understood more fully by reference to the following detailed description, illustrative examples of specific embodiments and the appended figures.

FIG. 1 The dityrosyl cross-link and example proteins which can be stabilized according to methods of the invention. A. Schematic representation of a dityrosyl cross-link. Addition of a cross-linking catalyst and an oxidizing reagent to a protein or protein complex preparation wherein at least two tyrosine residues occur in close proximity and in proper orientation results in a dityrosyl cross-link and one water molecule. B. Schematic representation of the canonical fold of  $\alpha/\beta$  hydrolases, a group of enzymes which includes lipases. The topological positions of the active site residues are indicated as solid circles. From K.-E. Jaeger et al., 1999, *Ann. Rev. Microbiol.* 53, 315-351. C. Schematic representation of secondary structure of *Candida antarctica* lipase B. The topological positions of the active site residues are indicated as residues S105, D187, and H224. From J. Uppenberg et al., 1994, *Structure* 2, 293-308. D. Schematic representation of an immunoglobulin molecule (IgG). The immunoglobulin hetero-tetramer comprises two identical light chains, and two identical heavy chains. The complex is stabilized by inter-chain disulfide bonds; the disulfide bonds are indicated by the "S-S" links in the schematic representation. Both antigen-binding domains, one at either end of the "fork", consist of a pair of heavy and light chain variable regions, and are referred to as the "Fv fragments". The antigen-binding domain is the Fv fragment, consisting of the variable region of both the heavy and light chain consist of four relatively conserved Framework



Regions that provide the overall structure, and of three Complementarity Determining Regions that lend the Fv fragment its specificity for a specific antigen. The Fab fragment, which comprises both the light and heavy chain variable regions (Vl & Vh), constant region of light chain (Cl), and the first constant region of the heavy chain (Ch1), is stabilized by an inter-chain disulfide bond. In the Fv fragment none of the immunoglobulin inter-chain disulfide bonds are present, as indicated, resulting in the requirement for this protein complex to be stabilized artificially.

FIG. 2. A. Schematic representation of a tyrosyl side-chain, consisting of an alpha carbon (A) which is still part of the polypeptide back-bone, a beta carbon (B), the first atom in the side-chain not part of the back-bone, an aromatic ring, which, in turn, consists of six carbon atoms, and a hydroxyl group (OH). The angle  $\beta$  in the beta carbon between the beta carbon-hydroxyl oxygen axis and the alpha carbon-beta carbon bond is indicated. B. Schematic representation of a tyrosyl-tyrosyl bond indicating in addition the angle  $\beta$ , the angle  $\omega$ , which is the angle between the dityrosyl bond and the carbon-carbon bond in the aromatic ring of the cross-linked tyrosyl side chain that is proximal to the beta-carbon of the same side chain, projected into the two plane of the two aromatic rings. Also indicated are the angle  $\alpha$ , the angle between all carbon residues in the plane of the aromatic rings ( $120^\circ$ ), and the degrees of rotational freedom (1) in the dityrosine bond itself, and (2), of the alpha carbon around the beta carbon-gamma carbon (most proximal carbon atom in the aromatic ring) axis. C. Three-dimensional angles formed by the alpha carbon-alpha carbon axis, the beta carbons ( $\psi$  and  $\phi$ ), and the two planes ( $\chi$ ) described by the alpha carbon-alpha carbon axis and (1) the alpha carbon-beta carbon bond of the first chain (A1-B1), and (2) the alpha carbon-beta carbon bond of the second chain (A2-B2).

FIG. 3. The angle  $\omega$ , indicated in Figure 2B, is  $+120^\circ$ . For this configuration, the alpha carbon distances, angles  $\psi$  and  $\phi$ , and the alpha-beta distance differences (see text) are represented geometrically for maximal and minimal configurations (that fall into one plane), given this angle  $\omega$ . The angle  $b$  is  $109.5^\circ$ , the tetrahedral angle of carbon atoms, and complete rotational freedom of the alpha carbon around the around the beta carbon-gamma carbon axis is assumed. In A, the length  $c$  is the distance between the two carbon atoms of a carbon-carbon bond; the length  $v$  is  $\cos((180^\circ-\alpha)/2) \times c$ , the length  $h$  is  $\sin((180^\circ-\alpha)/2) \times c$ , length  $a$  is half of the square root of the sum of  $7v$  squared and  $h$  squared, and the length  $b$  is the square root of the sum of the square of  $(a+v)$  and  $h$  squared. In B,  $v$  is the  $\cos(180^\circ-(\beta-(180^\circ-\alpha)/2+\arctan(h/7v))) \times c$ ,  $h$  is the  $\sin(180^\circ-(\beta-(180^\circ-\alpha)/2+\arctan(h/7v))) \times c$ , and, analogously, length  $a$  is half of the square root of the sum of  $7v$  squared and  $h$  squared, and the length  $b$  is the square root of the sum of the square of  $(a+v)$

and  $h$  squared. In the configuration depicted in A, at which the alpha carbon distance is maximal, the angles  $\psi$  and  $\phi$  are  $(180^\circ - \alpha)/2 - \arctan(h/7v)$ ; in the configuration in B, at which the alpha carbon distance is minimal for an angle  $w$  of  $+120^\circ$ ,  $\psi$  and  $\phi$  are  $\beta - (180^\circ - \alpha)/2 - \arctan(h/7v)$ .

5

FIG. 4. The angle  $\omega$ , indicated in Figure 2B, is  $-120^\circ$ . In Figure 4, the alpha carbon distances, angles  $\psi$  and  $\phi$ , and the alpha-beta distance differences (see text) are represented geometrically for maximal and minimal configurations (that fall into one plane), given this angle  $\omega$ . The angle  $\beta$  is kept constant at  $109.5^\circ$ , the tetrahedral angle of carbon atoms, and complete rotational freedom of the alpha carbon around the around the beta carbon-gamma carbon axis is assumed. In A, the length  $x$  is  $4v$ , the length  $y$  is the square root of the sum of  $h$  squared and  $3v$  squared, the length  $z$  is the  $\cos(180^\circ - 120^\circ + \arctan(h/3v))$   $\times y$ , the length  $a$  is half of the square root of the sum of  $(x+z)$  squared and  $y$  squared, the length  $v$  is the  $\cos(120^\circ - \beta) \times c$ , and the length  $b$  is the sum of the lengths  $a$  and  $v$ . In B, the length  $v$  is the  $\cos(\beta - 2x(180^\circ - \alpha)/2) \times c$ , and the length  $b$  is the difference of the lengths  $a$  and  $v$ . In the configuration depicted in A, at which the alpha carbon distance is maximal for an angle  $\omega$  of  $+120^\circ$ ,  $\psi$  and  $\phi$  are  $\alpha - \beta$ ; in the configuration in B, at which the alpha carbon distance is minimal,  $\psi$  and  $\phi$  are  $180^\circ - (\beta - 2x(180^\circ - \alpha)/2)$ .

20

FIG. 5. Structural Coordinate Data, the primary (or input-) data of a 3-D database. First two amino acid residues of a representative Fv Fragment heavy (H) and light (L) chain, in Angstroms; the data of each atom is represented in rows, the atoms are listed in columns. Coordinate data is represented for all residue atoms other than Hydrogen atoms, including those involved in the polypeptide backbone and those in the amino acid's side-chain. In the left-hand column, under the heading "Chain", the identity of the polypeptide chain is listed, with which an atom's coordinates are associated. An Fv fragment consists of two polypeptides: a heavy chain (H; below) and a light chain (L; above). The number under the heading "K&W" indicates the position of the atom's residue within the Kabat & Wu (K&W) alignment system. Under the heading "Atom", the identity of an atom of the specific amino acid present in the representative polypeptide at that particular residue are indicated (identified under the heading "Amino Acid" in three letter code). The  $x$ ,  $y$ , and  $z$  three-dimensional coordinates of each atom are represented in the right-hand columns, as indicated.

35

FIG. 6. Schematic representation of 3 actual Fv fragment entries into a 3-D database. Arrays of alpha-carbon coordinate data of heavy and light chain residues of the

Fv fragments, and, as an example of relevant derivative data, calculated inter-chain, inter-atomic distances. Heavy chain alpha-carbon data is represented in rows, as described in the description of Figure 5, and light chain alpha-carbon data is transposed, and the light chain data described in Figure 5 is represented in columns. Derivative data describing the inter-chain, 3-D relationships of the atoms on both chains is represented at the intersection of each heavy chain row and light chain column.

FIG. 7. Statistical measurements in a 3-D database of alpha carbon distances between of Fv fragment heavy and light chain residue pairs, as an example of relevant derivative data. A. Illustrative statistical measurements of the alpha carbon distances between residue pairs of the three representative Fv Fragment heavy and light chains in the description of Figure 6 (i.e. data shown for n=3). B. Actual statistical measurements of the alpha carbon distances between the residue pairs of all Fv fragment heavy and light chains in the sample of Fv fragments used for the selection (data shown for n=17).

FIG. 8. Schematic representation of a Fv fragment entry (Fv Fragment 1 of Figure 6) into a 3-D database. Arrays of beta-carbon coordinate data of heavy and light chain residues of the Fv fragment, and, as an example of relevant derivative data, calculated inter-chain, inter-atomic distances. Heavy chain beta-carbon data is represented in rows, and light chain beta-carbon data is transposed and represented in columns, as described in the description of Figure 5. Derivative data describing the inter-chain, 3-D relationships of the atoms on both chains is represented at the intersection of each heavy chain row and light chain column.

FIG. 9. Schematic Representation of the approach taken to calculate the differences between the inter-chain, inter-atomic residue pair alpha-carbon and beta-carbon distances ('alpha-beta distance differences') for an individual Fv fragment in the 3-D database (Fv Fragment 1 of Figure 6 and 8). Heavy chain alpha- (top) and beta-carbon (middle) data is represented in rows, and light chain alpha- and beta-carbon data is transposed, and represented in columns, as described in the description of Figure 5. Derivative data describing the inter-chain, inter-atomic distances in the top and middle panels, and the alpha-beta distance differences in the bottom panel, is represented at the intersection of each heavy chain row and light chain column.

FIG. 10. Alpha-beta distance difference data, derived as describe in Figure 9, of representative Fv fragments (Fv fragments 1, 2, and 3 of Figure 6) in a 3-D database.

Heavy and light chain residues are represented in arrays, where the heavy chain residues are listed vertically, and the light chain residues are listed horizontally. Data correlated with heavy and light chain residues is represented at the intersection of each heavy chain row and light chain column.

5

FIG. 11. Statistical measurements in a 3-D database of alpha-beta distance differences of Fv fragment heavy and light chain residue pairs, as an example of relevant derivative data. A. Illustrative statistical measurements of the alpha-beta distance differences of the pairs between the three representative Fv Fragment heavy and light chains in Figure 6 (i.e. data shown for n=3). B. Actual statistical measurements of the alpha-beta distance differences of the pairs between all Fv fragment heavy and light chains in the sample of Fv fragments used in the for selection (data shown for n=17).

FIG. 12. Quantification of amino acid side-chain physical properties, as an example of relevant derivative data, at (the first four, representative) residues of the Fv fragment heavy chain, based on Fv fragment polypeptide sequence data, compiled in a 2-D database. A. Amino Acid Sequence Data. Representation of primary data compiled in a 2-D database. Amino acids (AA) occurring at each residue are sorted by the frequency (F) of their occurrence at that specific residue. B. Amino Acid Side-chain Quantification Tables. Representation of numeric values used in a 2-D database to obtain relevant derivative data by quantifying the physical properties of amino acids: e.g. van der Waals volume [ $A^3$ ] (Richards, F.M.) and numeric hydrophobicity values (Eisenberg, D.). C. Quantification of the physical properties, exemplified here by van der Waals volumes, of the amino acid side-chains present at each residue in the sample of Fv fragment sequences in the 2-D database.

25

FIG. 13. Statistical measurements in a 2-D database of side-chain physical properties at each residue of Fv fragment heavy chains present in the 2-D database (sample), as an example of relevant derivative data, quantified as described in the description of Figure 12. In the third column from the left, under the heading "Cons", the consensus, or most frequently occurring amino acid for each represented residue is listed. As representative statistical measures, average and standard deviations are shown, both weighted and un-weighted by the frequency of each amino acid's occurrence in the sample at each residue represented in this figure. A. Average and standard deviations are shown for residue van der Waals volumes, both weighted and un-weighted by the frequency of each amino acid's occurrence in the sample at each residue represented in this figure. B. Average and standard deviations are shown for residue Hydrophobicity quantities, both

35

weighted and un-weighted by the frequency of each amino acid's occurrence in the sample at each residue represented in this figure.

FIG. 14. Schematic illustration of a successive array and a parallel array of  
5 filters designed for automation using a computer system and software for the residue pair selection process. The filters shown are an illustrative set of filters taken from the filters described above (see Identification of Suitable Residues for the Reaction). In this illustration, the number of selected residues that "passed" each filter, either in succession (left) or in parallel (right), is derived from an analysis of the 106 amino acids of the Fv  
10 fragment light chain, the 120 amino acids of the Fv fragment heavy chain, and the resultant 12720 possible residue pairs in a given Fv fragment. The percentages indicating the permissiveness of each filter are also illustrative of the Fv fragment example. See text for further discussion (Software for Selection Process).

## 15 **5. DETAILED DESCRIPTION OF THE INVENTION**

The invention described herein comprises methods for stabilizing polypeptides and polypeptide complexes. Also provided are polypeptides and polypeptide complexes stabilized using the described methods. The stabilization reaction is controlled such that the polypeptides and polypeptide complexes maintain their original functionality  
20 by providing specifically localized reactive side-chains. The stabilized polypeptides and polypeptide complexes can be maintained and utilized under a wide variety of physiological and non-physiological conditions without exogenous chemical structures that could be immunogenic and/or significantly decrease their efficacy.

By taking a statistical approach to analyzing databases of structural and  
25 sequence information for domains of proteins, suitable residue pairs may be identified at which the cross-link reaction is likely to be least disruptive of the overall structure.

At these residues, reactive side-chains are placed via site-directed point mutations. In the polypeptide chains that are to be cross-linked, the codons of potentially reactive side-chains at other positions are also altered to introduce a maximally conservative  
30 point mutation that will not support the reaction.

### **5.1. POLYPEPTIDES AND POLYPEPTIDE COMPLEXES SUITABLE FOR APPLICATION OF THE INVENTION**

Polypeptides and polypeptide complexes that can be stabilized by the  
35 methods described herein are single polypeptides or complexes that consist of two or more polypeptides and that remain functionally active upon application of the instant invention.

Nucleic acids encoding the foregoing polypeptides are also provided. The term "functionally active" material, as used herein, refers to that material displaying one or more functional activities or functionalities associated with one or more of the polypeptides of the complex. Such activities or functionalities may be the polypeptide complexes' original, natural or wild-type activities or functionalities, or they may be designed and/or engineered. Such design and/or engineering may be achieved, for example, either by deleting amino acids, or adding amino acids to, parts of one, any, both, several, or all of the polypeptides, by fusing polypeptides of different polypeptides or polypeptide complexes, by adding or deleting post-translational modifications, by adding chemical modifications or appendices, or by introducing any other mutations by any methods known in the art to this end as set forth in detail below.

The compositions may consist essentially of the polypeptides of a complex, and fragments, analogs, and derivatives thereof. Alternatively, the proteins and fragments and derivatives thereof may be a component of a composition that comprises other components, for example, a diluent, such as saline, a pharmaceutically acceptable carrier or excipient, a culture medium, etc.

In specific embodiments, the invention provides fragments of a stabilized polypeptide consisting of at least 3 amino acids or of a stabilized polypeptide complex consisting of at least 6 amino acids, 10 amino acids, 20 amino acids, 50 amino acids, 100 amino acids, 200 amino acids, 500 amino acids, 1000 amino acids, 2000 amino acids, or of at least 5000 amino acids.

#### **5.1.1. POLYPEPTIDE DERIVATIVES AND ANALOGS**

Derivatives or analogs of proteins include those molecules comprising regions that are substantially homologous to a protein or fragment thereof (e.g., in various embodiments, at least 40% or 50% or 60% or 70% or 80% or 90% or 95% identity over an amino acid or nucleic acid sequence of identical size or when compared to an aligned sequence in which the alignment is done, for example, by a computer homology program known in the art) or whose encoding nucleic acid is capable of hybridizing to a coding gene sequence, under high stringency, moderate stringency, or low stringency conditions.

Further, one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity that acts as a functional equivalent, resulting in a silent alteration. Substitutions for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs. For example, the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophane and methionine. The polar neutral amino acids include glycine,

serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Such substitutions are generally understood to be conservative substitutions.

5           The derivatives and analogs of the polypeptides of the complex to be stabilized by application of the instant invention can be produced by various methods known in the art. The manipulations that result in their production can occur at the gene or protein level. For example, a cloned gene sequence can be modified by any of numerous strategies known in the art.

10           Chimeric polypeptides can be made comprising one or several of the polypeptides of a complex to be stabilized by the instant invention, or fragment, derivative, analog thereof (preferably consisting of at least a domain of a protein complex to be stabilized, or at least 6, and preferably at least 10 amino acids of the protein) joined at its amino- or carboxy-terminus via a peptide bond to an amino acid sequence of a different  
15 protein.

          Such a chimeric polypeptide can be produced by any known method, including: recombinant expression of a nucleic acid encoding the polypeptide (comprising a polypeptide coding sequence joined in-frame to a coding sequence for a different polypeptide); ligating the appropriate nucleic acid sequences encoding the desired amino  
20 acid sequences to each other in the proper coding frame, and expressing the chimeric product; and protein synthetic techniques, for example, by use of a peptide synthesizer.

#### **5.1.2. MANIPULATIONS OF A PROTEIN SEQUENCE AT THE PROTEIN LEVEL**

25           Included within the scope of the invention are polypeptides, polypeptide fragments, or other derivatives or analogs, which are differentially modified during or after translation or synthesis, for example, by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, etc.

          Any of numerous chemical modifications may be carried out by known  
30 techniques, including but not limited to, specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH<sub>4</sub>, acetylation, formylation, oxidation, reduction, metabolic synthesis in the presence of tunicamycin, etc.

          In addition, polypeptides, polypeptide fragments, or other derivatives or analogs that can be stabilized using the methods of the instant invention can be chemically  
35 synthesized. For example, a peptide corresponding to a portion of a protein can be synthesized by use of a peptide synthesizer. Furthermore, if desired, non-classical amino

acids or chemical amino acid analogs can be introduced as substitutions and/or additions into the sequence of one, any, both, several or all of the polypeptides of the complex.

Non-classical amino acids include, but are not limited to, the D-isomers of the common amino acids, fluoro-amino acids, designer amino acids such as  $\beta$ -methyl amino acids, C  $\gamma$ -methyl amino acids, N  $\gamma$ -methyl amino acids, and amino acid analogs in general.

Examples of non-classical amino acids include:  $\alpha$ -aminocaprylic acid, Acpa; (S)-2-aminoethyl-L-cysteine•HCl, Aecys; aminophenylacetate, Afa; 6-amino hexanoic acid, Ahx;  $\gamma$ -amino isobutyric acid and  $\alpha$ -aminoisobutyric acid, Aiba; 10 alloseleucine, Aile; L-allylglycine, Alg; 2-amino butyric acid, 4-aminobutyric acid, and  $\alpha$ -aminobutyric acid, Aba; p-aminophenylalanine, Aphe; b-alanine, Bal; p-bromophenylalanine, Brphe; cyclohexylalanine, Cha; citrulline, Cit;  $\beta$ -chloroalanine, Clala; cycloleucine, Cle; p-chlorophenylalanine, Clphe; cysteic acid, Cya; 2,4-diaminobutyric acid, Dab; 3-amino propionic acid and 2,3-diaminopropionic acid, Dap; 3,4-dehydroproline, 15 Dhp; 3,4-dihydroxyphenylalanine, Dhphe; p-fluorophenylalanine, Fphe; D-glucoseaminic acid, Gaa; homoarginine, Hag;  $\delta$ -hydroxylysine•HCl, Hlys; DL- $\beta$ -hydroxynorvaline, Hnvl; homoglutamine, Hog; homophenylalanine, Hoph; homoserine, Hos; hydroxyproline, Hpr; p-iodophenylalanine, Iphe; isoserine, Ise;  $\alpha$ -methyleucine, Mle; DL-methionine-S-methylsulfoniumchloride, Msmet; 3-(1-naphthyl) alanine, 1Nala; 3-(2-naphthyl) alanine, 20 2Nala; norleucine, Nle; N-methylalanine, Nmala; Norvaline, Nva; O-benzylserine, Obser; O-benzyltyrosine, Obtyr; O-ethyltyrosine, Oetyr; O-methylserine, Omser; O-methylthreonine, Omthr; O-methyltyrosine, Omtyr; Ornithine, Orn; phenylglycine; penicillamine, Pen; pyroglutamic acid, Pga; pipercolic acid, Pip; sarcosine, Sar; t-butylglycine; t-butylalanine; 3,3,3-trifluoroalanine, Tfa; 6-hydroxydopa, Thphe; L- 25 vinylglycine, Vig; (-)-(2R)-2-amino-3-(2-aminoethylsulfonyl) propanoic acid dihydrochloride, Aaspa; (2S)-2-amino-9-hydroxy-4,7-dioxanonanoic acid, Ahdna; (2S)-2-amino-6-hydroxy-4-oxahexanoic acid, Ahoha; (-)-(2R)-2-amino-3-(2-hydroxyethylsulfonyl) propanoic acid, Ahsopa; (-)-(2R)-2-amino-3-(2-hydroxyethylsulfonyl) propanoic acid, Ahspa; (2S)-2-amino-12-hydroxy-4,7,10- 30 trioxadodecanoic acid, Ahtda; (2S)-2,9-diamino-4,7-dioxanonanoic acid, Dadna; (2S)-2,12-diamino-4,7,10-trioxadodecanoic acid, Datda; (S)-5,5-difluoronorleucine, Dfnl; (S)-4,4-difluoronorvaline, Dfnv; (3R)-1,1-dioxo-[1,4]thiazine-3-carboxylic acid, Dtca; (S)-4,4,5,5,6,6,6-heptafluoronorleucine, Hfnl; (S)-5,5,6,6,6-pentafluoronorleucine, Pfnl; (S)-4,4,5,5,5-pentafluoronorvaline, Pfnv; and (3R)-1,4-thiazine-3-carboxylic acid, Tca. 35 Furthermore, the amino acid can be D (dextrorotary) or L (levorotary). For a review of



classical and non-classical amino acids, see Sandberg *et al.* (Sandberg M. *et al.* J. Med. Chem.; vol. 41(14): pp. 2481-91, 1998).

### 5.1.3. MOLECULAR BIOLOGICAL METHODS

5

Nucleic acids encoding one or more polypeptides stabilized by the methodology of instant invention are provided. The polypeptides, their derivatives, analogs, and/or chimers, of the complex can be made by expressing the DNA sequences that encode them *in vitro* or *in vivo* by any known method in the art. Nucleic acids encoding one, any, both, several, or all of the derivatives, analogs, and/or chimers of the complex to be stabilized by the methodology of the instant invention can be made by altering the nucleic acid sequence encoding the polypeptide or polypeptides by substitutions, additions (e.g., insertions) or deletions that provide for functionally active molecules. The sequences can be cleaved at appropriate sites with restriction endonuclease(s), followed by further enzymatic modification if desired, isolated, and ligated *in vivo* or *in vitro*. Additionally, a nucleic acid sequence can be mutated *in vitro* or *in vivo*, to create and/or destroy translation, initiation, and/or termination sequences, or to create variations in coding regions and/or to form new, or destroy preexisting, restriction endonuclease sites to facilitate further *in vitro* modification.

20

Due to the degeneracy of nucleotide coding sequences, many different nucleic acid sequences which encode substantially the same amino acid sequence as one, any, both, several, or all of the polypeptides of complex to be stabilized may be used in the practice of the present invention. These can include nucleotide sequences comprising all or portions of a domain which is altered by the substitution of different codons that encode the same amino acid, or a functionally equivalent amino acid residue within the sequence, thus producing a "silent" (functionally or phenotypically irrelevant) change.

Any technique for mutagenesis known in the art can be used, including but not limited to, chemical mutagenesis, *in vitro* site-directed mutagenesis, using, for example, the QuikChange Site-Directed Mutagenesis Kit (Stratagene), etc.

30

### 5.2. APPLICATIONS OF THE STABILIZATION TECHNOLOGY

The polypeptide and polypeptide complex stabilization methods of the invention have broad applicability. Some non-limiting examples are set forth below.

35

### 5.2.1. GENERAL

Polypeptide complexes which are held together in nature by domains that mediate protein-protein interactions may be stabilized using the methods of the invention. Further, single polypeptide chains may be stabilized using the methods of the invention to engineer intra-chain di-tyrosine cross links. As used herein, terms "complex", "protein or polypeptide complex", or "stabilized complex" mean of include either a single, or more than one polypeptide chain(s). For example, hormones (*e.g.* insulin, erythropoietin, human growth hormone or bovine growth hormone), other growth factors (*e.g.* insulin-like growth factors, neurotrophic factors) can be stabilized, either alone or together as a complex with a receptor or other protein binding partner (McInnes C. and Sykes B.D. *Biopolymers*; vol. 43(5): pp. 339-66, 1997). Examples of protein-protein interaction domains which may be stabilized using the methods of the invention include, but are not limited to, leucine-zipper domains (Alber T. *Curr. Opin. Genet. Dev.*; vol. 2(2): pp. 205-10, 1992), SH2 and SH3 domains (Pawson T. *Princess Takamatsu Symp.*; vol. 24: pp. 303-22, 1994), PTB and PDZ domains (Cowburn D. *Curr. Opin. Struct. Biol.*; vol. 7(6): pp. 835-8, 1997; Bockaert J. and Pin J.P. *EMBO J.*; vol. 18(7): pp. 1723-9, 1999), WD40 domains (Royet J. *et al.* *EMBO J.*; vol. 17(24): pp. 7351-60, 1998), death- and death effector domains (Strasser A. and Newton K. *Int. J. Biochem. Cell. Biol.*; vol. 31(5): pp. 533-7, 1999), disintegrin domains (Black R.A. and White J.M. *Curr Opin Cell Biol.*; vol. 10(5): pp. 654-9, 1998), and CARD domains (Chou J.J. *et al.* *Cell*; vol. 94(2): pp. 171-80, 1998).

Proteins which dimerize or multimerize to function may be stabilized using the methods of the invention. Such proteins include most immunoglobulin complexes, including the fragments that retain immunoglobulin functionality, such as, for example, Fab, F(ab)<sub>2</sub>, Fc, and Fv fragments (Penuche M.L. *et al.* *Hum Antibodies*; vol. 8(3): pp. 106-18, 1997; Sensel M.G. *et al.* *Chem. Immunol.*; vol. 65: pp. 129-58, 1997). Most cell-surface receptors that transmit extracellular signals to intracellular signaling systems dimerize and contain some of the above mentioned domains that mediate protein-protein interactions (McInnes C. and Sykes B.D. *Biopolymers*; vol. 43(5): pp. 339-66, 1997; Guogiang J. *et al.*; *Nature*; vol. 401: pp.606-610, 1999). Further examples are intracellular protein complexes, such as, for example, the caspases (Chou J.J. *et al.* *Cell*; vol. 94(2): pp. 171-80, 1998).

Growth factors which may be stabilized using the methods of the invention include, but are not limited to, those that dimerize to function, such as interleukin-8 (Leong S.R. *et al.* *Protein Sci.*; vol. 6(3): pp. 609-17, 1997) and members of the NGF/TGF family. These proteins are generally characterized as having 110-120 amino acid residues, up to 50% homology with each other, and are used for the treatment of a variety of health

disorders, such as cancer, osteoporosis, spinal cord injury and neuronal regeneration. Examples of the NGF family include, but are not limited to, NGF, BDNF, NT-3, NT-4/5, and NT-6, TRAIL, OPG, and FasL polypeptides (Lotz M. *et al.* J. Leukoc. Biol.; vol. 60(1): pp. 1-7, 1996; Casaccia-Bonnel P. *et al.* Microsc Res Tech.; vol. 45(4-5): pp. 217-24, 1999; Natoli G. *et al.* Biochem. Pharmacol.; vol. 56(8): pp. 915-20, 1998). TRAIL is currently in clinical trials, and may be useful to induce apoptosis in cancer cells. OPG is also in clinical trials and may be useful to strengthen bone tissue and prevent bone loss during menopause (Wickelgren I. Science; vol. 285(5430): pp. 998-1001, 1999).

Growth factors that do not dimerize to function in nature may also be stabilized using the methods of the invention. Such growth factors include, but are not limited to, insulin, erythropoietin, and any of the colony stimulating factors (CSFs) and PDGFs. These polypeptides can be stabilized by introducing intra-chain di-tyrosine bonds according to the invention.

Biocatalysts that may be stabilized using the methods of the invention include, but are not limited to, enzymes with applications in basic, applied, or industrial research, or industry sectors, that include, for example, the chemical, detergent, pharmaceutical, agricultural, food, cosmetics, textile, materials-processing, and paper industries. Within such industry sectors, stabilized biocatalysts may be utilized, e.g., for product synthesis, as active agents in products, in diagnostic testing equipment, or in any other applications known in the art. Such applications include, but are not limited to, wastewater and agricultural soil treatment, and crude oil refinement. Examples of synthetic applications include, but are not limited to, amino acid manufacturing and fine chemical synthesis. An example of use of a stabilized biocatalyst as an active agent in a product is in biological washing powders.

Biocatalysts to be stabilized may be selected from enzymes of any class, family, or other categorization of enzymes known in the art. Such enzymes include, but are not limited to, proteases, hydrolases, ligases, and polymerases. Each stabilized biocatalyst may comprise a single polypeptide chain or two or more polypeptide chains of a polypeptide complex.

### 5.2.2. IMMUNOGLOBULIN Fv FRAGMENTS

Antibodies or immunoglobulin molecules (Ig) are among the most therapeutically useful molecules. Their utility results from their ability to bind to given target molecules with extremely high specificity and affinity. Their function in the immune system is to bind to foreign molecules (such as those present on the surface of pathogens)

and to trigger the removal of these foreign molecules from the body using a variety of effector mechanisms.

With the advent of hybridoma technology, based on the work of G. Kohler and C. Milstein in the early 1980s, it has become possible to engineer pure clones of cells expressing a single antibody. The utility of such monoclonal antibodies (MAbs), whose unique binding specificity can be characterized in detail, is vast. From a monoclonal population of antibody-producing cells it is possible to isolate the genes encoding the polypeptide chains that make up the antibody. Efficient large-scale production of recombinant immunoglobulin in yeast or bacterial expression systems is an active interest of the biotechnology industry. More importantly, however, molecular biological techniques allow us to manipulate these genes and thereby produce antibody-derived proteins custom-tailored to individual applications, such as those described below.

One of the major limitations to the clinical effectiveness of antibodies is their size. Full-length immunoglobulin molecules are effective as humoral agents, but their size makes it difficult for them to penetrate tissues such as solid tumors. As a result, smaller, engineered versions of antibodies have been designed. Such engineered antibodies are designed to retain normal functional specificity with respect to antigen binding in a much smaller molecule, while at the same time uncoupling this binding function from the immunoglobulin molecule's other biological effector functions (e.g. complement activation or macrophage binding, Figure 1D).

Fv fragments have been shown to be the smallest Ig-derived fragments that retain full binding specificity (Figure 1D). The Fv fragment essentially comprises only those amino acid sequences of the antibody molecule that constitute the "variable domain" responsible for antigen binding. Due to their minimal size, Fv fragments show significantly better tissue penetration and can therefore be used in a broader range of contexts (e.g. solid tumor therapy). As used herein, Fv fragments shall include the variable region of immunoglobulin molecules or the equivalent or homologous region of a T cell receptor.

Amino acid sequence comparisons of the 110-120 residue long VH and VL regions reveal that each is made up of four relatively conserved sequence segments, called the "Framework Regions" (FRs), and three highly variable sequence segments, called "Complementarity Determining Regions" (CDR I, II, & III), which largely determine the specificity of the antibody (Figure 1D, "right arm").

The heavy and light chain Fv fragment polypeptides associate with each other largely at sites within the conserved FRs. Fv fragments, however, lack the structural stabilizing inter-chain di-sulfide bonds present in the Ig constant regions. In order to keep

recombinant Fv heavy and light chains associated and achieve functional stability and affinity, the two chains of the molecule must be "stabilized" by some other means.

### 5.3. BIOCATALYSTS

5

Biocatalysts are a preferred class of catalysts for industrial process development, due to their high specificity and process yields. Specifically, they allow for the use of less energy and less expensive feedstocks (starting materials), reduce the number of individual steps leading to a product, and reduce waste products. Their commercial use is, however, still limited by instability, curtailing key applications. This invention provides  
10 methods for stabilizing such enzymes, improving their performance as industrial catalysts, and prolonging their half-lives and shelf-lives. Application of the instant invention also enables the industrial use of novel, previously unstable, biocatalysts, and thereby also shortens industrial process innovation cycle times.

15

Specifically, application of the instant invention stabilizes biocatalysts, for example, by preventing the unfolding of the protein. This increases their ability to catalyze chemical reactions under adverse reaction conditions, prolongs their half- and shelf-lives, and maximizes their activity at milder, actual process temperatures.

20

### 5.4. OBTAINING POLYPEPTIDES TO BE STABILIZED

Any method known to one skilled in the art may be used to obtain a polypeptide or polypeptide complex to be stabilized according to the methods of the invention.

25

#### 5.4.1. PURIFICATION OF POLYPEPTIDES

A polypeptide or polypeptide complex to be stabilized using the methods of the instant invention may be obtained, for example, by any protein purification method known in the art. Such methods include, but are not limited to, chromatography (e.g. ion  
30 exchange, affinity, and/or sizing column chromatography), ammonium sulfate precipitation, centrifugation, differential solubility, or by any other standard technique for the purification of proteins. A polypeptide may be purified from any source that produces it. For example, polypeptides may be purified from sources including, prokaryotic, eukaryotic, mono-cellular, multi-cellular, animal, plant, fungus, vertebrate, mammalian, human, porcine,  
35 bovine, feline, equine, canine, avian, tissue culture cells, and any other natural, modified, engineered, or any otherwise not naturally occurring source. The degree of purity may vary,

but in various embodiments, the purified protein is greater than 50%, 75%, 85%, 95%, 99%, or 99.9% of the total mg protein. Thus, a crude cell lysate would not comprise a purified protein.

Where it is necessary to introduce one or more tyrosine residues to be cross-linked into a purified polypeptide or polypeptide complex, the polypeptide(s) can be micro-sequenced to determine a partial amino acid sequence. The partial amino acid sequence can then be used together with library screening and recombinant nucleic acid methods well known in the art to isolate the clones necessary to introduce tyrosines.

#### 5.4.2. EXPRESSION OF DNA ENCODING A POLYPEPTIDE

##### Source of DNA

Any prokaryotic or eukaryotic cell can serve as the nucleic acid source for molecular cloning. A nucleic acid sequence encoding a protein or domain to be cross-linked or stabilized may be isolated from sources including prokaryotic, eukaryotic, mono-cellular, multi-cellular, animal, plant, fungus, vertebrate, mammalian, human, porcine, bovine, feline, equine, canine, avian, etc.

The DNA may be obtained by standard procedures known in the art from cloned DNA (e.g., a DNA "library"), by chemical synthesis, by cDNA cloning, by the cloning of genomic DNA, or fragments thereof, purified from the desired cell (see e.g., Sambrook *et al.*; Glover (ed.). MRL Press, Ltd., Oxford, U.K.; vol. I, II, 1985). The DNA may also be obtained by reverse transcribing cellular RNA, prepared by any of the methods known in the art, such as random- or poly A-primed reverse transcription. Such DNA may be amplified using any of the methods known in the art, including PCR and 5' RACE techniques (Weis J.H. *et al.* Trends Genet. 8(8): pp. 263-4, 1992; Frohman M.A. PCR Methods Appl. 4(1): pp. S40-58, 1994).

Whatever the source, the gene should be molecularly cloned into a suitable vector for propagation of the gene. Additionally, the DNA may be cleaved at specific sites using various restriction enzymes, DNase may be used in the presence of manganese, or the DNA can be physically sheared, as for example, by sonication. The linear DNA fragments can then be separated according to size by standard techniques, such as agarose and polyacrylamide gel electrophoresis and column chromatography.

##### Cloning

Once the DNA fragments are generated, identification of the specific DNA fragment containing the desired gene may be accomplished in a number of ways. For example, clones can be isolated by using PCR techniques that may either use two

oligonucleotides specific for the desired sequence, or a single oligonucleotide specific for the desired sequence, using, for example, the 5' RACE system (Cale J.M. *et al.* Methods Mol. Biol.; vol.105: pp. 351-71, 1998; Frohman M.A. PCR Methods Appl.; vol. 4(1): pp. S40-58, 1994). The oligonucleotides may or may not contain degenerate nucleotide  
5 residues. Alternatively, if a portion of a gene or its specific RNA or a fragment thereof is available and can be purified and labeled, the generated DNA fragments may be screened by nucleic acid hybridization to the labeled probe (e.g. Benton and Davis. Science; vol. 196(4286): pp. 180-2, 1977). Those DNA fragments with substantial homology to the probe will hybridize. It is also possible to identify the appropriate fragment by restriction  
10 enzyme digestion(s) and comparison of fragment sizes with those expected according to a known restriction map if such is available. Further selection can be carried out on the basis of the properties of the gene.

The presence of the desired gene may also be detected by assays based on the physical, chemical, or immunological properties of its expressed product. For example,  
15 cDNA clones, or DNA clones which hybrid-select the proper mRNAs, can be selected and expressed to produce a protein that has, for example, similar or identical electrophoretic migration, isoelectric focusing behavior, proteolytic digestion maps, hormonal or other biological activity, binding activity, or antigenic properties as known for a protein.

Using an antibody to a known protein, other proteins may be identified by  
20 binding of the labeled antibody to expressed putative proteins, for example, in an ELISA (enzyme-linked immunosorbent assay)-type procedure. Further, using a binding protein specific to a known protein, other proteins may be identified by binding to such a protein either in vitro or a suitable cell system, such as the yeast-two-hybrid system (see e.g. Clemmons D.R. Mol. Reprod. Dev.; vol. 35: pp. 368-374, 1993; Loddick S.A. *et al.* Proc.  
25 Natl. Acad. Sci., U.S.A.; vol. 95: pp. 1894-1898, 1998).

A gene can also be identified by mRNA selection using nucleic acid hybridization followed by *in vitro* translation. In this procedure, fragments are used to isolate complementary mRNAs by hybridization. Such DNA fragments may represent  
30 available, purified DNA of another species (e.g., *Drosophila*, mouse, human). Immunoprecipitation analysis or functional assays (e.g. aggregation ability *in vitro*, binding to receptor, etc.) of the *in vitro* translation products of the isolated products of the isolated mRNAs identifies the mRNA and, therefore, the complementary DNA fragments that contain the desired sequences.

35 In addition, specific mRNAs may be selected by adsorption of polysomes isolated from cells to immobilized antibodies specifically directed against protein. A radiolabeled cDNA can be synthesized using the selected mRNA (from the adsorbed

polysomes) as a template. The radiolabeled mRNA or cDNA may then be used as a probe to identify the DNA fragments from among other genomic DNA fragments.

Alternatives to isolating the genomic DNA include, chemically synthesizing the gene sequence itself from a known sequence or making cDNA to the mRNA which  
5 encodes the protein. For example, RNA for cDNA cloning of the gene can be isolated from cells that express the gene.

### Vectors

The identified and isolated gene can then be inserted into an appropriate  
10 cloning or expression vector. A large number of vector-host systems known in the art may be used. Possible vectors include plasmids or modified viruses, but the vector system must be compatible with the host cell used. Such vectors include bacteriophages such as lambda derivatives, or plasmids such as PBR322 or pUC plasmid derivatives or the Bluescript vector (Stratagene).

15 The insertion into a cloning vector can, for example, be accomplished by ligating the DNA fragment into a cloning vector that has complementary cohesive termini. However, if the complementary restriction sites used to fragment the DNA are not present in the cloning vector, the ends of the DNA molecules may be enzymatically modified. Alternatively, any site desired may be produced by ligating nucleotide sequences (linkers)  
20 onto the DNA termini; these ligated linkers may comprise specific chemically synthesized oligonucleotides encoding restriction endonuclease recognition sequences. Furthermore, the gene and/or the vector may be amplified using PCR techniques and oligonucleotides specific for the termini of the gene and/or the vector that contain additional nucleotides that provide the desired complementary cohesive termini. In alternative methods, the cleaved  
25 vector and a gene may be modified by homopolymeric tailing (Cale J.M. *et al.* Methods Mol. Biol.; vol. 105: pp. 351-71, 1998). Recombinant molecules can be introduced into host cells via transformation, transfection, infection, electroporation, etc., so that many copies of the gene sequence are generated.

### Preparation of DNA

30 In specific embodiments, transformation of host cells with recombinant DNA molecules that incorporate an isolated gene, cDNA, or synthesized DNA sequence enables generation of multiple copies of the gene. Thus, the gene may be obtained in large quantities by growing transformants, isolating the recombinant DNA molecules from the transformants and, when necessary, retrieving the inserted gene from the isolated  
35 recombinant DNA.



The sequences provided by the instant invention include those nucleotide sequences encoding substantially the same amino acid sequences as found in native proteins, and those encoded amino acid sequences with functionally equivalent amino acids, as well as those encoding other derivatives or analogs, as described below for derivatives and analogs.

### Structure of Genes and Proteins

The amino acid sequence of a protein can be derived by deduction from the DNA sequence, or alternatively, by direct sequencing of the protein, for example, with an automated amino acid sequencer.

A protein sequence can be further characterized by a hydrophilicity analysis (Hopp T.P. and Woods K.R. Proc. Natl. Acad. Sci., U.S.A.; vol. 78: pp. 3824, 1981). A hydrophilicity profile can be used to identify the hydrophobic and hydrophilic regions of the protein and the corresponding regions of the gene sequence which encode such regions.

Secondary, structural analysis (Chou P.Y. and Fasman G.D. Biochemistry; vol. 13(2): pp. 222-45, 1974) can also be done, to identify regions of a protein that assume specific secondary structures. Manipulation, translation, and secondary structure prediction, open reading frame prediction and plotting, as well as determination of sequence homologies, can also be accomplished using computer software programs available in the art. Other methods of structural analysis include X-ray crystallography, nuclear magnetic resonance spectroscopy and computer modeling.

## **5.5. SUITABLE RESIDUES FOR A CROSS-LINKING REACTION**

The identification and/or engineering of suitable residues for a cross-linking reaction may involve one or more of the several steps set forth below.

### **5.5.1. INTRODUCTION OF POINT MUTATIONS TO CONTROL THE CROSS-LINK REACTION**

Engineering the overall structure and function of a stabilized polypeptide or polypeptide complex is achieved by controlling the availability of tyrosyl side-chains for the cross-linking reaction, for example, but not limited to, via mutagenesis. Functionality of a polypeptide or polypeptide complex may be compromised or altered by a tyrosine-tyrosine cross-link reaction. In this case, an undesirable hydroxyl group of a tyrosyl side-chain may be removed by mutating such residues to phenylalanine, or may be asked to inhibit its participation in such a reaction. In this way, a tyrosyl residue available for the cross-linking reaction but that may lead to distortion of structure and compromise functionality and/or

specificity of the polypeptide or polypeptide complex is removed. Moreover, point mutations to tyrosine may be introduced at positions where the tyrosyl side-chains will react with each other to form a bond that causes the least distortion to structure and function; these positions are identified as described in detail below. Thereby, the overall structure and functionality of the polypeptide or polypeptide complex is maintained.

### 5.5.2. REMOVING UNDESIRABLE REACTIVE SIDE-CHAINS

Reactive side-chains identified in a polypeptide chain or in the polypeptide chains of a complex are identified that subjected to the conditions of the oxidative cross-link described above would result in a bond that would distort the structure of the complex. These residues are identified by comparison of the polypeptides' amino acid sequences to available structural information on such or similar complexes (see below). Such a bond can be formed either between two polypeptide chains of the complex (inter-chain bond) or between two residues of one and the same polypeptide chain (intra-chain bond). The effect of the formation of a bond is determined by both of the reactive side-chains involved in the formation of such a bond, and therefore these residues would be identified in pairs.

To neutralize this damaging effect of the cross-link reaction, masking reagents that protect aromatic side chains (Pollitt S. and Schultz P. Agnew. Chem. Int. Ed.; vol. 37(15): pp. 2104-2107, 1998) may be use, or amino acid substitutions to phenylalanine, or any other amino acid, may be introduced at least at one of the residues involved, for example, by introducing a point mutation in the cDNA of the gene directing the expression of the polypeptide.

### 5.5.3. INTRODUCING REACTIVE SIDE-CHAINS

To achieve a stabilized polypeptide or polypeptide complex without disrupting its structure and/or function, positions within each polypeptide are identified at which a reactive side-chain would be able to form a bond with a reactive side-chain on the, or one of the, other polypeptide chain(s). Such positions are selected both with respect toward maintaining the overall structure of the same polypeptide, and with respect toward the suitability of a position in the other polypeptide involved in the bond, and the positions are therefore selected in pairs (see below for detailed description of selection process).

When at a selected residue of either, or any, polypeptide(s) the reactive tyrosyl side-chain is not already present, a point mutation may be introduced, for example, but not limited to, by using molecular biological methods to introduce such a point mutation

into the cDNA of the gene directing its expression, such that a reactive side-chain is present and available for the reaction.

## 5.6. STRUCTURALLY CONSERVED DOMAINS

### 5.6.1. RELATIONSHIP BETWEEN STRUCTURE AND FUNCTION

It is the three-dimensional, or the tertiary, structure of every protein, and the quaternary structure of every protein complex that lends them the functionality that has allowed them to be maintained and developed through the evolutionary process over time.

- 10 A point mutation in the gene of a polypeptide or polypeptide complex that leads to an amino acid substitution at any given residue will alter the structure of the polypeptide and/or of the overall complex to a greater or lesser extent. The extent of such an amino acid substitution's effect on the structure of the polypeptide or polypeptide complex is dependent on the structural context of the residue, and on the nature of the resultant amino acid's side-chain.

- 15 chain.
- Protein domains that show extensive similarity in their amino acid sequences to domains in other proteins are referred to as "conserved domains". Within conserved domains individual residues are more conserved than others; some can be 100% conserved, and others not at all. Most conserved domains are not only similar in their amino acid
- 20 sequences, but also in their three-dimensional structures, and also in their functions. In the absence of evolutionary pressures that require a residue of a domain to be conserved, it is thought that the amino acid present at a residue would vary widely due to the rate of mutation that drives evolutionary diversification. Hence, the residues within a conserved domain that are highly conserved are thought to be important contributors to the overall
- 25 structure, or the architecture, of the domain. Among the residues that are less conserved are those that contribute to the specificity of the individual domain of the group.

- Conserved domains, however, can also show very little sequence homology and yet have conserved structures, such as, for examples, leucine zippers (Alber T. Curr. Opin. Genet. Dev.; vol. 2(2): pp. 205-10, 1992). Since a conserved structure also yields
- 30 structurally conserved residues, the distinction between the above described 'architectural' and 'specificity determining' residues can also be made in the absence of sequence conservation. For the purposes of the instant invention, a conserved domain is defined, depending on the availability of data, either by sequence homology, which can be as low as 5% identity or similarity, or by the group of domains' structure or functionally.

35

### 5.6.2. ALIGNMENT OF CONSERVED RESIDUES

Alignment of the two-dimensional sequences of conserved domains reveals further that between conserved residues there are frequently interspersed by chains of varying lengths, i.e. there are varying numbers of amino acid residues between conserved residues important for the overall structure of the domain. In order to be able to compare the sequences of individual domains to determine where to direct the cross-link reaction to, it is essential that the sequences are aligned in such a way that amino acids that correspond structurally to one another are compared. For residues identified from amino acid and nucleotide sequence analyses as highly conserved, this is easily accomplished.

### 5.7. STATISTICAL SELECTION METHOD

The selection of residue pairs to which the cross-link can be directed to stabilize a polypeptide or complex functionally is preferably carried out by analyzing data on several structures of a group of conserved domains and their ligands statistically and selecting the residue pairs based on selection criteria developed as described below. From the measurements that are made on a set of data, it is possible to make predictions for the suitability of residue pair selections of such domains that are, and that are not, present in the sample. A residue that is highly conserved in the sample has a high likelihood of having similarity in all individual domains, including those not present in the sample. Therefore, using statistical analyses to determine to which residue pair(s) the cross-link reaction should be directed lends this technology a higher degree of generally applicability.

Where it is not possible or inconvenient to obtain the required data for such analyses, residue pairs can also be selected in any other way, including, for example, trial and error. Such selection processes yield residue pairs to which the cross-link can be directed while maintaining the functionality of the polypeptide or polypeptide complex.

Given the availability of relevant data, it is often possible to assign quantitative values for certain characteristics of an amino acid side chain present at each residue of a domain. Furthermore, given the relevant data on polypeptides or polypeptide complexes, it is possible to give pairs of amino acids values that describe their relationship.

These values can be compared between individual domains by aligning the data in such a way that the sets of values to be compared are structurally and functionally related (see above). If there is a sufficiently large number of individual domains for which such data is available, it is also possible to analyze these sets of data statistically.

Statistical analysis of such sets of data provides information concerning the degree of a residue's structural conservation and/or variability in the sample, and an

indication to what extent a residue is involved in providing the underlying architecture of a domain. This information is derived from statistical measurements such as variance, standard deviation, range, maximum and minimum, and others. High values from such measurement imply high variability of the residue's values, and thus a low degree of conservation, and *vice versa*.

## 5.8. SELECTION CRITERIA FOR AMINO ACID RESIDUE SUBSTITUTIONS

10

### 5.8.1. STRUCTURAL SUITABILITY

The object of the analyses is to determine which residue pairs will be most suited for the cross-link reaction in order to main the structure, function, and specificity of a polypeptide or polypeptide complex. Therefore, many of the criteria the residue pairs are selected for relate to the pairs' potential to accommodate two cross-linked reactive side-chains without distorting the peptide-bond backbone and altering the structure of the polypeptide or complex at positions that enable and define its function and specificity.

Measurements that can be made to attain information concerning this potential relate to the determinants of the space available for the reactive side-chains and the bond. Such measurements include the distance between the residue pairs' alpha-carbons, which are the carbon atoms that are a part of the "backbone" formed by the peptide bonds between all amino acids of the polypeptide. The selected residue pairs should have an average alpha-carbon distance close to the distance that the alpha-carbons of the cross-linked tyrosyl side-chains would be from each other if point mutations were introduced, and the cross-link reaction were directed to that residue pair. The selected residue pairs should be should be so close to the distance of the alpha-carbons of cross-linked tyrosyl side-chains to ensure that the functionality of the polypeptide or polypeptide complex is maintained. The criteria for this selection are described in detail below (Selection Process: Determination of the Alpha Carbon Distance in the Tyrosyl-tyrosyl Bond, The Filters). Since the variability of a residue pair's structural characteristics is also an important criterion in the selection of suitable residue pairs for the cross-link reaction (see below), the required proximity to the optimal distance is calculated for each residue pair, dependent on the variability of its alpha-carbon distances in the sample. The calculation of this requirement is also described in detail below (Selection Process: The Filters).

35

Measurements can also be made to determine whether the protein will fold in such a way that the reactive side-chains will be directed toward each other. Selection

criteria can be developed based on the angles of the reactive side-chains and of the cross-link, the rotational freedom of the reactive side-chains, and measurements concerned with the three-dimensional geometrical relationship between the alpha-carbons and the beta-carbons of each residue pair. The beta carbon is the first carbon atom of the amino acid side-chains not part of the backbone. Such selection criteria are described in detail below (Selection Process: Calculations of Side-chain Angles in the Tyrosyl Bond, The Filters). The smallest amino acid, glycine, does not have a beta-carbon, and therefore residue pairs of which one or both of the amino acids is a conserved glycine cannot be analyzed in this way. Since mutation of a conserved glycine would likely lead to a significant structural distortion, residue pairs of which one or both residues are a conserved glycine are eliminated. This selection criterion is also described in detail below (Selection Process: The Filters).

Furthermore, the structural context of the residue pair is preferably considered to ascertain the availability of three-dimensional space for the reactive side-chains and the bond. The relevant amino acid side-chain characteristics of proximal residues therefore are preferably taken into account, to further substantiate that the reactive side-chains will be able to rotate such that the bond can be formed without distorting the polypeptide backbone. If the context is such that the reactive side-chains introduced by point mutation will not be able to rotate freely into the desired position, the bond will either not readily be formed, or distortions will occur that could potentially impair or alter the function and/or specificity of the polypeptide or polypeptide complex. Therefore, selection criteria are developed to allow more conservative point mutations to be introduced that will be less likely to cause structural distortions. Such criteria are based on the amino acids present at, and surrounding, the residues of a pair, and are quantified based on numeric values of the physical properties of those amino acid side-chains. The calculation of such requirements is described in detail below (Selection Process: The Filters).

If a suitable residue pair can be identified that is already an appropriated reactive amino acid on both chains at some frequency in the sample, this pair would be an ideal selection. However, reactive side-chains present in the polypeptide or polypeptides of the complex to be cross-linked that would cause structural distortions by forming either inter- or intra-chain bonds should be neutralized, either by a means of masking/protecting them (Pollitt S. and Schultz P. Agnew. Chem. Int. Ed.; vol. 37(15): pp. 2104-2107, 1998) or by introducing maximally conservative point mutations. Such reactive residue pairs are identified using the same criteria as for the positive selection of residue pairs suitable for cross-linking. However, the presence of undesirable side-chains can only be determined by

analyzing the specific sequence of an individual domain, and by comparing it with the structural information used for the positive selection.

### 5.8.2. VARIABILITY

5

The specificity of each individual domain and its counterpart in the same polypeptide or in another polypeptide of a complex is generally determined by residues that are less, or not, conserved. Therefore, considering the specificity of an individual domain, a residue with high variability can be a less desirable choice to which to direct the cross-link  
10 reaction. However, considering the overall structure and architecture of a domain, the architecture of the domain can more likely accommodate a mutation at a residue that exhibits a high degree of variability. Thus, from this perspective, high variability indicates that a residue is a better candidate at which to introduce a point mutation, and place a reactive side-chain.

15

Depending on the reliability and accuracy of these analyses, which, in turn, depends on the reliability of the inputs into the analyses (see below), it is possible to vary the requirement for a position's, or a pair's variability (which indicates a certain degree of flexibility and/or robustness). Thus, if the inputs are highly accurate, and sufficient data is present in the sample, it is possible to determine that a residue pair is highly suitable for the  
20 reaction although its variability is low. However, in cases where there is insufficient data or insufficient accuracy in the inputs for the analyses to allow for low variability, a residue that is important for the specificity, but not for the overall architecture of the domain may be selected.

In the absence of functional data it is very difficult to determine a residue's  
25 contribution to the specificity of the domain.

## 5.9. GENERATION AND USE OF DATABASES

### 5.9.1. GENERATING DATA RELEVANT TO THE SELECTION CRITERIA

30

The increasing availability of data concerning the genes, proteins, and other bio-molecules of many living species, make it possible to compile a significant amount of data on several protein domains/modules for statistical analyses to make the predictions described above. This data can be transformed into data that can be utilized for such analyses directly.

35

Such transformations can, for instance, be done by converting nucleotide data into amino acid sequence data, and further by converting amino acid sequence data into

numeric data concerning the physical properties of the amino acids' side-chains of a given residue. Such properties, for instance, can be the charge or the degree of hydrophobicity of a residue's side-chains.

Furthermore, structural data of a polypeptide or of two or more polypeptides  
5 in a complex can be transformed into numerical data that describes the structural  
relationships among the individual residues of a single polypeptide and/or among the  
several polypeptides of a the complex. An example for such a transformation would be the  
calculation of the distances between the alpha carbons of a residue pair using three-  
dimensional coordinate data derived from crystallographic resolution of a structure using  
10 Pythagorean three-dimensional geometry.

It is possible to generate many different sets of data relevant for the  
stabilization according to the procedure of this invention concerning many of the structural  
features of the residues and residues pairs of a domain or a complex. As often more  
qualitative judgements are required to determine the reliability of the selection inputs, it  
15 also becomes a more qualitative decision how many different sets of data should be used in  
the selection of the residue pairs that should form the stabilizing bond. The less reliable the  
inputs, the more useful it is to implement additional information in the selection.

## 20 5.9.2. DATA SOURCES

### Sequence Data

The most direct way of accumulating sequences is by cloning and  
sequencing cDNAs of proteins that contain the domains/modules of interest. Sequence data  
is becoming more and more available through the efforts of the genome projects. Much of  
25 the sequence data is available in databases that can be accessed through the internet, or  
otherwise, and furthermore there are several published sources that have accumulated  
sequences of specific domains/modules. One such collection of specific sequence data is  
the Kabat Database of Sequences of Proteins of Immunological Interest  
(<http://immuno.bme.nwu.edu>; Johnson, G. *et al.* Weir's Handbook of Experimental  
30 Immunology I. Immunochemistry and Molecular Immunology, Fifth Edition, Ed. L. A.  
Herzenberg, W. M. Weir, and C. Blackwell, Blackwell Science Inc., Cambridge, MA,  
Chapter 6.1-6.21, 1996) that contains, among other things, sequences of immunoglobulin  
molecules (see Section VI, Examples). Such sequence data is also available from Genebank  
(<http://www.ncbi.nlm.nih.gov>).

### 35 Structural Data



Three-dimensional structures, as described by atomic coordinate data, of a polypeptide or complex of two or more polypeptides can be obtained in several ways.

The first approach is to mine databases of existing structural co-ordinates for the proteins of interest. The data of solved structures is often available on databases that are easily accessed in the form of three-dimensional coordinates (x, y, and z) in Angstrom units (Å or  $10^{-10}$  meters). Often this data is also accessible through the internet (e.g. on-line protein structure database of the National Brookhaven Laboratory: [www.nbl.pdb.gov](http://www.nbl.pdb.gov)).

The second utilizes diffraction patterns (by for example, but not limited to X-rays or electrons) of regular 2- or 3-dimensional arrays of proteins as for example used in the field of X-ray crystallography. Computational methods are used to transform such data into 3-dimensional atomic co-ordinates in real space.

The third utilizes Nuclear Magnetic Resonance (NMR) to determine inter-atomic distances of molecules in solution. Multi-dimensional NMR methods combined with computational methods have succeeded in determining the atomic co-ordinates of polypeptides of increasing size.

A fourth approach consists entirely of computational modeling. Algorithms may be based on the known physio-chemical nature of amino-acids and bonds found in proteins, or on iterative approaches that are experimentally constrained, or both. An example of software is the CNS program developed by Axel Brunger and colleagues at the HHMI at Yale University (Adams P.D. *et al.* Acta Crystallogr. D. Biol. Crystallogr.; vol. 55 ( Pt 1): pp. 181-90, 1999).

#### Functional Data

Functional data is not as easily used, as there is no uniform way of standardizing and compiling it, such as nucleotide or amino acid sequence data, or coordinates for structural data. It is generated in many different ways, such as genetic, biochemical, and mutational analyses, molecular biological dissection and the construction of chimerical domains. In many cases the data available is not always clearly interpretable and therefore its use becomes less clearly delineated. But when available, function data provides valuable information concerning the specificity and functionality of a domain/module, and where possible is preferably incorporated into the selection process.

Functional data is preferably also generated after the cross-link reaction according to the present invention to ensure that the predictions made were accurate for the specific application, and that the polypeptide or polypeptide complex actually retained its functionality and specificity.

### 5.9.3. CONSTRUCTION OF DATABASES

#### 3-D Database

A database of structural information including the atomic coordinate data of crystallographically solved polypeptides and polypeptide complexes of a group of conserved polypeptides or domains and their ligands, and derivative, relevant data is compiled. Input data is derived from structural coordinate data files. Data relevant to the selection process in this database is derived from coordinate data by applying coordinate geometry in three dimensions. This database preferably contains, for example, in addition to the structural coordinate data, the following, relevant data together with statistical measurements (e.g. mean, median, mode, standard deviation, maximum, and minimum) on each of the following features for each residue pair, whereby the sample polypeptides and polypeptide complexes are aligned as described above.

1. Inter-chain alpha carbon to alpha carbon distances of the polypeptide pair(s) of a polypeptide complex, in order to find residue pairs that are appropriately spaced for a tyrosyl-tyrosyl bond to be formed. These distances are calculated by, for instance, but not limited to, applying Pythagorean geometry to the 3D coordinates of the alpha carbons. For every residue pair statistical measurements are calculated, such as the average, standard deviation, range and median of corresponding alpha carbon-alpha carbon distances.
2. The three angles,  $\phi$ ,  $\chi$  and  $\psi$  (Figure 2c) in relation to which the side-chains of each residue pair are oriented toward each other relative to the inter-chain alpha carbon - alpha carbon axes, are calculated from the coordinates of the alpha and beta carbons of each pair for each polypeptide or polypeptide complex in the sample. The angles are calculated by defining two planes, each of which are defined by both alpha carbon positions and one of the beta carbons' positions. By applying analytical geometry, each of the angles in the alpha carbons (scalar products), and the angle formed by the planes (vector products) are calculated. Statistical measurements are also made from this set of data, as described for the alpha carbon spacing.

The difference between the alpha carbon distance (i.e. the backbone carbon distance) and the beta carbon distance (i.e. the distance between the first carbons in each side chain) of each residue pair can also be calculated as a proxy of the orientation of the side chains relative to each other (see below).

#### 2-D Database

A database of DNA or amino acid sequences of a polypeptide or polypeptides involved in complexes of a kind, including residue side-chain usage from sequence data and derivative, relevant data is compiled. Data relevant to the selection

process in this database is derived from sequence data by applying a numeric value representing the physical properties of every occurring amino acid side chain at each residue, whereby sample polypeptides and polypeptide complexes are aligned as described above. This database contains, for example, in addition to sequence data, the following, relevant data together with statistical measurements (e.g. mean, median, mode, standard deviation, maximum, and minimum) on each of the following features for each residue pair. The statistical measurements can be made and stored on the occurring amino acids at each residue both weighted and un-weighted by the frequency at which the specific side chain occurs at this residue.

1. Numeric data concerning the bulk/volume of residues' side chains, such as, but not limited to, chemical composition, molecular weight and van der Waals volumes (Xia X. and Li W.H.; Richards, F.M.).

2. Numeric data concerning the polarity of the residues side-chains, such as, but not limited to, charge, isoelectric point, and hydrophobicity (Xia X. and Li W.H.; Eisenberg, D.).

Examples of other amino acid side chain property measurements that can be incorporated in such a database are that can be analyzed are aromaticity, aliphaticity, hydrogenation, and hydroxythiolation (Xia X. and Li W.H.).

#### Database of Functional Data

Where it is possible to obtain functional data that indicates the importance of a residue/residue pair for a polypeptide or polypeptide complex' overall structure and/or specificity, it is preferably incorporated into the selection process, as it enhances the accuracy of the statistical predictions made. Such data is preferably quantified, to whatever degree possible, with respect to individual residues and/or residue pairs of a polypeptide or complex, or with respect to sub-domains or domains that mediate protein folding or protein-protein interactions, and compiled in a suitable database.

#### **5.9.4. REQUIRED SAMPLE SIZE (N)**

Often the availability of data is limiting for this approach. However, to make statistical measurements on a sample of polypeptides or polypeptide complexes in order to predict which residue pairs the cross-link should be directed to, it is, of course, best to use a large sample, as it will yield more accurate predictions. But often it is very labor-intensive accumulating and/or aligning the data in such a way that measurements become meaningful (see above). Since there is always a limited range of values, and since therefore their variability is also limited, accurate predictions can also be made from smaller sets of data.

A sample with more than 15 individual structures, sequences or functional units is preferable.

However, previously methods have been used to position other cross-links, such as di-sulfide bonds, by examining only the one polypeptide or complex in which the point mutations are to be made, and this has resulted in functional complexes (Pastan *et al.*, United States Patent No. 5,747,654 issued May 5, 1998). Therefore it is possible to make predictions that can be accurate on a small sample. However, in order to make predictions based on statistics that include such measurements as standard deviations, it is not meaningful to use a sample size less than three (a standard deviation on 2 points of data is not a meaningful measurement). Therefore the minimum of a sample size is three for any statistical analyses.

### 5.10. SELECTION PROCESS

#### 5.10.1. DETERMINATION OF THE ALPHA CARBON DISTANCE IN THE TYROSYL-TYROSYL BOND

As stated above, selected residue pairs should have an average alpha-carbon distance close to the distance of the alpha-carbons of cross-linked tyrosyl side-chains. The range of distances that is possible between the alpha carbons of two cross-linked tyrosines is calculated for the epsilon-epsilon bonded isoform of the cross-link by applying standard geometry, pythagorean geometry, and trigonometry. The calculations are based on all carbon-carbon bonds di-tyrosine bond forming 120 degree angles due to the planar structure of the aromatic ring with the exception of the angle in the beta carbon, which forms the tetrahedral angle of 109.5 degrees (Figure 2A).

Furthermore, these calculations take into consideration that the structure of the di-tyrosine has significant degrees of rotational freedom, and that therefore the distance between the alpha carbons of the two tyrosines can be quite different depending on its conformation. Specifically, the rotational freedoms in the beta carbon-gamma carbon bonds, and the rotational freedom in the bond linking the aromatic rings are considered. Other isoforms of the cross-link are, however, possible, which would enable even closer distances between the alpha-carbons of the di-tyrosine, which is further taken into consideration in setting the possible ranges in the selection process of the residue pairs, as described below in the "Filters".

The angle  $\chi$  in figure 2C is the angle formed by the two planes, each defined by the alpha carbon-alpha carbon axis, and individually by the positions of each of the beta carbons of the two tyrosyl side-chains involved in the bond. The angle  $\omega$ ,

determined by the rotational freedom in the di-tyrosine bond itself, is  $120^\circ$  in Figure 3, and  $-120^\circ$  in Figure 4.

The schematic depictions of possible bond configurations for an angle  $\omega$  of  $120^\circ$  in Figure 3 represent an angle  $\chi$  of  $180^\circ$ , at which both the maximal and minimal angles are in the projected plane. The schematic depictions of possible bond configurations for an angle  $\omega$  of  $120^\circ$  in Figure 4 represent an angle  $\chi$  of  $0^\circ$ , at which both the maximal and minimal angles are in the projected plane.

For an angle  $\omega$  of  $120^\circ$  and an angle  $\chi$  of  $180^\circ$ , and in the configuration at which the alpha carbon distance is at a minimum (Figure 3A), the alpha carbon distance is 11.74Å; in the configuration, in which the alpha carbon distance is at a maximum (Figure 3B), the alpha carbon distance is 9.56Å.

For an angle  $\omega$  of  $-120^\circ$  and an angle  $\chi$  of  $180^\circ$ , and in the configuration at which the alpha carbon distance is at a minimum (Figure 4A), the alpha carbon distance is 10.73Å; in the configuration, in which the alpha carbon distance is at a maximum (Figure 4B), the alpha carbon distance is 5.70Å.

#### 5.10.2. CALCULATIONS OF SIDE-CHAIN ANGLES IN THE TYROSYL BOND

The angles  $\phi$  and  $\psi$  (Figure 2C) are the angles in each of the alpha carbon atoms between the alpha carbon-alpha carbon axis and the alpha carbon-beta carbon bond. They are calculated for the maximum and minimum distances between the alpha carbon atoms based on the rotational flexibility of the carbon-carbon bonds in the beta carbon atom. The schematic depictions of possible bond configurations for an angle  $\omega$  of  $120^\circ$  in Figure 3 represent an angle  $\chi$  of  $180^\circ$ , at which both the maximal and minimal angles are in the projected plane. The schematic depictions of possible bond configurations for an angle  $\omega$  of  $120^\circ$  in Figure 4 represent an angle  $\chi$  of  $0^\circ$ , at which both the maximal and minimal angles are in the projected plane.

For an angle  $\omega$  of  $120^\circ$  and an angle  $\chi$  of  $180^\circ$ , and in the configuration at which the alpha carbon distance is at a minimum (Figure 3A), the angles  $\phi$  and  $\psi$  are maximal and equal at approximately 77.1°; in the configuration, in which the alpha carbon distance is at a maximum (Figure 3B), the angles  $\phi$  and  $\psi$  are minimal and equal, at approximately 34.5°.

For an angle  $\omega$  of  $-120^\circ$  and an angle  $\chi$  of  $0^\circ$ , at which the alpha carbon distance is at a minimum (Figure 4A), the angles  $\phi$  and  $\psi$  are maximal and equal at 130.5°;

in the configuration, in which the alpha carbon distance is at a maximum (Figure 3B), the angles  $\phi$  and  $\psi$  are minimal and equal, at 10.5°

#### Differences in the alpha-alpha and beta-beta distances

5 As a proxy to the orientation of the side-chains, the difference in the alpha-alpha and beta-beta distances ("alpha-beta distance difference") and its range are calculated again based on the extremes of alpha carbon spacing for angles  $\omega$  of 120° and -120° (Figures 3 and 4). The maximum and minimum of the alpha-beta distance difference is calculated for both  $\omega$  angles at which the both aromatic rings of the tyrosyl side-chains are in the same plane, and at which the alpha-beta distance difference is at its extremes. This difference is  
10 calculated by subtracting twice the length a from twice the length b in Figures 3 and 4.

For an angle  $\omega$  of 120° (Figure 3), and in the configuration, at which the alpha carbon distance is maximal, the alpha-beta distance difference is 2.37Å; in the configuration, at which the alpha carbon distance is minimal, the alpha-beta distance  
15 difference is 0.19Å. For an angle  $\omega$  of -120° (Figure 4), and in the configuration, at which the alpha carbon distance is maximal, the alpha-beta distance difference is 3.03Å; in the configuration, at which the alpha carbon distance is minimal, the alpha-beta distance difference is +2.00Å.

20

### 5.11. THE FILTERS

In cases where sufficient data is available, the selection process preferably consists of a series of statistical tests or "filters" aimed at successively narrowing down the residue pairs most likely to result in an inter-chain cross-linked tyrosine pair of a  
25 polypeptide or polypeptide complex that minimally alters the polypeptide's or polypeptide complex' structural characteristics. The filters are the following:

1. Selection based on residue pair alpha carbon spacing, based on (1) the calculated maximal and minimal distances in a cross-linked tyrosine pair (see above), and (2) the distances measured and compiled in a 3-D database. The selection is carried out  
30 on the average, median, mode, or any other statistical value suitable to determine whether the pair is likely to be spaced in such a way that the cross-link will minimally distort the overall structure. The optimal range of residue pair alpha carbon distances to be selected is determined by averaging first the minimal distances in a cross-linked tyrosine pair of the isoform depicted in figure 2B for  $\omega$  angles of 120° and -120°, and then, analogously,  
35 averaging the maximal distances, as calculated above. These calculations result in the following optimal range:

Min: 7.63 Å, Max: 11.24 Å.

Since distances are possible in a larger range, and because other isoforms are also possible that would allow for configurations with zero distance, the average between a zero-distance and the minimal distance between alpha carbons for either angle  $\omega$  provides the lower limit and the maximal distance between alpha carbons for either angle  $\omega$  provides the upper limit of the preferred range. Therefore, the preferred range is:

Min: 2.85 Å, Max: 11.74 Å

Furthermore, it has been demonstrated in several cases that a protein structure can often absorb a certain amount of structural changes, and that the specificity and functionality is nonetheless maintained. It is therefore also possible, though less preferred, to introduce the reactive side-chains into residue pairs that are spaced even beyond the preferred range. Given this degree of structural flexibility the largest range possible is:

Min: 0 Å, Max: 13.74 Å.

2. Selection based on positional flexibility is carried out, as examples, on the measured/calculated standard deviations or ranges of the alpha-carbon distances in the sample, or any other statistical measure that quantifies the variability of the pairs' distances measured/calculated and compiled in a 3-D database. The range for this selection is preferably set in such a way that the average measured alpha-carbon distance of the selected residue pairs is within less than one standard deviation of the preferred range. However, 2 standard deviations are also possible as a selection criterion.

3. Selection based on side-chain orientation, determined either by calculating the three-dimensional angles relative to the alpha-carbon-alpha carbon axis ( $\psi$ ,  $\phi$ , and  $\chi$  angles, as described in Figure 2C), or by calculating a proxy, e.g. an estimate of the orientation based on the alpha-beta distance difference described above. The selection is carried out on the average, median, mode, or any other statistical value of the angles, or the proxy, suitable to determine whether the side-chains of the pair are likely to be oriented such that the cross-link will minimally distort the overall structure.

The angle  $\chi$  can vary by  $360^\circ$ , and the bond is still possible without any distortion of the structure, so long as the angles  $\psi$  and  $\phi$  adjust correspondingly. Therefore, the selection range based on the angle  $\chi$  should be set by a metric driven by the angles  $\psi$ ,  $\phi$ , and  $\chi$  with a degree of flexibility similar to that for the angles  $\psi$  and  $\phi$ , or for the alpha-beta distance difference, the range for which is described below.

The range for the angles  $\psi$  and  $\phi$  is, analogous to the optimal range of alpha carbon distances in Filter 1, optimally between the averages of the extreme values calculated for the isoform of the di-tyrosine pair depicted in Figure 2B, and for  $\omega$  angles of 120° and 120°. This optimal range is thus between:

Min: 22.49°, Max: 103.80°.

Since these angles are possible in a larger range even within this one isoform of the di-tyrosine bond, and since the above optimal range is often too restrictive, the minimal angle for either angle  $\omega$  provides the lower limit and the maximal angle for either angle  $\omega$  provides the upper limit of the preferred range. Therefore, the preferred range is:

Min: 10.5°, Max: 130.5°.

Furthermore, it has been demonstrated in several cases that a protein structure can often absorb a certain amount of structural changes, and that the specificity and functionality is nonetheless maintained. It is therefore also possible, though less preferred, to introduce the reactive side-chains into residue pairs that have angles  $\psi$  and  $\phi$  even beyond the preferred range. Given this degree of structural flexibility the largest range possible is:

Min: 0°, Max: 140°.

The optimal range of residue pair alpha carbon distances to be selected is determined by averaging first the minimal alpha-beta distance difference in a cross-linked tyrosine pair of the isoform depicted in Figure 2B, and for  $\omega$  angles of 120° and 120°, and then, analogously, averaging the maximal alpha-beta distance difference, as calculated above. These calculations result in the following optimal range:

Min: 0.90Å, Max: 2.70 Å.

Since distance differences are possible in a larger range, and since the above optimal range is often too restrictive, the minimal alpha-beta distance difference for either angle  $\omega$  provides the lower limit and the maximal alpha-beta distance difference for either angle  $\omega$  provides the upper limit of the preferred range. Therefore, the preferred range is:

Min: -2.00Å, Max: 3.03Å.

Furthermore, it has been demonstrated in several cases that a protein structure can often absorb a certain amount of structural changes, and that the specificity and functionality is nonetheless maintained. Furthermore, other isoforms of the di-tyrosine bond are possible. It is therefore also possible, though less preferred, to introduce the



reactive side-chains into residue pairs that have alpha-beta distance difference even beyond the preferred range. Given this degree of structural flexibility the largest range possible is:

Min: -2.75Å, Max: 3.08Å.

5                   4.       The flexibility of the side-chains' orientation toward each other is measured on the standard deviation or range of the sample, as examples, or any other statistical measure that quantifies the variability of the side-chains of the pairs measured and compiled in a 3-D database. The range for this selection is preferably set in such a way that the average measured alpha-beta distance difference of the selected residue pairs is within  
10 less than one standard deviation of the preferred range. However, 2 standard deviations are also possible as a selection criterion.

                  5.       Pairs that contain one or both residues that are at least 95% or more, preferably 80% or more, possibly also 50% or more conserved among the domains in the sample are eliminated, as they are likely to be important for the overall architecture of the  
15 domain, e.g. cysteines in the formation of di-sulfide bonds, leucines in the formation of leucine zippers, etc.

                  6.       Side-chain physical properties, e.g. charge, hydrophobicity, van der Waals volumes, molecular weight, etc. The selection is carried out on the average, median, mode, or any other statistical value of these properties, individually or combined, suitable to  
20 determine whether the mutations to tyrosine and the cross-link between a residue pair will minimally distort the overall structure. The degree, to which a residue is conserved, is measured by the standard deviation or range, as examples, or any other statistical measure of the sample that quantifies the variability of the side-chains physical properties which are measured and compiled in a 2-D database.

25                   The range can be set, as an example, in the following manner: the value of a physical property for a tyrosine pair (2 x value of tyrosine) is compared with the combined value of both residues of a pair, and the difference is obtained by subtraction. The difference is then compared with the combined standard deviations of the residue pair. A  
30 multiple smaller than 2 of the combined standard deviations should make up for the difference between the value of a tyrosine pair and the combined averages of the residue pair. However, more direct or intuitive measures, as well as more sophisticated and accurate measures, can also be used to score and select for physical properties of residue pairs.

35                   7.       Elimination of pairs of which one or both residues are at a minimum 90% or more, conserved glycines, preferably 60% or more. Glycine is the smallest of the amino acids and has no beta carbon. Glycine is often associated with turns in protein

structures, and substitution of a glycine with one of the largest amino acids, tyrosine, would likely have too great an impact on the overall structure.

8. The above structural and/or amino acid side-chain conservation  
5 and/or physical properties of residues/residue pairs proximal to each residue/residue pair. Proximity can be determined with regard to both the polypeptide sequences (2-D) and the overall structure of the polypeptide or polypeptide complex (3-D).

9. Functional properties concerning the effect of a residue/residue pair  
on the functionality and/or specificity of the polypeptide or polypeptide complex.  
10

#### 5.11.1. INCORPORATION OF DATA DERIVED FROM MODELING

Particularly in embodiments of the instant invention, in which a single polypeptide is stabilized, such as, for example, a peptide growth factor or a biocatalyst, any  
15 of the known methods in the art may be employed to calculate and/or compute the effects of the mutations and/or the cross-link on the structure, stability, activity, or specificity of the resultant polypeptide. One example of such a software package is the above mentioned CNS (Adams P.D. et al. Acta Crystallogr. D. Biol. Crystallogr.; vol. 55 ( Pt 1): pp. 181-90, 1999) using the CHARMM energy minimization plug-in. Data derived from such analyses  
20 may be used to further narrow down the selection or residue pairs, and may also be used to inform the settings of the above selection parameters, such as, for example, the selection ranges.

#### 5.11.2. MINIMALLY REQUIRED FILTERS FOR SELECTION

25 Depending on the nature of the polypeptide or polypeptide complex, and on the availability of data, a subset of filters can, however, suffice to select a suitable pair for the cross-link reaction. For instance, a filter based on the average of residue alpha carbon spacing (Filter 1, above) can be used alone. It is also possible to make a selection using the  
30 above filters 6 and 7, both based on the degree to which residues are conserved, if structural data is available for at least one structure of such a polypeptide or polypeptide complex. Any one or more of the above filters, and any combination thereof can be used for the selection.

The order of the filters is not of importance. Furthermore, where it would  
35 add to the quality of the selection, the above filters can be split in to two or more filters to stress certain aspects of the filter. Filters can additionally be combined by designing metrics that quantify several criteria simultaneously. Thereby, for instance, the selection

can be refined further by selecting one criterion taking the value of another criterion into account.

5

## 5.12. DNA VECTOR CONSTRUCTS

The nucleotide sequence coding for the polypeptide, or for one, any, both, several or all of the polypeptides of a complex, or functionally active analogs or fragments or other derivatives thereof, can be inserted into an appropriate expansion or expression vectors, i.e., a vector which contains the necessary elements for the transcription alone, or  
10 transcription and translation, of the inserted protein-coding sequence(s). The native genes and/or their flanking sequences can also supply the necessary transcriptional and/or translational signals.

Expression of a nucleic acid sequence encoding a polypeptide or peptide fragment may be regulated by a second nucleic acid sequence so that the polypeptide is  
15 expressed in a host transformed with the recombinant DNA molecule. For example, expression of a polypeptide may be controlled by any promoter/enhancer element known in the art.

Promoters which may be used to control gene expression include, as  
20 examples, the SV40 early promoter region, the promoter contained in the 3' long terminal repeat of Rous sarcoma, the herpes thymidine kinase promoter, the regulatory sequences of the metallothionein gene; prokaryotic expression vectors such as the  $\beta$ -lactamase promoter, or the lac promoter; plant expression vectors comprising the nopaline synthetase promoter or the cauliflower mosaic virus 35S RNA promoter, and the promoter of the photosynthetic  
25 enzyme ribulose biphosphate carboxylase; promoter elements from yeast or other fungi such as the Gal 4 promoter, the alcohol dehydrogenase promoter, phosphoglycerol kinase promoter, alkaline phosphatase promoter, and the following animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals:  
elastase I gene control region which is active in pancreatic acinar cells (Swift et al. Cell;  
30 vol. 38: pp. 639-646, 1984); a gene control region which is active in pancreatic beta cells (Hanahan D., Nature; vol. 315: pp. 115-122, 1985), an immunoglobulin gene control region which is active in lymphoid cells (Grosschedl R. et al. Cell; vol. 38: pp. 647-658, 1984),  
mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder A. et al. Cell; vol. 45: pp. 485-495, 1986), albumin gene control  
35 region which is active in liver (Pinkert C.A. et al. Genes Dev.; vol. 1: pp. 268-276, 1987), alpha-fetoprotein gene control region which is active in liver (Krumlauf R. et al. Mol. Cell. Biol.; vol. 5: pp. 1639-1648, 1985); alpha 1-antitrypsin gene control region which is active

in the liver (Kelsey G.D. *et al.* Genes Dev.; vol. 1: pp. 161-171, 1987), beta-globin gene control region which is active in myeloid cells (Magram J. *et al.* Nature; vol. 315: pp. 338-340, 1985); myelin basic protein gene control region which is active in oligodendrocyte cells in the brain (Readhead C. *et al.* Cell; vol. 48: pp. 703-712, 1987); myosin light chain-2 gene control region which is active in skeletal muscle (Shani M. Nature; vol. 314: pp. 283-286, 1985), and gonadotropic releasing hormone gene control region which is active in the hypothalamus (Mason A.J. *et al.* Science; vol. 234: pp. 1372-1378, 1986).

In a specific embodiment, a vector is used that comprises a promoter operably linked to a gene nucleic acid, one or more origins of replication, and, optionally, one or more selectable markers (e.g., an antibiotic resistance gene). In bacteria, the expression system may comprise the lac-response system for selection of bacteria that contain the vector. Expression constructs can be made, for example, by subcloning a coding sequence into one the restriction sites of each or any of the pGEX vectors (Pharmacia, Smith D.B. and Johnson K.S. Gene; vol. 67: pp. 31-40, 1988). This allows for the expression of the protein product.

Vectors containing gene inserts can be identified by three general approaches: (a) identification of specific one or several attributes of the DNA itself, such as, for example, fragment lengths yielded by restriction endonuclease treatment, direct sequencing, PCR, or nucleic acid hybridization ; (b) presence or absence of "marker" gene functions; and, where the vector is an expression vector, (c) expression of inserted sequences. In the first approach, the presence of a gene inserted in a vector can be detected, for example, by sequencing, PCR or nucleic acid hybridization using probes comprising sequences that are homologous to an inserted gene. In the second approach, the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "marker" gene functions (e.g., thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of a gene in the vector. For example, if the gene is inserted within the marker gene sequence of the vector, recombinants containing the insert are identified by the absence of the marker gene function. In the third approach, recombinant expression vectors can be identified by assaying the product expressed by the recombinant expression vectors containing the inserted sequences. Such assays can be based, for example, on the physical or functional properties of the protein in *in vitro* assay systems, for example, binding with anti-protein antibody.

Once a particular recombinant DNA molecule is identified and isolated, several methods known in the art may be used to propagate it. Once a suitable host system

and growth conditions are established, recombinant expression vectors can be propagated and prepared in quantity. Some of the expression vectors that can be used include human or animal viruses such as vaccinia virus or adenovirus; insect viruses such as baculovirus; yeast vectors; bacteriophage vectors (e.g., lambda phage), and plasmid and cosmid DNA  
5 vectors.

Once a recombinant vector that directs the expression of a desired sequence is identified, the gene product can be analyzed. This is achieved by assays based on the physical or functional properties of the product, including radioactive labeling of the  
10 product followed by analysis by gel electrophoresis, immunoassay, etc.

### 5.13. SYSTEMS OF GENE EXPRESSION AND PROTEIN PURIFICATION

A variety of host-vector systems may be utilized to express the protein-coding sequences. These include, as examples, mammalian cell systems infected with virus  
15 (e.g., vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (e.g., baculovirus); microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage, DNA, plasmid DNA, or cosmid DNA. The expression elements of vectors vary in their strengths and specificities. Depending on the host-vector system utilized, any one of a number of suitable transcription and translation elements may  
20 be used.

In a specific embodiment, the gene may be expressed in bacteria that are protease deficient, and that have low constitutive levels and high induced levels of expression where an expression vector is used that is inducible, for example, by the addition  
25 of IPTG to the medium.

In yet another specific embodiment, the polypeptide, or one, any, both, several or all of the polypeptides of a complex may be expressed with signal peptides, such as, for example, *pelB* bacterial signal peptide, that directs the protein to the bacterial periplasm (Lei *et al.* J. Bacteriol., vol. 169: pp. 4379, 1987). Alternatively, protein may be  
30 allowed to form inclusion bodies, and subsequently be resolubilized and refolded (Kim S.H. *et al.* Mo Immunol, vol. 34: pp. 891, 1997).

In yet another embodiment, a fragment of the polypeptide, or one, any, both, several or all of the polypeptides a complex comprising one or more domains of the protein is expressed. Any of the methods previously described for the insertion of DNA fragments  
35 into a vector may be used to construct expression vectors containing a chimeric gene consisting of appropriate transcriptional/translational control signals and the protein coding

sequences. These methods may include in vitro recombinant DNA and synthetic techniques and in vivo recombinants (genetic recombination).

In addition, a host cell strain may be chosen that modulates the expression of  
5 the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Expression from certain promoters can be elevated in the presence of certain inducers; thus, expression of the genetically engineered polypeptides may be controlled. Furthermore, different host cells have characteristic and specific mechanisms for the translational and post-translational processing and modification (e.g., glycosylation,  
10 phosphorylation of proteins. Appropriate cell lines or host systems can be chosen to ensure the desired modification and processing of the foreign polypeptide(s) expressed. For example, expression in a bacterial system can be used to produce a non-glycosylated core protein product. Expression in yeast will produce a glycosylated product. Expression in mammalian cells can be used to ensure "native" glycosylation of a heterologous protein.  
15 Furthermore, different vector/host expression systems may effect processing reactions to different extents.

In other embodiments of the invention, the polypeptide, or one, any, both, several or all of the polypeptides a complex, and/or fragments, analogs, or derivative(s) thereof may be expressed as a fusion-, or chimeric, protein product (comprising the protein,  
20 fragment, analog, or derivative joined via a peptide bond to a heterologous protein sequence of a different protein). Such a chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other by methods known in the art, in the proper coding frame, and expressing the chimeric product by methods commonly known in the art. Alternatively, such a chimeric product may be made  
25 by protein synthetic techniques, for example, by use of a peptide synthesizer.

The polypeptides of a complex may be expressed together in the same cells either on the same vector, driven by the same or independent transcriptional and/or translational signals, or on separate expression vectors, for example by cotransfection or cotransformation and selection, for example, may be based on both vectors' individual  
30 selection markers. Alternatively, one, any, both, several or all of the polypeptides a complex may be expressed separately; they may be expressed in the same expression system, or in different expression systems, and may be expressed individually or collectively as fragments, derivatives or analogs of the original polypeptide.

35

## **5.14. THE CROSS-LINK REACTION**

### **5.14.1. INTRODUCTION OF POINT MUTATIONS TO PHENYLALANINE**

One of the codons of every tyrosine residue pair that may react with each  
5 other and cause undesirable structural and/or functional distortions is preferably point  
mutated to codons that direct the expression of phenylalanine.

Point mutations can be introduced into the DNA encoding the polypeptide,  
or one, any, both, several or all of the polypeptides of a complex by any method known in  
the art, such as oligonucleotide mediated site-directed mutagenesis. Such methods may  
10 utilize oligonucleotides that are homologous to the flanking sequences of such codons, but  
that encode tyrosine at the selected site or sites. With these oligonucleotides, DNA  
fragments containing the point mutation or point mutations are amplified and inserted into  
the gene or genes, for example, by subcloning. One example of such methods is the  
application of the QuikChange™ Site-Directed Mutagenesis Kit (Stratagene, Catalog #  
15 200518); this kit uses the Pfu enzyme having non-strand-displacing action in any double  
stranded plasmid mutation in PCR reactions. Other methods may utilize other enzymes  
such as DNA polymerases, or fragments and/or analogs thereof.

The plasmid or plasmids containing the point mutation or point mutations  
20 are, for example, transformed into bacteria for expansion, and the DNA is prepared as  
described above. The isolated, expanded, and prepared DNA may be examined to verify  
that it encodes the polypeptide or polypeptides of the complex, and that the correct mutation  
or mutations were achieved. This may, for example, be verified by direct DNA sequencing,  
DNA hybridization techniques, or any other method known in the art.

25

### **5.14.2. PURIFICATION OF GENE PRODUCTS**

The gene product may be isolated and purified by standard methods  
including chromatography (e.g., ion exchange, affinity, and sizing column  
chromatography), ammonium sulfate precipitation, centrifugation, differential solubility, or  
30 by any other standard technique for the purification of proteins.

The functional properties may be evaluated using any suitable assay. The  
amino acid sequence of the protein can be deduced from the nucleotide sequence of the  
chimeric gene contained in the recombinant vector. As a result, the protein can be  
synthesized by standard chemical methods known in the art (e.g., see Hunkapiller M. *et al.*  
35 Nature; vol. 310(5973): pp. 105-11, 1984).

### 5.14.3. THE REACTION

The cross-link reaction can utilize any chemical reaction or physical known in the art that specifically introduces dityrosine cross-links, such as peroxidase catalysed cross-linking, or photodynamically in the presence or absence of sensitizers (see Section II).  
5 Preferably, however, the reaction is catalyzed by a metallo-ion complex, as described in detail below.

Partially purified polypeptides containing appropriate tyrosine residues may be equilibrated by dialysis in a buffer, such as phosphate buffered saline (PBS), together or  
10 separately before mixing them. The catalyst is then added (on ice or otherwise). The catalyst of the reaction is any compound that will result in the above cross-link reaction. The catalyst should have the structural components that convey the specificity of the reaction, generally provided by a structure complexing a metal ion, and the ability to abstract an electron from the substrate in the presence of an oxidizing reagent, generally  
15 provided by the metal ion. An active metal is encased in a stable ligand that blocks non-specific binding to chelating sites on protein surfaces. For example, either a metalloporphyrin, such as, but not limited to, 20-tetrakis (4-sulfonateophenyl) - 21H,23H-porphine manganese (III) chloride (MnTPPS) or hemin iron (III) protoporphyrin IX chloride (Campbell L.A. et al. Bioorganic and Medicinal Chemistry, vol. 6: pp. 1301-1037,  
20 1998), or a metal ion-peptide complex, such as the tripeptide NH<sub>2</sub>-Gly-Gly-His-COOH complexing Ni<sup>++</sup> can serve as the catalyst of the reaction. Metalloporphyrins are a class of oxidative ligand-metal complexes for which there are few, if any, high affinity sites in naturally occurring eukaryotic proteins. The reaction can also be catalyzed by intramolecular Ni<sup>++</sup> peptide complexes, such as N- and C-terminal amino acids consisting  
25 either of 3 or more histidine residues (his-tag), or of the above GGH tripeptide. The reaction is initiated by the addition of the oxidizing reagent at room temperature or otherwise. Oxidizing reagents include, but are not limited to, hydrogen peroxide, oxone, and magnesium monoperxypthalic acid hexahydrate (MMPP) (Brown K.C. et al. Biochem.; vol. 34(14): pp. 4733-4739, 1995). Higher specificity can be achieved by using a  
30 photogenerated oxidant, such as the oxidant used in the process described by Fancy D. and Thomas Kodadek, which involves brief photolysis of tris-bipyridylruthenium(II) dication with visible light in the presence of an electron acceptor, such as ammonium persulfate (Fancy D.A. and Kodadek T. Proc. Natl. Acad. Sci., U.S.A.; vol. 96: pp. 6020-24, 1999). The optimal reaction period is preferably determined for each application; however, in cases  
35 where an optimization process is not possible, the reaction should preferably be stopped after one minute. Using a photogenerated oxidant, such as above described, the exposure to



light can be less than one second. The reaction is stopped by the addition of a sufficient amount of reducing agent, such as b-mercaptoethanol, to counteract and/or neutralize the oxidizing agent.

5 Alternatively, the reaction may be stopped by the addition of a chelating reagent, such as, for example, EDTA or EGTA. The solution is again equilibrated by dialysis in a buffer, such as phosphate buffered saline (PBS), to remove the reagents required for the cross-link reaction, such as the oxidizing reagent, the catalyst, or the metal ion, reducing agents, chelating reagents, etc. The cross-link reaction conditions are  
10 preferably adjusted such that the polypeptides or polypeptides of a complex that have been mutated to remove undesirable tyrosyl side-chains no longer form a bond. These conditions are adjusted by varying the reaction temperature, pH, or osmolarity conditions, or by varying the concentration of the polypeptides, the catalyst, the oxidizing agent, or any other reagents that are applied toward such a reaction. The catalyst is a small molecule that  
15 diffuses easily, and can be used at varying concentrations. Tightly packed polypeptide hydrophobic cores have a degree of solvent accessibility. This may be modulated by any known method in the art, including, but not limited to, by altering the reaction temperature, or by the addition of salts, detergents, deoxycholate, or guanidinium.

## 20 **5.15. ACHIEVING A STABILIZED POLYPEPTIDE OR COMPLEX**

### **5.15.1. POINT MUTATION TO TYROSINE AND GENE PRODUCT PURIFICATION**

The codons of the residues identified as a suitable pair to which the cross-link should be directed, as described above, and selected for a particular embodiment of the  
25 instant invention, are point mutated such that the resultant residue pairs direct the expression of tyrosyl side-chains. Point mutations are introduced as described above.

The gene products are again purified as described above.

### 30 **5.15.2. CROSS-LINKING THE POLYPEPTIDE OR COMPLEX**

The polypeptides now containing tyrosyl side-chains at the residues to which the cross-link reaction should be directed are subjected to the cross-link reaction under the conditions determined as described above and carried out, also as described above. The efficiency of the reaction may be examined, for example, by Western blotting experiments,  
35 in which a cross-linked complex should run at approximately the molecular weight of both or

all polypeptides of the complex. If, the bond is readily formed under the above conditions, the strength of the reaction may still be further adjusted to the minimally required strength.

In embodiments of the invention wherein the cross-link is directed to residue pairs that are buried and/or are not readily accessible to the catalyst or oxidizing reagents, secondary and higher order polypeptide structure can be temporarily dissociated to permit reagent access. For example, such an approach may be necessary when directing the cross-link to the hydrophobic core of a single polypeptide or to a buried residue pair of polypeptide complex having very high affinity among subunits. Any means known in the art may be used to reversibly denature polypeptide structure to permit reagent access to buried residue pairs. Such means include, but are not limited to, manipulating (increasing or decreasing) salt concentration or reaction temperature, or employing detergents, or such agents as guanidine HCl. As denaturing conditions are withdrawn (e.g., by dialysis) and the polypeptide or complex begins to refold/reassociate, the catalyst and oxidizing reagents may be added, as described above.

#### 5.16. PURIFICATION OF CROSS-LINKED COMPLEXES

The cross-linked polypeptide or complex may be isolated and purified from proteins in the reaction that failed to cross-link, or any other undesirable side-products, by standard methods including chromatography (e.g., sizing column chromatography, glycerol gradients, affinity), centrifugation, or by any other standard technique for the purification of proteins. In specific embodiments it may be necessary to separate polypeptides that were not cross-linked, but that homo- or heterodimerize with other polypeptides due to high affinity binding. Separation may be achieved by any means known in the art, including, for example, addition of detergent and/or reducing agents.

Yield of functionally cross-linked polypeptides or complexes can be determined by any means known in the art, for example, by comparing the amount of stabilized complex, purified as described above, with the starting material. Protein concentrations are determined by standard procedures, such as, for example, Bradford or Lowry protein assays. The Bradford assay is compatible with reducing agents and denaturing agents (Bradford, M. Anal. Biochem.; vol. 72: pp. 248, 1976), the Lowry assay is better compatibility with detergents and the reaction is more linear with respect to protein concentrations and read-out (Lowry, O. J. Biol. Chem.; vol. 193: pp. 265, 1951).

## 5.17. ASSAY OF A CROSS-LINKED POLYPEPTIDE OR COMPLEX

### 5.17.1. RETAINED FUNCTION

5

#### Functionality

Depending on the nature of the polypeptide or polypeptide complex, retained functionality can be tested, for example, by comparing the functionality of the cross-linked complex, cross-linked as described above, with that of the polypeptide or complex before stabilization, cross-linked or stabilized by another method, or naturally stabilized by a post-translational modification that, for example, regulates the association of certain polypeptides. Assays for retained functionality can be based, for example, on the biochemical properties of the protein in *in vitro* assay systems. Alternatively, the polypeptide or complex can be tested for functionality by using biological assay systems. For example, the activity of a kinase can be tested in *in vitro* kinase assays, and a growth factor, such as a member of the IL-8 family, can be tested for activity in chemotactic cell migration assays or beta-glucuronidase release assays (Leong S.R. et al. Protein Sci.; vol. 6(3): pp: 609-17, 1997). As another example, retained enzymatic activity of a biocatalyst can be determined by any method known to one skilled in the art. The activity of an enzyme is preferably measured directly by comparing the activity of the enzyme on a substrate before and after stabilization, and quantitating the product of the reaction. As examples, such assays include, but are not limited to, visualization upon chromatographic separation of the compounds in the reaction, spectrophotometric and fluorometric analyses of reaction products, analysis of incorporated or released detectable markers, such as, for example, radioactive isotopes. Indirect methods, that include, but are not limited to, computational, structural, or other thermodynamic analyses, may also be used for the determination of the activity of the stabilized biocatalyst. More specifically, as an example of a biocatalyst, the activity of a lipase, or specifically the activity of carboxylesterases catalyzing the hydrolysis of long-chain acylglycerols, is determined by any method known in the art, including, but not limited to the measurement of the hydrolysis of p-nitrophenylesters of fatty acids with various chain lengths ( $\geq C-10$ ) in solution by spectrophotometric detection of p-nitrophenol at 410 nm. Where it is necessary to distinguish between lipases and esterases, the triglyceride derivative 1,2-O-dilauryl-rac-glycero-3-glutaric acid resorufin ester (available from Boehringer Mannheim Roche GmbH, Germany), may also be used as a substrate, yielding resorufin, which can be determined spectrophotometrically at 572 nm, or fluorometrically at 583 nm (Jaeger K-E et al. Annu. Rev. Microbiol. 1999. 53: pp. 315-51).

### Specificity

Depending on the nature of the polypeptide or polypeptide complex, retained specificity can be tested, as examples, by comparing the specificity of the cross-linked polypeptide or complex with that of the polypeptide or complex before stabilization, cross-linked or stabilized by another method, or naturally stabilized by a post-translational modification. Assays for retained specificity can be based, for example, on enzymatic substrate specificity, or ELISA-type procedures. For example, the retained or resultant specificity of a lipase (carboxylesterase) may be determined by any method known to one skilled in the art. Non-limiting examples of such methods include using a number of fluorogenic alkyl diacylglycerols as substrates for an analysis of the biocatalyst's stereoselectivity. For a detailed description of such methods and of certain such compounds, see the article "New fluorescent glycerolipids for a dual wavelength assay of lipase activity and stereoselectivity" (Zandonella G. et al., 1997, J. Mol. Catal. B: Enzym. 3: pp. 127-30).

### 5.17.2. STABILITY

#### *In vitro*

Stability of the polypeptide or complex may be tested *in vitro* in, for example but not limited to, time-course experiments incubating the polypeptide or complex at varying concentrations and temperatures. Polypeptide or complex stability may also be tested at various pH levels and under various redox conditions. For all of the above conditions, the remaining levels of functional polypeptides or polypeptide complexes is determined by assaying as described above (Functionality). In the above example of a biocatalyst, improved or altered stability of a stabilized polypeptide or complex can be determined by any method known to one skilled in the art. Such methods include, but are not limited to, calorimetric and/or structural analyses, thermodynamic calculations and analyses, and comparison of the activities of the stabilized and unstabilized enzymes under their optimal conditions and under suboptimal, or adverse reaction conditions, such as higher or lower temperature, pressure, pH, salt concentration, inhibitory compound, or enzyme and/or substrate concentration. Any of the above analyses may also include time course experiments directed to the determination of stabilized biocatalyst half-life and/or shelf-life. Stabilization of a biocatalyst according to the invention can also be evaluated in the context of other methods of biocatalyst stabilization. As non-limiting examples, the above enzymatic activities can be tested in immobilizing gels or other matrices, or in partial or pure organic solvents. Furthermore, a biocatalyst stabilized by any of the methods

known in the art (such as directed evolution or designed mutagenesis, see Background) can also be subjected to the methods of the instant invention to achieve further stabilization.

### *In vivo*

5                   Pharmaceutical and therapeutic applications are best tested *in vivo* or under conditions that resemble physiological conditions (see also, below). The stability of the polypeptide or complex may be tested in, for example but not limited to, serum, incubating the polypeptide or complex in time-course experiments at various temperatures (e.g. 37, 38, 39, 40, 42, and 45 °C), and at different serum concentrations, and assaying for the  
10 remaining levels of functional polypeptides or complexes. Furthermore, stability of a polypeptide or complex in the cytoplasm may be tested in time-course experiments in cell-lysates, lysed under various conditions (e.g. various concentrations of various detergents) at different temperatures (e.g. 37, 38, 39, 40, 42, and 45 °C), and assaying for the remaining levels of functional polypeptides or complexes. More directly, stability in the cytoplasm  
15 may be tested in time-course experiments by scrape-loading tissue culture cells with stabilized polypeptide or complex and assaying for the remaining levels of function. The stability of the polypeptide or complex may also be tested by injecting it into an experimental animal and assaying for specific activity. Alternatively, the compound may be recovered from the animal at an appropriate time point, or several time points, and assayed  
20 for activity and stability, as described above.

### **5.17.3. BIODISTRIBUTION**

To determine the utility of a stabilized polypeptide or polypeptide complex more directly, biodistribution and/or other pharmacokinetic attributes may be determined.  
25 In a specific embodiment, a stabilized polypeptide or polypeptide complex may be injected into a model organism and assayed by tracing a marker, such as but not limited to, <sup>125</sup>I or <sup>18</sup>F radio labels (Choi C.W. *et al.* Cancer Research, vol. 55: pp. 5323-5329, 1995), and/or by tracing activity as described above (Colcher D. *et al.* Q.J. Nucl. Med. vol. 44(4): pp. 225-  
30 241, 1998). Relevant information may be obtained, for example, by determining the amount of functional polypeptide or polypeptide complex that can be expected to be pharmaceutically active due to its penetration of the specifically targeted tissue, such as, for example, a tumor. Half-life in the circulation and at the specifically targeted tissue, renal clearance, immunogenicity, and speed of penetration may also be determined in this  
35 context.

#### 5.17.4. ANIMAL AND CLINICAL STUDIES

Utility of a stabilized polypeptide or complex can be determined directly by measuring its pharmacological activity, either in animal studies or clinically. In a specific embodiment, such measurements may include, for example, measurements with which tumor pro- or regression is monitored upon treatment of an animal model or one or several patients with a stabilized polypeptide or complex designed as an anti-cancer pharmacological agent. In another embodiment, such measurements may include, for example, measurements, of bone mass, such as x-ray measurements, upon treatment of an animal model or one or several patients with a stabilized polypeptide or complex designed as an anti-menopausal bone-loss pharmacological agent.

#### 5.18. TROUBLE SHOOTING

##### 5.18.1. POLYPEPTIDE OR COMPLEX NOT CROSS-LINKED

If a polypeptide or complex should not become cross-linked and stabilized by the above-described reaction (as determined, for example, by non-reducing sodium dodecyl sulfate polyacrylamide gel electrophoresis or SDS PAGE), there may be several explanations and solutions to the problem.

##### Adjust Polypeptide Concentration, Salt/Osmolarity and/or pH Conditions

For stabilization of a polypeptide complex, one problem that may be encountered is that the polypeptides, as they are not yet stabilized, do not form a sufficiently stable complex in solution for the cross-link to form under the present conditions of the reaction. In this instance, varying the reaction conditions is indicated. Too loose an association among complex members may be determined, for example, by immunoprecipitating one of the polypeptides and assaying for the presence and relative quantity of the other polypeptide(s) in the precipitate (e.g., by Western blotting). It may be possible to increase the strength of association among polypeptides using any known means in the art. Such means may include, but are not limited to, adjusting certain conditions of the reaction, such as salt, Tris, polypeptide concentration, or pH. If thereby the strength of the polypeptides' association is increased, for example, as determined by non-reducing SDS PAGE, the cross-link reaction should be tried again under these conditions.

The opposite problem may also occur. That is, the polypeptides of a complex (or the secondary or higher order structure of a single polypeptide), may associate with each other too tightly such that the tyrosyl side-chains are not exposed to the catalyst or oxidizing reagents and the di-tyrosine bond does not form. In such cases, secondary or

higher order structure should be “loosened” or partially denatured. This can be accomplished using any means known in the art, as described above, by adjusting, for example, concentration of salt, detergent, guanidine HCl, and/or any other agent that causes reversible denaturation (e.g. temperature, pressure, and/or reaction time). It may also be possible to add the oxidizing agent and catalyst at an earlier or later time-point. For example, as denaturing conditions are reversed, as described above, and the polypeptide or polypeptide complex begins to refold/reassociate.

#### Increase Strength of Reaction Conditions

Should the cross-link not form in spite of appropriate polypeptide folding or adequate complex formation under the conditions of the reaction, the next solution could be to increase the strength of the conditions of the reaction, e.g. by increasing the concentration of the oxidizing reagent and/or of the catalyst. A preferred method would still use the minimal strength of the reaction required for the cross-link to form.

#### Direct Cross-linking Reaction to an Alternative Residue Pair

A cross-linking reaction may sometimes fail because the cross-link is directed to a pair of tyrosines that cannot be cross-linked due to structural considerations not captured in the selection process. Should the above approaches not permit the cross-link to form between the selected residues of a pair, another residue pair may be selected, and the cross-link reaction tried again, where necessary adjusting the reaction conditions, as described above.

#### Combined Approach

It may be necessary to employ several of the above approaches to troubleshooting to achieve the desired stabilizing di-tyrosine bond.

### **5.18.2. COMPROMISED FUNCTIONALITY OF POLYPEPTIDE OR COMPLEX**

#### Decrease Strength of Reaction Conditions

Reducing the strength of the reaction by adjusting, for example, but not limited to, the concentration of either the catalyst or the oxidizing reagent, the temperature, pressure, and/or reaction time, may result in a stabilized polypeptide or polypeptide complex with better retained functionality.

#### Adjust Protein Concentrations, Salt/Osmolarity and/or pH Conditions

Non-specific cross-link reactions may compromise the functionality of the polypeptide or polypeptide complex, that may occur under certain reaction conditions, such

as, but not limited to, high protein concentrations relative to the optimum, certain pH levels, or salt, detergent, denaturing, and/or any other concentrations of the components in the reaction. These conditions may be adjusted to minimize or eliminate the formation of non-specific, compromising di-tyrosine bonds.

#### Direct Cross-linking Reaction to an Alternative Residue Pair

If input data for the selection process is less than completely accurate, or for any other reason, the selected residue pair could yield a cross-link that distorts the overall structure of the polypeptide or polypeptide complex, and thereby compromises or alters its functionality. Should this be the case, another residue pair should be chosen and mutated such that both residues encode tyrosine, and the cross-link reaction should be tried again.

#### Combined Approach

It may be necessary to employ several or all of the above approaches to trouble-shooting to achieve the desired stabilizing di-tyrosine bond.

### **5.19. SOFTWARE FOR SELECTION PROCESS**

This invention provides software that permits automated selection of suitable residue pairs at which a di-tyrosine bond can be placed. Such software can be used in accordance with the geometrical, physical, and chemical criteria described above (see especially Identification of Suitable Residue Pairs for the Reaction), and a Residue Pair Selection Flowchart such as is set forth in Section 6 below. As described above, a successive array of Filters is implemented and residue pairs that "pass" through the filters comprise the selected residue pairs (Figure 14, left side). Alternatively, filters can be implemented to process all residue pairs in a parallel array (Figure 14, right side). Residue pairs that "pass" through a filter define that filter's set of passed pairs. In a preferred embodiment, residue pairs that are in all filters' passed sets (*i.e.* residue pairs that form the intersection of all filter sets) are the selected pairs. The filter requirements are as described above (Identification of Suitable Residue Pairs for the Reaction).

### **5.20. PHARMACEUTICAL COMPOSITIONS**

In one embodiment, this invention provides a pharmaceutical composition comprising an effective amount of a stabilized polypeptide or polypeptide complex, and a pharmaceutically acceptable carrier. As used herein, "an effective amount" means an amount required to achieve a desired end result. The amount required to achieve the desired end result will depend on the nature of the disease or disorder being treated, and can be



determined by standard clinical techniques. In addition, *in vitro* assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed will also depend on the route of administration and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each subject's  
5 circumstances. Effective doses may be extrapolated from dose-response curves derived from *in vitro* or animal model test systems.

Various delivery systems are known and can be used to administer a pharmaceutical composition of the present invention. Methods of introduction include but  
10 are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compounds may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (*e.g.*, oral mucosa, rectal and intestinal mucosa, *etc.*) and may be administered together with other biologically active agents. Administration can  
15 be systemic or local. In addition, it may be desirable to introduce the pharmaceutical compositions of the invention into the central nervous system by any suitable route, including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration can also be employed, *e.g.*, by use of an  
20 inhaler or nebulizer, and formulation with an aerosolizing agent.

In a specific embodiment, it may be desirable to administer the pharmaceutical compositions of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, by injection, by means of a catheter, or by means of an implant, said implant being  
25 of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. In one embodiment, administration can be by direct injection at the site (or former site) of a malignant tumor or neoplastic or pre-neoplastic tissue.

In another embodiment, pharmaceutical compositions of the invention can be delivered in a controlled release system. In one embodiment, a pump may be used (*see*  
30 Langer, *supra*; Sefton, CRC Crit. Ref. Biomed. Eng.; vol. 14: pp. 201, 1987; Buchwald *et al.*, Surgery; vol. 88: pp. 507, 1980; Saudek *et al.*, N. Engl. J. Med.; vol. 321: pp. 574, 1989). In another embodiment, polymeric materials can be used (*see* Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida, 1974; Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball  
35 (eds.), Wiley, New York, 1984; Ranger and Peppas, J. Macromol. Sci. Rev. Macromol. Chem.; vol. 23: pp. 61, 1983; *see also* Levy *et al.* Science; vol. 228: pp. 190, 1985; During

et al. Ann. Neurol.; vol. 25: pp. 351, 1989; Howard et al. J. Neurosurg; vol. 71: pp. 105, 1989). In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic target, i.e., the brain, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in Medical Applications of Controlled Release, *supra*, vol. 2, pp. 115-138, 1984).

Other controlled release systems are discussed in the review by Langer (Science; vol. 249: pp. 527-1533, 1990).

In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lidocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

#### 5.21. CONSIDERATIONS FOR PHARMACEUTICAL COMPOSITIONS

Stabilized polypeptides or polypeptide complexes of the invention should be administered in a carrier that is pharmaceutically acceptable. The term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia or receiving specific or individual approval from one or more generally recognized regulatory agencies for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water, organic solvents, such as certain alcohols, and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Buffered saline is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These

compositions can take the form of solutions, suspensions, emulsion and the like. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin. Such compositions will contain a therapeutically effective amount of the  
5 Therapeutic, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration. In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous  
10 administration are solutions in sterile isotonic aqueous buffer.

## 6. EXAMPLES

The following examples illustrate certain variations of the methods of the invention for protein and protein complex stabilization. These examples are presented by  
15 way of illustration and not by way of limitation to the scope of the invention.

### 6.1. INTRODUCTION

Several polypeptides and polypeptide complexes with significant  
20 commercial value have been identified in recent years, and furthermore, several modular domains have been identified that mediate protein-protein interactions. For many of these domains, the interaction sites with other proteins have also been mapped.

In the following section, methods of stabilizing one such complex, an Fv fragment complex, for which an abundance of data is available, are described in detail.  
25 Specifically, described below are the assembly of relevant databases for the selection process, the selection process itself, the introduction of point mutations, bacterial expression of the polypeptides and their purification, adjustment of the cross-link reaction conditions, the cross-link reaction itself, and analysis of the resulting stabilized complex.

The input data for the 2-D database is obtained from Weir's Handbook of  
30 Experimental Immunology I. Immunochemistry and Molecular Immunology, Fifth Edition. The input data for the 3-D database is obtained from the Brookhaven National Laboratory Protein Database. The derivative data relevant to the selection process in both databases is calculated as described. The selection process is carried out using a set of filters that is convenient and appropriate for this application of the instant invention.

35 Point mutations to tyrosine (directing the cross-link reaction) are introduced according to the final selection of the selection process, and point mutations to

phenylalanine (limiting the cross-link reaction) according to the specific sequence of each Fv fragment and the corresponding and relevant structural information contained in the 3-D database. The polypeptides of the complex are expressed bacterially as GST fusion proteins, and purified over a GT-affinity column. The purified polypeptides of the complex  
5 are proteolytically cleaved from the GST parts of the fusion proteins, and the GST polypeptide is removed, again using a GT affinity column.

The minimally required reaction conditions are adjusted using a construct with the mutations to phenylalanine, but lacking the mutations to tyrosine, and the  
10 cross-link reaction is then carried out with the constructs containing both sets of point mutations. The efficiency of the reaction is tested for, and the resulting, stabilized Fv fragments are then tested for retained affinity, stability, immunogenicity, and biodistribution characteristics.

## 15           **6.2. ADVANTAGES OF THE TYROSYL-TYROSYL CROSS-LINK               FOR Fv FRAGMENTS**

---

The underlying chemistry of the technology covered by the present invention causes an oxidative cross-link to form between reactive side-chains of proteins that form  
20 stable complexes. Because the cross-linking reaction is catalyzed, once established, the cross-link is stable in the absence of the catalyst under a broad range of pH and redox conditions. The cross-link reaction requires very close proximity between the molecules that will cross-link and therefore only occurs between molecules that normally interact and associate closely in solution and is therefore limited to molecules that have legitimate  
25 functional interactions.

Thus, the current invention describes a new technology that will allow stabilization of immunoglobulin-derived conjugates and result in both a very high degree of stability and minimal immunogenicity in therapeutic contexts. This technology is designed to improve on preceding, and complement compatible, technologies.

30           The resultant stabilized Fv fragments will have the following characteristics:

1.       The conjugates will be stable under a broad range of pH and redox conditions and at high protein concentrations.
2.       The resultant cross-linked complex will be minimally immunogenic  
35 since no exposed residues are altered.

This Fv fragment stabilization technology is well suited for the development of new products with novel applications, the improvement of existing

immunoglobulin-based products, and the complementation of existing technologies for the development of novel immunoglobulin applications.

5

### **6.3. Fv FRAGMENT APPLICATIONS**

There is a wide spectrum of potential applications for immunoglobulin-based products, the limits of which are determined by the following factors:

The target must be in an environment that is accessible to immunoglobulin-derived products, such as, for example, serum, the extracellular matrix, the brain, or the intracellular space by way of liposomes (Hoffman R.M. J. Drug Target.; vol. 5(2): pp. 67-74, 1998) or peptide induced cellular uptake (Schwarze S.R. et al. Science; vol. 285: pp. 1565-72, 1999). For intracellular applications of immunoglobulin, see Bosilevac J.M. et al. J. Biol. Chem.; vol. 273(27): pp. 16874-79, 1998; Graus-Porta D. et al. Mol. Cell Biol.; vol 15: pp. 1182-91, 1995; Richardson J.H. et al. Proc. Nat. Acad. Sci., USA; vol. 92: pp. 3137-41, 1995; Maciejewski J.P. et al. Nat. Med.; vol. 1: pp. 667-73, 1995; Marasco W.A. et al. Proc. Nat. Acad. Sci., USA; vol. 90: pp. 7889-93, 1993; Levy Mintz P. et al. J. Virol.; vol. 70: pp. 8821-32, 1996; Duan L. et al. Hum. Gene Ther.; vol. 6(12): pp. 1561-73, 1995; and Kim S.H. et al. Mol. Immunol.; vol. 34(12-13): pp. 891-906, 1997. A favorable environment is present in all tissues and organs that are reached by the blood supply, and where the target molecule is present on the cell surface or in the extra-cellular matrix. Since the functionality of immunoglobulin-derived Fv fragments is primarily to bind to target molecules, binding to the target should preferably suffice to accomplish the desired therapeutic or diagnostic effect. Catalytic functionality is, however, also known for immunoglobulin, and may therefore also be achieved in pharmacological and/or industrial contexts (Pluckthun A. et al. Ciba Found. Symp.; vol. 159: pp. 103-12; discussion 112-7, 1991; Kim S.H. et al. Mol. Immunol, vol. 34: pp. 891-906, 1997).

There is a multitude of applications of potential immunoglobulin-based applications that meet these criteria, and it is the purpose of the following paragraphs only to point out certain relevant applications, as examples.

#### **6.3.1. DRUG DELIVERY /TISSUE TARGETING**

Many existing applications of immunoglobulin therapy make use of antibody's ability to direct therapeutic agents to the targeted tissues. Such therapeutic agents have thus far been toxins and radioisotopes targeted to tumors by linkage to anti-

tumor associated antigen or anti-tumor specific antibodies, on the one hand, and diagnostic agents, i.e. antibodies linked to an imaging agent, on the other hand.

#### 5      **6.3.2. MODULATION OF EXTRA-CELLULAR BIOCHEMICAL PROCESSES**

There are a multitude of biochemical processes that are of therapeutic, and thus of commercial relevance that occur in extra-cellular milieus, such as blood serum. One example of such a process is the process of blood clotting. In this example, the immunoglobulin binds to one of the proteins involved in the biochemical cascade of  
10 reactions that lead to the formation of blood clots, and interrupts this cascade, thereby blocking the formation of blood clots. The therapeutic value of being able to inhibit the formation of blood clots, indeed, spurred the development of one of the first immunoglobulin-based pharmaceutical to enter the market.

#### 15      **6.4. SELECTION OF OPTIMAL RESIDUES FOR TYROSYL-TYROSYL CROSS-LINK**

The selection process consisted of a series of statistical tests or 'filters' aimed at successively narrowing down the residue pairs most likely to result in a cross-linked  
20 heavy chain-light chain tyrosine pair that minimally alter the Fv fragment's structural characteristics.

##### **6.4.1. DATA USED FOR THE ANALYSIS**

25      Residue amino acid usage data is data compiled on amino acids encoded and expressed at each residue of known and sequenced Fv fragments. It is collected in, and obtained from, the publication "Proteins of Immunological Interest", Kabat and Wu, Government Printing Office, NIH Publication 91-3242, 1991 ("K&W"). The amino acid sequences in this publication are ordered according to a standardized numbering system that  
30 takes into account the gene structure of the heavy and light chain variable regions. In the variable regions of the heavy and light chains alike, four Framework Region segments (FRs) - which are relatively conserved - are interspersed by three - highly variable - Complementarity Determining Regions (CDRs). The CDRs contain the amino acids that determine the antibody's specificity, and that physically contact the antigen. Aligning all  
35 sequences according to the K&W numbering system was very important for the purpose of performing a statistical analysis as described in this example since the corresponding residues of the FRs are thereby always aligned, regardless of the varying sequence lengths

of the interspersed CDRs. This ensured that statistical measurements were made with sets of data containing appropriate and comparable data points. Coordinate data for distance calculations of all atoms other than hydrogens of 17 Fv fragments from crystallographically solved immunoglobulin structures was downloaded from the protein structure database  
5 Brookhaven National Laboratory (www.bnl.pdb.gov; Figure 5). These data provide the three-dimensional coordinates (x, y, and z) for each atom in a solved structure, expressed in metric units, i.e. Angströms (10<sup>-10</sup>m, Å). With this data it was possible to calculate the three-dimensional distances between any desired atoms (e.g. amino alpha and beta carbon  
10 atoms) and to calculate statistical measurements of the variability of such distance between the different Fv fragments in the sample being analyzed (Figures 5, 6, and 7).

#### 6.4.2. SELECTION METHODOLOGY

Optimal residues, to which the cross-link reaction is directed, were selected  
15 by a series of filters based on the statistical measurements of values in databases compiled for the purposes of this selection. These databases contain numeric measurements of (1) alpha carbon spacing, (2) beta carbon spacing and the difference between the alpha and beta distances, and (3) residue amino acid usage (see below).

20

#### 6.5. FILTER 1: ELIMINATION OF RESIDUE PAIRS WITH GLYCINES

Glycine is the smallest of the amino acids and has no beta carbon and is  
25 often associated with positional flexibility of protein structures. Substitution of a glycine with one of the largest amino acids, tyrosine, would likely have too great an impact on the overall structure of the protein complex, and thereby on the antigen-binding characteristics of the cross-linked Fv fragment. Therefore, as a first cut, from among all candidate residue pairs of the Framework Regions, those pairs, of which one of the residues is most frequently  
30 a glycine (as determined by comparison with the K&W data) were eliminated a priori. For the purposes of this analysis 'most frequent' occurrence of a particular amino acid at a given residue was defined as occurrence in more than 75% of the sample.

35

**Table 1.** Heavy chain-light chain candidate pairs with average alpha carbon distance measurements  $\mu$ , within the range of 5.70Å to 11.74Å (sorted by K&W numbering, first on the light chain, second on heavy chain positions).

	Light	Heavy	AVERAGE	STDEV	Light	Heavy	AVERAGE	STDEV
5	36	45	10.38	0.23	44	91	9.33	0.33
	36	103	10.99	0.31	44	92	10.91	0.40
	37	45	11.49	0.36	44	93	9.74	0.29
	38	39	11.49	0.18	44	103	6.92	0.30
10	38	45	10.17	0.43	44	105	8.95	0.55
	38	103	11.26	0.41	45	93	10.43	0.41
	40	41	11.27	1.50	45	103	7.40	0.41
	40	43	11.68	1.34	45	105	10.95	0.45
15	42	39	11.04	0.84	46	93	10.78	0.40
	42	89	10.28	0.99	46	94	11.19	0.25
	42	90	11.72	0.88	46	103	8.98	0.33
	42	91	10.5	0.66	85	43	11.04	0.49
20	42	103	10.13	0.34	85	45	10.93	0.37
	42	105	7.14	0.40	86	45	10.63	0.35
	42	107	11.18	0.82	87	43	11.64	0.32
	43	4	11.50	0.56	87	45	8.19	0.25
25	43	37	10.94	0.87	87	46	10.90	0.33
	43	38	10.97	0.98	88	45	10.04	0.10
	43	39	10.34	0.79	88	46	11.69	0.21
	43	45	10.78	0.71	98	37	10.24	0.31
30	43	89	9.95	0.71	98	38	11.25	0.25
	43	90	10.23	0.72	98	39	11.17	0.20
	43	91	8.04	0.71	98	43	11.60	0.39
	43	92	10.21	0.59	98	45	6.49	0.18
35	43	93	10.14	0.65	98	46	6.66	0.29
	43	103	6.74	0.51	98	48	7.65	0.57
	43	105	5.74	0.44	98	49	11.37	0.58
	43	107	10.66	0.62	100	39	11.42	0.29
	44	37	10.58	0.39	100	43	8.27	0.41
	44	38	11.31	0.50	100	45	7.82	0.27
	44	39	10.73	0.48	100	46	9.56	0.46
	44	45	9.43	0.48	102	43	11.47	0.36



## 6.6. FILTER 2: IDENTIFICATION OF APPROPRIATELY SPACED RESIDUE PAIRS

To find residue pairs spaced appropriately for a tyrosyl-tyrosyl bond, the  
5 alpha carbon to alpha carbon distances from every residue in the light chain to every residue  
in the heavy chain in Fv fragments represented in the Brookhaven National Protein  
Structure Database were calculated in a 3D database. This calculation was performed by  
applying Pythagorean geometry to the 3D coordinates of the alpha carbons (Figure 6). For  
every combination of heavy and light chain residues, the average, standard deviation, range  
10 and median of the alpha carbon-alpha carbon distance was calculated on the Fv fragments in  
the sample (Figure 7). Based on the calculations above, as a second cut, all residue pairs  
were selected whose alpha carbons are spaced at an average,  $m$ , within the selection range.  
The range that was selected for was the following:

$$\text{Min } 5.70\text{\AA}, \text{Max } 11.74\text{\AA}.$$

15 The optimal distance ( $T$ ) was calculated by averaging the maximum and the  
minimum of the range. Therefore,

$$T = (5.70\text{\AA} + 11.74\text{\AA}) / 2 = 8.72\text{\AA}.$$

In this example, 64 residue pairs met this criterion, listed in Table 1.

20

## 6.7. FILTER 3: IDENTIFICATION OF RESIDUE PAIRS WITH SUFFICIENT POSITIONAL FLEXIBILITY

In order to identify residue pairs at which substitution to tyrosine is  
25 minimally disruptive, residues pairs with significant positional flexibility were selected.  
Therefore, residue pairs were eliminated from among those in Table 1 in which the optimal  
distance,  $8.72\text{\AA}$ , does not fall within 2 times of that specific residue pair's standard deviation  
from its average. In this example, 36 residue pairs met this criterion.

Furthermore, the relative positional flexibility of the remaining 12 candidate residue pairs  
30 was rated according to the following formula:

$$\text{Rating } I = a_x^2 / \sigma_x.$$

$$a_x = T - \mu_x + 2\sigma_x, \text{ for all } \mu_x \geq T$$

$$35 \quad a_x = \mu_x + 2\sigma_x - T, \text{ for all } \mu_x < T$$

$$T = \text{optimal distance}$$

$\mu_x$  = the average distance for any given residue pair

$\sigma_x$  = standard deviation of the distance for any given residue pair

Thus, residues that scored highly under this metric are those that (i) have an  
 5 average spacing close to the optimal distance, and/or (ii) have a large standard deviation.  
 The remaining 12 residue pairs are listed, sorted by Rating I in Table 2.

**Table 2.** Residue pairs of Table 1 selected<sup>1</sup> and rated by Rating I<sup>2</sup>.

	Heavy	Light	Rating I	AVG	STDEV
10	44	105	1.35	8.95	0.55
	43	91	0.76	8.04	0.71
	46	103	0.49	8.98	0.33
	100	43	0.33	8.27	0.41
15	43	37	0.26	10.9	0.87
	42	89	0.17	10.3	0.99
	40	41	0.14	11.3	1.50
	44	45	0.13	9.43	0.48
20	43	89	0.06	9.95	0.71
	100	46	0.01	9.56	0.46
	98	48	0.01	7.56	0.57
	44	91	0.01	9.33	0.33

25

<sup>1</sup> Selection criterion: optimal distance (T) must fall within the range of the residue pair's specific distance average ( $\mu_x$ ) +/- 2 times the residue pair's specific standard deviation ( $\sigma_x$ ).

<sup>2</sup> Rating I formula:  $a_x^2/\sigma_x$ , where T is the optimal distance, and  $a_x = T - \mu_x + 2\sigma_x$ , for all  $\mu_x \geq T$ , and  $a_x = \mu_x + 2\sigma_x - T$ , for all  $\mu_x \leq T$ .

30

#### 6.8. FILTER 4: SIDE-CHAIN ORIENTATION

In the space that the heavy and light chains occupy, the tyrosine side chains should be oriented toward each other for a cross-link to form with minimal structural distortion. The difference between the alpha carbon distance (i.e. the backbone carbon  
 35 distance; Figure 6) and the beta carbon distance (i.e. the distance between the first carbons

in each side chain; Figure 8) of each residue pair was calculated as a proxy, i.e. an estimate of the orientation of the side chains relative to each other (Figure 9).

The range that was selected for was the following:

5

Min  $-0.5\text{\AA}$ , Max  $2.0\text{\AA}$ .

The optimal distance difference (D) was calculated by averaging the maximum and the minimum of the range. Therefore,

$$D = (-0.5\text{\AA} + 2.0\text{\AA}) / 2 = 0.75\text{\AA}.$$

Again, based on 3D coordinate geometry, for each residue pair, the distance between the beta carbons was calculated (Figure 8). The beta distance was then subtracted from the alpha distance of the residue pair (Figure 9). This filter was based on whether the average difference in the alpha and beta distances of a residue pair (Figures 10 and 11) falls within the estimated optimal range. In this example, 12 residue pairs met this criterion, listed in Table 3.

15

**Table 3.** Residue pairs of Table 2 selected by average alpha-beta distance difference.

	Heavy	Light	Rating I	AVG	STDEV	AVG	STDEV
20	91	43	0.76	8.04	0.71	1.33	0.70
	45	43	0.56	10.78	0.71	-0.04	0.31
	103	46	0.49	8.98	0.33	0.81	0.18
	39	42	0.48	11.04	0.84	0.21	0.14
25	91	42	0.30	10.5	0.66	-0.14	0.17
	37	43	0.26	10.94	0.87	0.81	0.59
	89	42	0.17	10.28	0.99	0.01	0.06
	92	43	0.15	10.21	0.59	-0.23	0.61
30	89	43	0.06	9.95	0.71	0.71	0.36
	93	43	0.02	10.14	0.65	1.07	0.73
	48	98	0.01	7.65	0.57	0.87	0.17
	30	43	0.00	10.34	0.79	0.41	0.28

35 Furthermore, analogously to the selection based on alpha carbon distances, those pairs were eliminated for which the optimal average distance difference,  $0.75\text{\AA}$ , does not fall within 2 times that residue pair's specific standard deviation from its average.

$$\text{Rating II} = a_x^2 / \sigma_x$$

$$a_x = D - u_x + 2\sigma_x, \text{ for all } \mu_x \geq D$$

$$a_x = u_x + 2\sigma_x - D, \text{ for all } \mu_x < D$$

$D$  = optimal distances difference

$\mu_x$  = the average distance difference for any given residue pair

$\sigma_x$  = standard deviation of the distance difference for any given residue pair

Of the set of potential residue pairs listed in Table 4, five pairs met these criteria. This set of potential residue pairs is listed in Table 5.

Table 4. Residue pairs of Table 5 selected<sup>1</sup> and rated according to Rating II<sup>2</sup>

15	Difference between C-							
	Heavy	Light	alpha and C-beta distances			Alpha Carbon distance		
			Rating II	Average	Stdev	Rating I	Average	Stdev
20	92	43	0.10	-0.23	0.61	0.15	10.21	0.59
	39	43	0.17	0.41	0.28	0.00	10.34	0.79
	48	98	0.30	0.87	0.17	0.01	7.65	0.57
	103	46	0.49	0.81	0.18	0.49	8.98	0.33
	91	43	0.96	1.33	0.70	0.76	8.04	0.71
25	89	43	1.27	0.71	0.36	0.06	9.95	0.71
	93	43	1.79	1.07	0.73	0.02	10.14	0.65
	37	43	2.10	0.81	0.59	0.26	10.94	0.87

<sup>1</sup> Selection criterion: Optimal difference in alpha and beta distances ( $D$ ) must fall within the range of the residue pair's average alpha-beta distance-difference ( $\delta_x$ )  $2 \times$  the residue pair's specific standard deviation ( $\sigma_x$ ).

<sup>2</sup> Rating II formula:  $a_x^2 / \sigma_x$ , whereby  $D$  is the optimal distance difference, and  $a_x = D - \delta_x + 2\sigma_x$ , for all  $\delta_x \geq D$ , and  $a_x = \delta_x + 2\sigma_x - D$ , for all  $\delta_x < D$ .

Note that optimal alpha-alpha distance and alpha-beta distance difference (Target) also falls comfortably within the range of actually measured values of most of the residue pairs selected, as shown in Table 5. This is important, because it further

underscores the likelihood that the selected candidate pairs will result in cross-linked tyrosine side chains that minimally disrupt the Fv fragment structure and function.

- 5 **Table 5.** Average, median, standard deviation, and range of actually measured alpha-alpha distances and alpha-beta distance differences. The remaining residue pairs are identified in the top two rows by their heavy and light chain K&W residue numbers.

	Heavy	37	39	89	91	92	93	103	48
	Light	43	43	43	43	43	43	46	98
10	Average	10.94	10.34	9.95	8.04	10.21	10.14	8.98	7.65
	Stdev	0.87	0.79	0.71	0.71	0.59	0.65	0.33	0.57
Alpha Carbon	Max	13.23	12.37	11.75	9.82	11.81	11.81	9.63	8.68
	Min	9.94	9.63	9.05	7.32	9.56	9.42	8.39	6.78
15	Median	10.81	10.10	9.80	7.92	9.99	9.95	8.95	7.89
	Average	0.81	0.41	0.71	1.33	-0.23	1.07	0.81	0.87
	Stdev	0.59	0.28	0.36	0.70	0.61	0.73	0.18	0.17
	Max	1.42	0.84	1.17	2.02	0.33	1.74	1.09	1.37
20	Ca-Cb								
	Min	-0.64	-0.10	-0.08	-0.25	-1.86	-0.69	0.40	0.63
	Median	1.03	0.45	0.75	1.65	0.05	1.29	0.77	0.81

#### 6.9. FILTER 5: AMINO ACID SIDE-CHAIN USAGE

Since residue pairs are to be substituted with tyrosine such that the  
 25 substitutions are minimally disruptive to the structure and function of the resulting cross-linked complex, residue pairs were selected from among those in Tables 4 and 5 such that the properties of the original amino acid side-chains were as similar as possible to those of tyrosine. The principal side chain properties that were measured are (i) van der Waals volume and (ii) hydrophobicity. These measurements were used as proxies for the size and  
 30 charge of the amino acid side chains, respectively.

At each residue, every occurring amino acid side chain was given a numeric value representing its van der Waals volume and its hydrophobicity (Figure 12). Based on amino acid usage data for these residues (Kabat & Wu), the average and standard deviation  
 35 of the residue's van der Waals volume and hydrophobicity were calculated, both weighted, and un-weighted by the frequency at which the specific side chain occurs at this residue. A weighted statistical measurement is calculated on every value present in the sample ( $n =$

number of sequences in 2-D database), and an un-weighted statistical measurement is calculated on the value of each occurring amino acid (n = 20 maximally) (Figure 13).

For example, given 10 sequences in a database, whereby at a given residue alanine occurs 8 times, and leucine twice, the weighted average of the van der Waals volumes would be:

$$\begin{aligned} & (8 \times \text{ala value} + 2 \times \text{leu value})/10 \\ & = (8 \times 67 + 2 \times 124)/10 = 78.4. \end{aligned}$$

In the same example, the un-weighted average would be

$$\begin{aligned} & (\text{ala value} + \text{leu value})/2 \\ & = (67 + 124)/2 = 95.5. \end{aligned}$$

The numeric values of all 20 amino acids of both van der Waals volume and hydrophobicity used for the selection are listed in Table 6.

Each of the 6 residue pairs identified in the structural analysis was examined for its ability to be "conservatively" substituted with two tyrosine residues, by comparing the pair's average van der Waals and hydrophobicity scores and their standard deviations with those of a tyrosine pair.

**Table 6.** Numeric values of amino acid side chain van der Waals volumes (Richards, F.M.\_ J. Mol. Evol. 82, 1-14, 1974) and hydrophobicity (Eisenberg, D.\_ Ann. Rev. Biochem. 53, 595-623, 1984).

5	Amino Acid	Van der Walls volumes [A <sup>3</sup> ]	Hydrophobicity
	Ala	67	0.62
	Arg	148	-2.50
	Asn	96	-0.78
10	Asp	91	-0.90
	Cys	86	0.29
	Gln	114	-0.85
	Glu	109	-0.79
15	Gly	48	0.48
	His	118	-0.40
	Ile	124	1.40
	Leu	124	1.10
20	Lys	135	-1.50
	Met	124	0.64
	Phe	135	1.20
	Pro	90	0.12
	Ser	73	-0.18
25	Thr	93	-0.05
	Trp	163	0.81
	Tyr	141	0.26
30	Val	105	1.10

For each of the residues listed in Table 5, the average van der Waals volumes and hydrophobicity values and their standard deviations, weighted and unweighted, are listed in Table 7 and 8, respectively.

**Table 7.** Van der Waals scores for residue pairs and comparison to a tyr-tyr pair.

	Heavy	37	39	89	91	92	93	103	48
5	Consensus	VAL	GLN	VAL	TYR	CYS	ALA	TRP	VAL
	Average	109	113	110	141	86	69	160	110
	Stdev	8	12	12	1	-	9	11	9
	unweighted Average	116	103	122	138	86	78	136	116
	Stdev	10	51	18	4	-	26	27	10
10	Light	43	43	43	43	43	43	46	98
	Consensus	ALA	ALA	ALA	ALA	ALA	ALA	LEU	PHE
	weighted Average	72	72	72	72	72	72	124	135
	Stdev	14	14	14	14	14	14	3	2
	unweighted Average	94	94	94	94	94	94	118	128
15	Stdev	24	24	24	24	24	24	11	6
	Heavy	37	39	89	91	92	93	103	48
	Light	43	43	43	43	43	43	46	98
20	2 x tyr value	282	282	282	282	282	282	282	282
	Comb. value <sup>1</sup>	181	185	182	213	158	141	283	245
	weighted Difference <sup>2</sup>	101	97	100	69	124	141	1	38
	Comb. Stdev. <sup>3</sup>	22	26	26	15	14	23	14	11
	Rating III <sup>4</sup>	0.21	0.27	0.26	0.21	0.11	0.16	10.39	0.28
25	2 x tyr value	282	282	282	282	282	282	282	282
	Comb. value <sup>1</sup>	210	197	216	232	180	172	253	244
	unweighted Difference <sup>2</sup>	72	85	66	50	102	110	29	39
	Comb. Stdev. <sup>3</sup>	35	75	43	29	24	50	38	17
	Rating IV <sup>4</sup>	0.49	0.89	0.64	0.57	0.24	0.46	1.32	0.43
30									

<sup>1</sup> Sum of the residue pair's average van der Waals values<sup>2</sup> Size of the difference (square root of squared difference) between the sum of the value for two tyrosine residues (282) and the sum of the residue pairs' average values (<sup>1</sup>)<sup>3</sup> Sum of both residue's standard deviation



<sup>4</sup> Formula used: Stdev/Difference (<sup>3/2</sup>)

**Table 8.** Hydrophobicity scores for residue pairs and comparison to a tyr-tyr pair.

5	Heavy		37	39	89	91	92	93	103	48
	Consensus		VAL	GLN	VAL	TYR	CYS	ALA	TRP	VAL
	Weighted	Average	1.14	-0.86	0.90	0.30	0.29	0.58	0.79	1.14
		Stdev	0.14	0.35	0.66	0.20	-	0.19	0.30	0.11
	10	Unweighted	Average	1.07	-0.96	0.41	0.73	0.29	0.54	0.41
Stdev			0.27	1.49	1.37	0.66	-	0.47	1.05	0.17
Light		43	43	43	43	43	43	46	98	
15	Consensus		ALA	ALA	ALA	ALA	ALA	ALA	LEU	PHE
	Weighted	Average	0.50	0.50	0.50	0.50	0.50	0.50	1.08	1.20
		Stdev	0.33	0.33	0.33	0.33	0.33	0.33	0.09	0.03
	Unweighted	Average	0.47	0.47	0.47	0.47	0.47	0.47	0.95	1.23
		Stdev	0.59	0.59	0.59	0.59	0.59	0.59	0.27	0.15
20	Heavy		37	39	89	91	92	93	103	48
	Light		43	43	43	43	43	43	46	98
	25	Weighted	2 x tyr value	0.52	0.52	0.52	0.52	0.52	0.52	0.52
Comb. value <sup>1</sup>			1.64	-0.36	1.40	0.80	0.79	1.08	1.87	1.82
Difference <sup>2</sup>			1.12	0.88	0.88	0.28	0.27	0.56	1.35	0.13
Comb. Stdev. <sup>3</sup>			0.46	0.69	1.00	0.53	0.33	0.53	0.38	0.07
Rating V <sup>4</sup>			0.42	0.78	1.13	1.89	1.24	0.97	0.28	0.06
30	Unweighted	2 x tyr value	0.52	0.52	0.52	0.52	0.52	0.52	0.52	0.52
		Comb. value <sup>1</sup>	1.54	-0.49	0.88	1.20	0.76	1.01	1.35	2.48
		Difference <sup>2</sup>	1.02	1.01	0.36	0.68	0.24	0.49	0.83	1.96
		Comb. Stdev. <sup>3</sup>	0.87	2.09	1.97	1.26	0.59	1.07	1.32	0.33
		Rating IV <sup>4</sup>	0.85	2.07	5.44	1.86	2.49	2.20	1.58	0.17

<sup>1</sup> Sum of the residue pair's average hydrophobicity values

<sup>2</sup> Size of the difference (square root of squared difference) between the sum of the value for two tyrosine residues (0.52) and the sum of the residue pairs' average values (<sup>1</sup>)

<sup>3</sup> Sum of both residue's standard deviation

<sup>4</sup> Formula used: Stdev/Difference (<sup>3/2</sup>)

#### 6.10. FILTER 6: PARTIAL ELIMINATION OF PAIRS WITH HIGHLY CONSERVED RESIDUES

All residues under consideration are within the Framework Regions of either the heavy or the light chain of Fv fragments, and can therefore be expected to be conserved. Therefore, for the purpose of this analysis, residues that are more than 80% conserved (see Table 9) are eliminated, with the exception of pairs in which an aromatic amino acid is conserved (see below).

Table 9. Residue amino acid identity conservation

		Consensus <sup>1</sup>	Occurrence of consensus <sup>2</sup>	Sample size, N <sup>3</sup>	No. occurring AAs <sup>4</sup>	AA identity conservation <sup>5</sup>
<b>Heavy Chain</b>						
	37	VAL	31	40	4	78%
	39	GLN	35	37	3	95%
25	48	VAL	30	42	4	71%
	89	VAL	25	40	7	63%
	91	TYR	42	44	2	95%
	92	CYS	44	44	1	100%
30	93	ALA	37	42	4	88%
	103	TRP	30	33	3	91%
<b>Light Chain</b>						
	43	ALA	49	65	6	75%
35	46	LEU	54	57	3	95%
	98	PHE	66	68	3	97%

<sup>1</sup> Most frequently occurring amino acid the indicated residue

<sup>2</sup> Number of the consensus amino acid (<sup>1</sup>) occurrences at the indicated residue

<sup>3</sup> Number of amino acids known for an Fv fragment at the indicated residue

5 <sup>4</sup> Number of different amino acids (AAs) occurring at the indicated residue

<sup>5</sup> Occurrence of the consensus amino acid (<sup>2</sup>) divided by the sample size, N(<sup>3</sup>).

10 Of the residues of the residue pairs of tables 4, 5, 6, 8, and 9, four pairs either do not contain a conserved aromatic amino acid, or do contain a residue that is more than 80% conserved, and are therefore eliminated.

The remaining residue pairs, that are predicted to be the optimal positions for the cross-link, are listed in Table 10 with all ratings described above.

15 **Table 10.** Selected potential residue pairs for the tyr-tyr cross-link to be directed to.

Residue pairs (H/L)	Rating I	Rating II	Rating III/IV	Rating V/VI
103/46	0.49	0.49	10.39/1.32	0.28/1.58
20 89/43	0.06	1.27	0.26/0.64	1.13/5.44
37/43	0.26	2.10	0.21/0.49	0.42/0.85
48/98	0.01	0.30	0.28/0.43	0.06/0.17

## 25 **6.11. RESIDUE PAIR SELECTION FLOWCHART FOR SOFTWARE**

### **Database Assembly**

30 **Starting Material**

### **2-D Database Import and Sorting of Data**

35 **Sequence Data**

- Import of 2D- polypeptide sequence data  
Define:  
 $s$  = sample size (number) of sequences of the individual polypeptide chains of the protein complex (preferably in polypeptide pairs of a complexes)  
5
- Alignment of data according to functional conservation (e.g. Kabat & Wu numbering system for Ig)  
Define:  
10  
 $i$  (subscript) = amino acid position within the alignment system to which any given atom belongs  
15
- Compilation of identity (three letter code) and frequency of amino acids occurring at each residue  
Define:  
 $f_i$  = frequency of the occurrence of a particular amino acid at a given residue,  $i$   
20  
 $n_i$  = number of amino acids occurring at a given residue,  $i$   
25
- Define and mark residues of both polypeptides within the conserved regions of both polypeptides (Framework Regions for Fv fragments)  
Assign:  
con = conserved residues  
non = variable residues  
30
- Assignment of consensus  
Define:  
The consensus is the most frequently occurring amino acid at any given residue of either polypeptide.  
35  
Assign:  
For each residue,  $i$ ,

Assign the consensus using, for example, amino acid single-letter code. For residues at which two or more amino acids occur most frequently, assign all most frequently occurring amino acids.

5

### **Data on physical properties of amino acid side-chains**

- Compilation of look-up tables with amino acids and corresponding numeric values  
Numeric values correspond to the most relevant physical properties of amino acid side-chains as they influence the overall structure of polypeptide complexes (e.g. side-chain volume, charge, hydrophobicity, and degrees of rotational freedom, etc.)

10

#### Define:

- 15 p (subscript): amino acid side-chain physical property chosen for the selection process

$N_{pi}$  = numeric value of a physical property corresponding to an occurring amino acid at a given residue, i

20

### **3-D Database Import and Sorting of Data**

#### **Sorting by Sequence (2-D)**

25

- Import of 3D-ordinate data of the polypeptides (from the structure of the complex as a whole)

#### Define:

30

m (subscript) = sample size (number) of different structures file imported (for both polypeptides of a complex)

- Alignment of data according to functional conservation (e.g. Kabat & Wu numbering system for Ig)

35

### Sorting by atomic, 3-D position

- Sorting of coordinate data by amino acid residue and atom position

5

Select alpha and beta carbons

Define:

$Ca1_i$  = alpha carbon belonging to the first of two polypeptides

10  $Ca2_i$  = alpha carbon belonging to the second of two polypeptides

$Cb1_i$  = beta carbon belonging to the first of two polypeptides

$Cb2_i$  = beta carbon belonging to the second of two polypeptides

Coordinates of  $Ca1_i$ :  $x_{A1i}$ ,  $y_{A1i}$ ,  $z_{A1i}$

15 Coordinates of  $Ca2_i$ :  $x_{A2i}$ ,  $y_{A2i}$ ,  $z_{A2i}$

Coordinates of  $Cb1_i$ :  $x_{B1i}$ ,  $y_{B1i}$ ,  $z_{B1i}$

Coordinates of  $Cb2_i$ :  $x_{B2i}$ ,  $y_{B2i}$ ,  $z_{B2i}$

### 20 Assembly of residue pairs

- Assembly of all possible inter-chain pairs of residues

Define

25  $j$  (subscript) = pair of amino acids as they fall within the above alignment system of both polypeptide chains

### Compilation of Relevant Measurements; Secondary, Derivative Data

30

#### 2-D derivative data

Computation of Residue characteristics for each physical property

- 35 • Retrieval of numeric values of each side-chain physical property for each amino acid occurring at each residue

Match every amino acid identity at each residue in the look-up table, and retrieve corresponding numeric values

5 • Calculation of weighted statistical measurements for each residue

Define:

10  $w\mu_{pi}$  = weighted average of the sample, s, of numeric values of a physical property at each residue, i, weighted by each occurring amino acid s frequency of occurrence,  $f_i$

15  $w\sigma_{pi}$  = weighted standard deviation of the sample, s, of numeric values of a physical property at any residue, i, weighted by each occurring amino acid s frequency of occurrence,  $f_i$

Calculate:

20 for the sample of sequences in the database, s, for each residue, h, and for each physical property, p

$$w\mu_{pi} = \sum (N_{pi} * f_{pi}) / \sum f_{pi}$$

$$w\sigma_{pi} = \text{SQRT}((\sum_{pi} * \sum (f_{pi} * N_{pi}^2) - \sum (f_{pi} * N_{pi})^2) / \sum f_{pi} * \sum (f_{pi} - 1))$$

25 • Calculation of un-weighted statistical measurements for each residue

Define:

30  $u\mu_{pi}$  = un-weighted average of the sample, s, of numeric values of a physical property at any residue, i, not weighted by each occurring amino acid's frequency of occurrence,  $f_i$

$u\sigma_{pi}$  = un-weighted standard deviation of the sample, s, of the numeric values of a physical property at any residue, i, not weighted by each occurring amino acid's frequency of occurrence,  $f_i$

35

Calculate:

for the sample of sequences in the database, s, for each residue, i, and for each physical property, p:

$$u\mu_{pi} = (\sum n_{pi}) / n_i$$

$$u\sigma_{pi} = \text{SQRT} \left( (n_i * \sum n_{pi}^2 - \sum (n_i * N_{pi})^2) / n_i * (n_i - 1) \right)$$

### Calculation of each pair's combined average and standard deviation

For both residues of each pair the sum of both average and standard deviation values are calculated for each physical property.

Calculate:

For every residue pair, j:

$$w\mu_{pj} = w\mu_{pi} + w\mu_{pi}$$

$$u\mu_{pj} = u\mu_{pi} + u\mu_{pi}$$

$$w\sigma_{pj} = w\sigma_{pi} + w\sigma_{pi}$$

$$u\sigma_{pj} = u\sigma_{pi} + u\sigma_{pi}$$

### 3-D derivative data

Calculation of residue pair inter-atomical carbon distances,  $D_\alpha$

- Application of Pythagorean geometry to the alpha carbon coordinates of each residue pair, j

30

Calculate:

For every residue pair, j:

$$D_{\alpha j} = \text{Sqrt}((x_{A1i} - x_{A2i})^2 + (y_{A1i} - y_{A2i})^2 + (z_{A1i} - z_{A2i})^2)$$

35

And for the sample of structures in the database, m



$\mu_{\alpha j}$  = Average of all  $D_{\alpha j}$

$v_{\alpha j}$  = Median of all  $D_{\alpha j}$

$\sigma_{\alpha j}$  = Standard deviation of all  $D_{\alpha j}$

5  $\text{Max}_{\alpha j}$  = Maximum of all  $D_{\alpha j}$

$\text{Min}_{\alpha j}$  = Minimum of all  $D_{\alpha j}$

**Calculation of difference between residue pair alpha - and beta carbon distances,  $\Delta_j$**

10

- Application of Pythagorean geometry to residue pair beta carbon coordinates, and subtraction

15 Calculate:

For every residue pair, j:

$D_{\beta j}$ : formula as described for alpha-carbon distance measurement with beta carbon distance measurement with beta carbon coordinates  $x_{B1 \text{ and } 2}$ ,

20

$y_{B1 \text{ and } 2}$ ,  $z_{B1 \text{ and } 2}$

$\Delta_j = D_{\alpha j} - D_{\beta j}$

And for the sample of structures in the database, m

25

$\mu_{\Delta j}$  = Average of all  $\Delta_j$

$v_{\Delta j}$  = Median of m  $\Delta_j$

$\sigma_{\Delta j}$  = Standard deviation of all  $\Delta_j$

$\text{Max}_{\Delta j}$  = Maximum of all  $\Delta_j$

30

$\text{Min}_{\Delta j}$  = Minimum of all  $\Delta_j$

**Calculation of 3D angles,  $\varphi_j$  and  $\psi_j$**

35

Define:

$\varphi_j$  = angle described by the atoms (points)  $C\beta 1_i - C\alpha 1_i - C\alpha 2_i$

$\psi_j$  = angle described by the points  $C\beta 2_i$  -  $C\alpha 2_i$  -  $C\alpha 1_i$ ,

$va1_j$  = vector from  $C\alpha 1_i$  to  $C\alpha 2_i$ ,

$va2_j$  = vector from  $C\alpha 2_i$  to  $C\alpha 1_i$ ,

5  $vb1_j$  = vector from  $C\alpha 1_i$  to  $C\beta 1_i$ ,

$vb2_j$  = vector from  $C\alpha 2_i$  to  $C\beta 2_i$ ,

Calculate:

10 vector coordinates, for every residue pair, j:

$va1_j$	$va2_j$	$va1_j$	$va2_j$
$X_{va1j} = X_{A2i} - X_{A1i}$	$X_{va2j} = X_{A1i} - X_{A2i}$	$X_{vb1j} = X_{B1i} - X_{A1i}$	$X_{vb2j} = X_{B1i} - X_{A2i}$
$Y_{va1j} = Y_{A2i} - Y_{A1i}$	$Y_{va2j} = Y_{A1i} - Y_{A2i}$	$Y_{vb1j} = Y_{B1i} - Y_{A1i}$	$Y_{vb2j} = Y_{B1i} - Y_{A2i}$
15 $Z_{va1j} = Z_{A2i} - Z_{A1i}$	$Z_{va2j} = Z_{A1i} - Z_{A2i}$	$Z_{vb1j} = Z_{B1i} - Z_{A1i}$	$Z_{vb2j} = Z_{B1i} - Z_{A2i}$

Calculate:

Angle  $\varphi_j$  (based on scalar products), for every residue pair, j

20

$$\varphi_j = \arccos \left( \frac{(x_{va1j} * x_{vb1j} + y_{va1j} * y_{vb1j} + z_{va1j} * z_{vb1j})}{\sqrt{x_{va1j}^2 + y_{va1j}^2 + z_{va1j}^2} * \sqrt{x_{vb1j}^2 + y_{vb1j}^2 + z_{vb1j}^2}} \right)$$

25

And for the sample of structures in the database, m

$\mu_{\varphi_j}$  = Average of all  $\varphi_j$

$v_{\varphi_j}$  = Median of all  $\varphi_j$

30

$\sigma_{\varphi_j}$  = Standard deviation of all  $\varphi_j$

$\text{Max}_{\varphi_j}$  = Maximum of all  $\varphi_j$

$\text{Min}_{\varphi_j}$  = Minimum of all  $\varphi_j$

Calculate:

35

Angle  $\psi_j$  (based on scalar products), for every residue pair, j

$$\Psi_j = \arccos \left( \frac{(x_{va2j} * x_{vb2j} + y_{va2j} * y_{vb2j} + z_{va2j} * z_{vb2j})}{\sqrt{x_{va2j}^2 + y_{va2j}^2 + z_{va2j}^2} * \sqrt{x_{vb2j}^2 + y_{vb2j}^2 + z_{vb2j}^2}} \right)$$

5 And for the sample of structures in the database, m

$\mu_{\psi_j}$  = Average of all  $\psi_j$

$v_{\psi_j}$  = Median of all  $\psi_j$

$\sigma_{\psi_j}$  = Standard deviation of all  $\psi_j$

10  $\text{Max}_{\psi_j}$  = Maximum of all  $\psi_j$

$\text{Min}_{\psi_j}$  = Minimum of all  $\psi_j$

### Calculation of the third 3D-angle

15

#### Define:

Vector  $g1_j$  ( $vg1_j$ ):  $A1_i - B2_i$

Plane  $E1_j$ , described by vectors  $va1_j$  and  $vb1_j$

20 Plane  $E2_j$ , described by vectors  $va1_j$  and  $vb1_j$

Vector  $n1_j$  ( $vn1_j$ ), perpendicular to  $E1_j$ , the vector product of  $va1_j$  and  $vb1_j$

Vector  $n2_j$  ( $vn2_j$ ), perpendicular to  $E2_j$ , the vector product of  $va1_j$  and  $vb1_j$

25

#### Calculate:

$vg1$  coordinates, for every residue pair, j

30

$$\begin{array}{c} \hline vg1_j \\ \hline X_{vg1j} = X_{B2i} - X_{A1i} \\ Y_{vg1j} = Y_{B2i} - Y_{A1i} \\ Z_{vg1j} = Z_{B2i} - Z_{A1i} \\ \hline \end{array}$$

35

#### Calculate:

$vn1$  and  $vn2$  coordinates (vector products), for every residue pair, j

$vn1_j$  = vector product of  $va1_j$  and  $va2_j$

$vn2_j$  = vector product of  $val_j$  and  $vgl_j$

	$vn1_j$	$vn2_j$
5	$x_{vn2j} = y_{valj} * z_{vblj} - y_{vblj} * z_{valj}$	$x_{vn2j} = y_{valj} * z_{vblj} - y_{vblj} * z_{valj}$
	$y_{vn2j} = z_{valj} * x_{vblj} - z_{vblj} * x_{valj}$	$y_{vn2j} = z_{valj} * x_{vblj} - z_{vblj} * x_{valj}$
	$z_{vn2j} = x_{valj} * y_{vblj} - x_{vblj} * y_{valj}$	$z_{vn2j} = x_{valj} * y_{vblj} - x_{vblj} * y_{valj}$

10

Calculate:

Angle between  $vn1_j$  and  $vn2_j$ , angle  $\chi_j$ , for every residue pair,  $j$

$$15 \quad \chi_j = \arccos \left( \frac{(x_{vn1j} * x_{vn2j} + y_{vn1j} * y_{vn2j} + z_{vn1j} * z_{vn2j})}{\sqrt{x_{vn1j}^2 + y_{vn1j}^2 + z_{vn1j}^2} * \sqrt{x_{vn2j}^2 + y_{vn2j}^2 + z_{vn2j}^2}} \right)$$

And for the sample of structures in the database,  $m$

20

$\mu_{\chi_i}$  = Average of all  $\chi_j$

$v_{\chi_i}$  = Average of all  $\chi_j$

$\sigma_{\chi_i}$  = Standard deviation of all  $\chi_j$

$\text{Max}_{\chi_i}$  = Maximum of all  $\chi_j$

25

$\text{Min}_{\chi_i}$  = Minimum of all  $\chi_j$

### Compilation of Residue Pair Ratings; Tertiary, Derivative Data

30

#### Residue pair Ratings based on 2-D Database

For each physical property chosen for the selection process

35

Define:

$T_p$  = sum of the numeric values of the physical properties of the amino acids to be substituted with in both polypeptide chains (2 x value of tyrosine for the tyrosine oxidative cross-link)

5  $v_p$  = allowable multiples of the weighted and un-weighted standard deviations of a physical property's values,  $u\sigma_{pj}$ .

- Rating (R) based on numeric values of a physical property, p, corresponding to occurring amino acids, weighted by the frequency of each amino acid's occurrence.

10

Calculate:

For each residue pair, j

$$wR_{pj} = v_p * w\sigma_{pj} / (\text{abs}(T_p - w\mu_{pj} - v_p * w\sigma_{pj}))$$

15

- Rating based numeric values of a physical property, p, corresponding to occurring amino acids.

20

Calculate:

For each residue pair, j

$$uR_{pj} = v_p * u\sigma_{pj} / (\text{abs}(T_p - u\mu_{pj} - v_p * u\sigma_{pj}))$$

## 25 **Residue pair Ratings based on 3-D Database**

Alpha carbon spacing

30

Define:

$v_{R\alpha}$  allowable multiples of the standard deviation of inter-chain alpha carbon distances,  $\sigma_{\alpha j}$

$v\text{Max}_{\alpha}$ : maximal value allowable for  $\mu_{\alpha j}$  in the selection process

$v\text{Min}_{\alpha}$ : minimal value allowable for  $\mu_{\alpha j}$  in the selection process

35

$T_{\alpha}$ : Target value for alpha carbon spacing

$R_{\alpha j}$ : Rating based on inter-chain alpha carbon spacing, scores high for residue pairs,  $j$ , with  $\mu_{\alpha j}$  values close to the target value,  $T_{\alpha}$ , and/or with high  $\sigma_{\alpha j}$  values (flexibility)

5

Calculate:

$T_{\alpha}$  = average of  $vMax_{\alpha}$  and  $vMin_{\alpha}$

10

For all residue pairs,  $j$

For all $\mu_{\alpha j} < T_{\alpha}$ :	For all $\mu_{\alpha j} > T_{\alpha}$ :
$R_{\alpha j} = (T_{\alpha} - \mu_{\alpha j} + v_{ra} * \sigma_{\alpha j})^2 / \sigma_{\alpha j}$	$R_{\alpha j} = (\mu_{\alpha j} + v_{ra} * \sigma_{\alpha j} - T_{\alpha})^2 / \sigma_{\alpha j}$

15

### $\Phi$ and $\psi$ Angles

Define:

20

$V_{R\phi\psi}$ : allowable multiples of the standard deviation of  $\phi_j$  and  $\psi_j$  angles,  $\sigma_{\phi j}$  and  $\sigma_{\psi j}$

$vMax_{\phi,\psi}$ : maximal value allowable for  $\mu_{\alpha j}$  in the selection process (same value for both angles)

$vMin_{\phi,\psi}$ : minimal value allowable for  $\mu_{\alpha j}$  in the selection process (same value for both angles)

25

$T_{\phi\psi}$ : Target value of  $\phi$  and  $\psi$  angles (same value for both angles)

$R_{\phi,\psi j}$ : Rating based on the angles  $\phi$  and  $\psi$ ; scores high for residue pairs,  $j$ , with  $\mu_{\phi j}$  and  $\mu_{\psi j}$  values close to the target value,  $T_{\phi,\psi}$ , and/or with high  $\sigma_{\phi j}$  and  $\sigma_{\psi j}$  values (flexibility)

30

$r_{\phi}$ : sub-rating based on the angle  $\phi$

$r_{\psi}$ : sub-rating based on the angle  $\psi$

35

Calculate:

$T_{\phi,\psi}$  = average of  $vMax_{\phi,\psi}$  and  $vMin_{\phi,\psi}$

For every residue pair, j

<p>5                      For all <math>\mu_{\phi j} &lt; T_{\phi, \psi}</math>:</p> $r_{\phi j} = (T_{\phi, \psi} - \mu_{\phi j} + v_{r\phi, \psi} * \sigma_{\phi j})^2 / \sigma_{\phi j}$ $r_{\psi j} = (T_{\phi, \psi} - \mu_{\psi j} + v_{R\phi, \psi} * \sigma_{\psi j})^2 / \sigma_{\psi j}$	<p>For all <math>\mu_{\psi j} &lt; T_{\phi, \psi}</math>:</p> $r_{\phi j} = (\mu_{\phi, \psi} + V_{R\phi, \psi} * \sigma_{\phi j} - T_{\phi, \psi})^2 / \sigma_{\phi j}$ $r_{\psi j} = (\mu_{\psi, \psi} + V_{R\phi, \psi} * \sigma_{\psi j} - T_{\phi, \psi})^2 / \sigma_{\psi j}$
$R_{\phi, \psi j} = \text{average of } r_{\phi j} \text{ and } r_{\psi j}$	

10                      **Difference between alpha- and beta carbon spacing**

Define:

- 15                       $v_{RD}$ : allowable multiples of the standard deviation for each residue pair, j, of m differences between inter-chain alpha- and beta carbon distances,  $\sigma_{\Delta j}$
- $vMax_{\Delta}$ : maximal value allowable for  $\mu_{\Delta j}$  in the selection process
- $vMin_{\Delta}$ : minimal value allowable for  $\mu_{\Delta j}$  in the selection process
- $T_{\Delta}$ : Target value for the difference between alpha beta carbon spacing
- 20                       $R_{\Delta j}$ : Rating based on differences between inter-chain alpha- and beta carbon distances, scores high for residue pairs, j, with  $\mu_{\Delta j}$  values close to the target value,  $T_{\Delta j}$ , and/or with high  $\sigma_{\Delta j}$  values (flexibility)

Calculate:

25                       $T_{\Delta} = \text{average of } vMax_{\Delta} \text{ and } vMin_{\Delta}$

For all residue pairs, j

30

<p>For all <math>\mu_{\Delta j} &lt; T_{\Delta}</math></p> $R_{\Delta j} = (T_{\Delta} - \mu_{\Delta j} + v_{RD} * \sigma_{\Delta j})^2 / \sigma_{\Delta j}$	<p>For all <math>\mu_{\Delta j} &gt; T_{\Delta}</math></p> $R_{\Delta j} = (\mu_{\Delta j} + v_{RD} * \sigma_{\Delta j} - T_{\Delta})^2 / \sigma_{\Delta j}$
--	--

35

## Selection Processes

The sequence of filters is of no significance

---

5

### **I 2D Selection Processes**

#### **Filter I.1: Selection for conserved residues**

10

For all residue pairs

If the amino acids of residue pair J are both assigned mark 'con' (conserved), select

If either amino acid of a residue pair j is assigned 'non' (variable), discard

15

#### **Filter I.2: Selection against residues that have glycine as consensus**

Selection of Pairs of which neither residue is most frequently glycine,

20

for all residue pairs:

If the consensus (most frequently occurring amino acid) of neither residue of a pair j is glycine, select

If the consensus (most frequently occurring amino acid) of either residue of a pair j is glycine, discard

25

#### **Filter I.3: Selection based on weighted statistical measurements**

Selection using statistical measurements of a physical property, p, of occurring amino acids  
30 at each residue, i, of every residue pair, j, weighted by the occurring amino acid's frequency of occurrence

Define:

35

$\text{Max}_{\text{wRp}}$ : maximum limit for the selection of an amino acid side-chain physical property, p, based on weighted statistical measurements

$\text{Min}_{\text{wRp}}$ : minimum limit for the selection of an amino acid side-chain physical property, p, based on weighted statistical measurements



Calculate:

IF  $[\text{Min}_{wRp} < wR_{pj} < \text{Max}_{wRp}]$  is True, select

IF  $[\text{Min}_{wRp} < wR_{pj} < \text{Max}_{wRp}]$  is False, discard

5

**Filter I.4: Selection based on un-weighted statistical measurements**

Selection using statistical measurements of a physical property, p, of occurring amino acids  
 10 at each residue, i, of every pair, j, not weighted by the occurring amino acid's frequency of  
 occurrence

Define:

$\text{Max}_{uRp}$ : maximum limit for the selection of an amino acid side-chain  
 physical property, p, based on weighted statistical measurements

15

$\text{Min}_{uRp}$ : minimum limit for the selection of an amino acid side-chain  
 physical property, p, based on weighted statistical measurements

Calculate:

IF  $[\text{Min}_{uRp} < uR_{pj} < \text{Max}_{uRp}]$  is True, select

IF  $[\text{Min}_{uRp} < uR_{pj} < \text{Max}_{uRp}]$  is False, discard

20

**II 3D Selection Process**

25

**Filter II.1: Selection for average alpha-carbon distances within selection range**Calculation:

For all residue pairs:

30

IF  $[\text{vMin}_\alpha < \mu_{\alpha j} < \text{vMax}_\alpha]$  is True, select

IF  $[\text{vMin}_\alpha < \mu_{\alpha j} < \text{vMax}_\alpha]$  is False, discard

35

**Filter II.2: Selection for sufficient flexibility of alpha carbon spacing**

Calculation:

For all residue pairs:

For all  $\mu_{\alpha j} < T_{\alpha}$

5 IF  $[\mu_{\alpha j} + v_{R\alpha} * \sigma_{\alpha jm} > T_{\alpha}] = \text{True}$ , select

IF  $[\mu_{\alpha j} + v_{R\alpha} * \sigma_{\alpha j} > T_{\alpha}] = \text{False}$ , discard

For all  $\mu_{\alpha} > T_{\alpha}$

IF  $[\mu_{\alpha j} - v_{R\alpha} * \sigma_{\alpha j} < T_{\alpha}] = \text{True}$ , select

10 IF  $[\mu_{\alpha j} + v_{R\alpha} * \sigma_{\alpha j} < T_{\alpha}] = \text{False}$ , discard

**Filter II.3: Selection for pairs with  $\phi$  and  $\psi$  angles within the selection range**

15 Calculation:

IF  $[v\text{Min}_{\phi,\psi} < \mu_{\phi j} < v\text{Max}_{\phi,\psi}] \text{ AND } [v\text{Min}_{\phi,\psi} < \mu_{\psi j} < v\text{Max}_{\phi,\psi}]$  is True, select

IF  $[v\text{Min}_{\phi,\psi} < \mu_{\phi j} < v\text{Max}_{\phi,\psi}] \text{ AND } [v\text{Min}_{\phi,\psi} < \mu_{\psi j} < v\text{Max}_{\phi,\psi}]$  is False, discard

20 **Filter II.4: Selection for average differences between alpha- and beta carbon distances within selection range**

$\mu_{\Delta j}$  = average difference between residue alpha carbon and beta carbon

distances

25

Calculation:

For all residue pairs

IF  $[v\text{Min}_{\Delta} < \mu_{\Delta j} < v\text{Max}_{\Delta}]$  is True, select

30

IF  $[v\text{Min}_{\Delta} < \mu_{\Delta j} < v\text{Max}_{\Delta}]$  is False, discard

**Filter II.5: Selection for sufficient flexibility of the pairs' difference between alpha and beta carbon distances**

35

Calculation:

For all residue pairs:

For all  $\mu_{\Delta j} < T_{\Delta}$

IF  $[\mu_{\Delta j} + v_{R\Delta} * \sigma_{\Delta j} > T_{\Delta}] = \text{True}$ , select

5 IF  $[\mu_{\Delta j} + v_{R\Delta} * \sigma_{\Delta j} > T_{\Delta}] = \text{False}$ , discard

For all  $\mu_{\alpha} > T_{\Delta}$

IF  $[\mu_{\Delta j} - v_{R\Delta} * \sigma_{\Delta j} > T_{\Delta}] = \text{True}$ , select

10 IF  $[\mu_{\Delta j} - v_{R\Delta} * \sigma_{\Delta j} > T_{\Delta}] = \text{False}$ , discard

### Final Selection

15 **Selected amino acid pairs**

All residue pairs, j, that are selected in all Filters (I.1-4 and II.1-6) are compiled and listed.

20 **Sort and Select by Ratings**

All listed residue pairs are compared by their Ratings, and the pair with the highest Ratings is the FINAL SELECTION.

25

## 6.12. POINT MUTAGENESIS AND SUB-CLONING INTO EXPRESSION

### VECTORS

30 **6.12.1. CONSERVATIVE SUBSTITUTIONS FOR UNDESIRE TYROSINE**

### RESIDUES

cDNA fragments encoding the Fv fragment heavy and light chains of the monoclonal anti- $\alpha 5$ -integrin antibody (example 1), or the monoclonal anti- $\beta 1$ -integrin antibody (example 2) are isolated from the hybridomas that produce them according to standard procedures known in the art. For example, RNA is isolated from the pellet of a suspension culture of hybridoma cells, the RNA is reversed transcribed using a mixture of poly-A and random primers, and cDNAs of the heavy and light chains are isolated by the

RACE method. The sequences of the heavy and light chains, that are to be cross-linked according to the procedures of the instant invention, are identified by standard procedures, and aligned with the K&W numbering system. Tyrosine residues identified are examined for their predicted proximity and positional flexibility toward each other. Residue pairs at which reactive side chains are found in the sequence that are either within an average of 15Å or less in the sample, or that have an average and standard deviation, such that the average less one standard deviation is 15Å or less in the sample are identified. Of these pairs, the residue of the pair at which tyrosine occurs at the lowest frequency in the 2-D Database, is point mutated to phenylalanine. Point mutations are introduced by using the QuikChange™ Site-Directed Mutagenesis Kit (Stratagene, Catalog # 200518).

#### 6.12.2. SUBSTITUTION OF RESIDUES OF A SELECTED PAIR WITH TYROSINE

At the residues of the pair selected, as described above, amino acid substitutions are introduced by point mutation, so far as tyrosine is not already present at the selected residues of the pair in the sequences of the heavy and light chains of the Fv fragment to be stabilized. Point mutations are introduced by using the QuikChange™ Site-Directed Mutagenesis Kit (see above).

#### 6.12.3. EXPRESSION VECTOR AND SYSTEM

DNA fragments encoding the Fv fragment heavy and light chains, all containing the conservative amino acid substitutions for undesired tyrosine residues, identified as described above, with and without the amino acid substitutions of residues of the selected pair with tyrosine are isolated. The isolated fragments (inserts) are subcloned into a pGEX expression vector containing the TEV-protease cleavage site. For the purposes of measuring the Fv fragments retained affinity for its antigen, the insert encoding the heavy chain is also fused with a nucleotide sequence encoding a Hemagglutinin (HA)-tag at the 3' end (C-terminus of the protein), for which a secondary antibody is commercially available. For the purposes of using the Fv fragment in diagnostic, therapeutic, or any other commercial applications, however, the HA-tag should be removed again. Subcloning is carried out by standard procedures known in the art.

### 6.13. Fv FRAGMENT BACTERIAL EXPRESSION AND PURIFICATION

The above-described expression plasmids encoding modified heavy and light Fv fragments are transformed competent BL21 or XA90 bacteria. Frozen glycerol stocks (0.5ml) are prepared from individual ampicillin resistant clones, with which expression cultures (e.g. 1000ml Luria Broth: 10gm tryptone, 5gm yeast extract, 5gm NaCl) containing 100µg/ml ampicillin) are inoculated. The cells are grown at 30°C on a rotary shaker (300rpm), and protein expression is induced with 1mM IPTG at an OD600 of 0.6. Following a three hour incubation, bacteria are harvested by centrifugation at 4000g at 4°C. The pellet is resuspended with ice-cold 50ml Lysis Buffer (20mM Tris.Cl pH 7.9, 500mM NaCl, 10% glycerol, 20mM β-mercaptoethanol, 1mM PMSF, 20µg/ml leupeptin, 20µg/ml pepstatin, 1% aprotinin) and then sonicated on ice until lysis is >90% complete. Insoluble matter is removed by centrifugation at 20,000g at 4°C for 20min. The supernatant is then incubated with 2ml Glutathione sepharose (Pharmacia) for 2hrs at 4°C. The beads are then pelleted by centrifugation at 4000g, and washed (re-suspended and pelleted) twice in 10 ml Lysis Buffer and twice in 10 ml TEV-protease Cleavage Buffer (Novagen). The beads are then incubated with 1µg His-tagged TEV protease (Novagen) at 30°C for 1hr in 2ml Cleavage Buffer. The protease is subsequently removed by adding 0.1ml equilibrated NTA-agarose (Qiagen) slurry to the suspension. Partially purified FvH and FvL fragments are present in the supernatant following centrifugation at 4000g.

### 6.14. INTRODUCTION OF THE OXIDATIVE TYROSYL-TYROSYL CROSS-LINK

The Fv fragment heavy and light chain gene products containing only the mutations of undesired reactive tyrosine residues to phenylalanine, without the mutations of the selected residue pair to tyrosine are partially purified and equilibrated by dialysis in phosphate buffered saline (PBS) before mixing them at equal molarity (0.1-1000µM). The catalyst, metalloporphyrin 20-tetrakis (4-sulfonatephenyl)-21H,23H-porphine manganese (III) chloride (MnTPPS) is then added on ice to a concentration of 1µM, 5µM, 10µM, 50µM and 100µM to the reaction. The reaction is then initiated by the addition of the oxidant potassium mono-persulfate to a concentration of 1-100µM, at room temperature or otherwise, for each of the concentrations of the catalyst, and at several protein concentrations. After 45 seconds the reaction is quenched by the addition of Tris.Cl pH7.9 to 50mM and β-mercaptoethanol to 10mM, and the solution is again dialyzed against PBS to remove the catalyst, oxidizing and reducing agents. Cross-linked and not cross-linked

hetero-dimers and monomers are isolated by gel filtration FPLC. The efficiency of the cross-link reaction is tested by non-reducing PAGE and Coomassie blue staining.

At each protein concentration, the maximal concentration of oxidizing reagent and catalyst at which a cross-link between the polypeptides of the reaction does not form is noted. These conditions are used to catalyze the reaction between the Fv fragment heavy and light chain gene products containing both the mutations of undesired reactive tyrosine residues to phenylalanine, and the mutations of the selected residue pair to tyrosine. Cross-linked and not cross-linked hetero-dimers and monomers are isolated by gel filtration FPLC. The efficiency of the cross-link reaction is tested by non-reducing PAGE and Coomassie blue staining.

## **6.15. TESTING THE STABILIZED COMPLEX**

### **6.15.1. YIELD OF FUNCTIONALLY STABILIZED Fv FRAGMENT COMPLEX**

Yield of functionally cross-linked Fv fragments is tested by passing a carefully determined amount of cross-linked, and glycerol gradient-purified Fv fragment protein over an immobilized antigen column, and comparing the flow-through with the starting material and the eluate of the column. Protein concentration measurements are carried out by standard procedures, such as Bradford or Lowrie assays (Bradford, 1976, and Lowrie, 1954), Coomassie-or silverstaining, or Western blotting.

### **6.15.2. RETAINED AFFINITY**

Fv fragments that are successfully cross-linked under the various conditions described above are tested for their retained affinity in ELISA-type procedures. Using 96 well-plates, the inside surfaces of the ELISA-assay plate wells are coated with antigen, for example integrin  $\alpha 5$  (Example 1) and integrin  $\beta 1$  (Example 2). The wells are washed, and with respect to one another, half the concentration of the full length antibody and an equal molar concentration of the F(ab) fragment of the antibody (see below) as positive controls, and the Fv fragment of the antibody, cross-linked as described above, are incubated in PBS for two hours at 37°C in serial dilutions in the wells coated with the respective antigen on one plate. F(ab) fragments are derived by pepsin digestion of the full length antibody and subsequent purification first by removal of the Fc fragments by running the antibody/protease solution through a Protein A column, and second by fractionating the flow-through of the Protein A column by ion exchange FPLC to remove the protease. The

wells are washed four times with 200  $\mu$ l of PBS and the anti-HA tag and alkaline phosphatase-coupled secondary antibody are sequentially incubated in PBS for an additional hour at 37°C. Wells are washed again four times with 200  $\mu$ l of PBS. The concentrations of bound IgG, F(ab) fragment, and Fv fragment are determined by standard procedures with an ELISA assay reader.

#### 6.15.3. STABILITY IN SERUM, LYSATE, AND THE CYTOPLASM

Stability of the complex in serum is tested in time-course experiments by incubating the complex in human serum at 37°C, 38°C, 39°C, 40°C, 42°C, and 45°C for up to two weeks, and testing for the remaining levels of functional Fv fragment complexes. As controls, the stability of Fab, scFv's and/or dsFv's are compared, all tagged with the same marker.

Stability of the complex in the cytoplasm is tested, also in time-course experiments, analogously to the incubation in serum, by incubating the complex in cell-lysates. More directly, the stability of the complex in the cytoplasm is tested by scrape-loading tissue culture cells with stabilized Fv fragments and assaying for the remaining levels of functional complexes. As controls, the stability of scFv's and dsFv's of the same original immunoglobulin molecule, both tagged with the same marker as the cross-linked Fv fragment, are compared.

In all of these experiments, the remaining levels of functional complexes will be determined in ELISA assays with the same secondary antibody, as described above.

#### 6.15.4. IMMUNOGENICITY

Mice are injected with various doses, ranging from 1  $\mu$ g to 10 mg, of stabilized complex. Stabilized complex is injected in the presence and absence of Freund's (Complete) Adjuvant. Further injections are given to the mice as boosts every five days (in the presence and absence of Incomplete Adjuvant). The mice receive a total of three or four boost-immunizations.

Tail-vein blood samples are taken before each injection, and one week after the final boost. Blood samples are spun at 3000g for 30 min. at 4°C.

ELISA plates are coated with the stabilized complex and a mixture of the unstabilized Fv fragment heavy and light chains, and ELISA assays are performed according to standard procedures, using a labeled anti-mouse secondary antibody.

The immunogenicity of complexes stabilized by the methods of the instant invention are compared to dsFv's and scFv's constructs of the same original immunoglobulin molecule as controls.

5

#### 6.15.5. BIODISTRIBUTION

<sup>18</sup>F radiolabeled stabilized Fv fragments, labeled according to the procedures published by Lang L. and Eckelmann U., 1994, are injected into mice. Each mouse is injected with 3 µg of roughly 4.5 MBq/µg of Fv fragment complex. Injected animals are sacrificed at 15, 45, 90, 360 min. and 24 h. and immediately exsanguinated by cardiac puncture. Tissues are separated, dried and weighed on an analytical balance, and counted in a gamma-radiation counter using a high energy setting (for <sup>18</sup>F). Aliquots of blood are also dried and counted. Counts are corrected for decay. Tissue:blood ratios, and the percentage of injected dose per gram tissue are calculated for each tissue.

15

Early-phase blood clearance studies are performed in mice injected with the same amount of above described <sup>18</sup>F radio-labeled stabilized Fv fragments. Serial tail-vein blood samples are taken at 1, 2, 5, 10, 15, and 30 min. The samples are dried and counted as described above, and the half-life of the Fv fragments in blood is calculated according to standard procedures (Choi C.W. *et al.* Cancer Research; vol. 55: pp. 5323-5329, 1995).

20

As controls for the above studies, single chain and disulfide Fv fragment constructs of the same original immunoglobulin molecule are compared.

### 7. EXAMPLE II

25

The following examples illustrate certain variations of the methods of the invention for protein stabilization. This example is presented by way of illustration and not by way of limitation on the scope of the invention.

30

#### 7.1. INTRODUCTION

Several polypeptides with significant commercial value have been identified in recent years, and furthermore, for many of these polypeptides structural data is available.

In the following section, methods of stabilizing one polypeptide, a biocatalyst, for which data is available only for the polypeptide itself, but not for other structurally or functionally related polypeptides, are described. Specifically, described below are the residue pair selection process and the cross-link reaction itself. For the

35



description of the introduction of point mutations, bacterial expression of the polypeptides and their purification, and adjustment of the cross-link reaction conditions, see Section 6, *supra*.

- 5                   The biocatalyst stabilized in the below example is lipase B of *Candida antarctica* ("CALB", Figure 1C), an enzyme for which multiple commercially highly relevant applications are possible due to its exquisite enantioselectivity, some of which are still uneconomic due to its lack of stability under certain adverse reaction conditions.

10                   The structure file containing the three dimensional atomic coordinates of the polypeptide's crystal structure is obtained from the Brookhaven National Laboratory Protein Database. The derivative data relevant to the selection process is calculated as described. The selection process is carried out using a set of filters that is convenient and appropriate for this application of the instant invention.

- 15                   Point mutations to tyrosine (directing the cross-link reaction) are introduced according to the final selection of the selection process, and point mutations to phenylalanine (limiting the cross-link reaction) as described in Section 6, *supra*. The polypeptide is expressed bacterially as a GST fusion protein, and purified, and proteolytically cleaved, also as described in Section 6, *supra*. The hydrophobic core of the protein, to which the cross-link is directed, is exposed by denaturing with guanidinium, at a  
20                   concentration which the protein refolds and the bond forms. The minimally required reaction conditions are adjusted using a construct with the mutations to phenylalanine, but lacking the mutations to tyrosine, and the cross-link reaction is then carried out with the constructs containing both sets of point mutations. The efficiency of the reaction is tested for stabilized biocatalyst, and the resulting stabilized biocatalyst is then tested for retained  
25                   activity and specificity, for improved stability in time, and under more adverse conditions.

## 7.2. ADVANTAGES OF THE TYROSYL-TYROSYL CROSS-LINK FOR BIOCATALYSTS

- 30                   The underlying chemistry of the technology covered by the present invention causes an oxidative cross-link to form between reactive side-chains of polypeptides that form stable complexes. Because the cross-linking reaction is catalyzed, the cross-link, once established, is stable in the absence of the catalyst under a broad range of pH and redox conditions. The cross-link reaction requires very close proximity between the reactive  
35                   side-chains that will cross-link.

Thus, the current invention describes a new technology that allows stabilization of biocatalysts and enables their use in a broader range of industrial applications. This technology is designed to improve on preceding, and complement compatible, technologies.

The resultant stabilized biocatalysts will have the following characteristics:

1. The enzymes will be more stable under a broad range of reaction conditions, including, but not limited to, temperature, pH, pressure, salinity, or concentration of other compounds in the reaction, such as a reducing agent, which is often a component of the chemical reaction for which the catalyst is required.

2. The resultant cross-linked and stabilized biocatalyst will retain its activity and specificity due to the specificity of the cross-link reaction and to the selection process.

This stabilization technology is well suited for the development of new products with novel applications, the improvement of existing industrial biocatalysts, and the complementation of existing technologies for the development of novel biocatalysts.

### **7.3. BIOCATALYST APPLICATIONS**

Biocatalytic enzymes constitute the preferred class of catalysts for industrial processes due to their high specificity and turnover rates, and their low development costs and cycle times. However, their utility is limited by the relative instability and limited shelf-life of protein molecules that is exacerbated by adverse reaction and/or storage conditions. The technology of this invention that can be applied to stabilize biocatalysts, thereby enhancing their utility and broadening their commercial application.

Application of the instant invention stabilizes enzymes with specifically placed internal cross-links, and thereby increases the stability of enzymes without impairing their activity in the desired reaction conditions. The resulting increase in enzyme stability thus not only addresses shelf-life limitations but also increases the enzymes' reaction rates and process yields.

Industrial biocatalytic processes are used in many industry sectors, including the chemical, detergent, pharmaceutical, agricultural, food, cosmetics, textile, materials-processing, and paper industries. Within these industries, biocatalysts have many applications, ranging from product synthesis (e.g. amino acid manufacturing, and fine chemical synthesis of small-molecule pharmaceuticals) through use as active agents in products (for example, in biological washing powders) to use in diagnostic testing

equipment. Biocatalysts also have industrial applications that range from wastewater and agricultural soil treatment, to crude oil refinement (e.g. desulfurication).

5

#### 7.4. SELECTION OF OPTIMAL RESIDUES

##### FOR TYROSYL-TYROSYL CROSS-LINK

The selection process consisted of a series of tests or 'filters' aimed at successively narrowing down the residue pairs most likely to result in a cross-linked tyrosine pair that minimally alter the activity or specificity of the enzyme, while lending  
10 maximal stability.

##### 7.4.1. DATA USED FOR THE ANALYSIS

Coordinate data for distance calculations of all atoms other than hydrogens  
15 from the crystallographically solved structure of was downloaded from the protein structure database Brookhaven National Laboratory (www.bnl.pdb.gov; Figure 5). These data provided the three-dimensional coordinates (x, y, and z) for each atom in the solved structure, expressed in metric units, i.e. Angströms (10<sup>-10</sup>m, Å). These data also contained the sequence and/or amino acid usage of the polypeptide. With this data it was possible to  
20 calculate the three-dimensional distances between any desired atoms (e.g. amino alpha and beta carbon atoms).

##### 7.4.2. SELECTION METHODOLOGY

Optimal residues, to which the cross-link reaction is directed, were selected  
25 by a series of filters based on the measurements of values in a database compiled for the purposes of this selection. This database contained numeric measurements of (1) alpha carbon spacing, (2) beta carbon spacing and the difference between the alpha and beta distances, and (3) residue amino acid usage (see below).

30

#### 7.5. FILTER 1: SELECTION OF SUFFICIENTLY SPACED AROMATIC RESIDUES

Because there are a significant number of aromatic residues available in the sequence of CALB, and because mutation of an aromatic residue (other than tyrosine, i.e.  
35 tryptophane, phenylalanine, or histidine) to tyrosine would be maximally conservative, for the selection process of this example, only aromatic residue pairs were analyzed.

Furthermore, to maximize the degree to which application of the instant invention stabilizes the enzyme, only pairs that are spaced more than 40 amino acids apart in the two-dimensional amino acid sequence were selected.

- 5 Table 11. Aromatic residue pairs with alpha carbon distances within the range of 5.70Å to 9.74Å, spaced more than 20 residues apart.

CALB residue pair		Alpha carbon	C $\alpha$ -C $\beta$ Distance
		distance	Difference
Phe9	Tyr82	9.29	-0.20
Phe48	Trp104	8.85	1.53
Trp52	Tyr234	8.71	0.02
Phe131	Tyr183	6.19	-1.31
Trp104	His224	9.33	0.33
Tyr135	Tyr203	7.58	0.10
Tyr183	His224	8.20	-1.09
Phe117	Tyr300	7.7	2.07

## 15 7.6. FILTER 2: IDENTIFICATION OF

### APPROPRIATELY SPACED RESIDUE PAIRS

To find residue pairs spaced appropriately for a tyrosyl-tyrosyl bond, the alpha carbon to alpha carbon distance between every residue pair in the polypeptide was  
 20 calculated in a 3D database. This calculation was performed by applying Pythagorean geometry to the 3D coordinates of the alpha carbons (Figure 6). Based on the calculations above, as a second cut, all residue pairs were selected whose alpha carbons are spaced within the selection range.

25 Because of the lack of statistical measurements that give insight to positional flexibility, the selection range was reduced by 2 Å, but only on the upper limit.

The range that was selected for was the following:

Min 5.70Å, Max 9.74 Å.

### 7.7. FILTER 3: SIDE-CHAIN ORIENTATION

The tyrosine side chains should be oriented toward each other for a cross-link to form with minimal structural distortion. The difference between the alpha carbon distance (i.e. the backbone carbon distance; Figure 6) and the beta carbon distance (i.e. the distance between the first carbons in each side chain; Figure 8) of each residue pair was calculated as a proxy, i.e. an estimate of the orientation of the side chains relative to each other (Figure 9).

The range that was selected for was the following:

Min  $-2\text{\AA}$ , Max  $3.0\text{\AA}$ .

Again, based on 3D coordinate geometry, for each residue pair, the distance between the beta carbons was calculated (Figure 8). The beta distance was then subtracted from the alpha distance of the residue pair (Figure 9). This filter was based on whether the difference in the alpha and beta distances of a residue pair falls within the estimated optimal range. In this example, all of the residue pairs in Table 11 met this criterion.

### 7.8. FILTER 3: PARTIAL ELIMINATION OF PAIRS WITH RESIDUES IN PROXIMITY TO THE ACTIVE SITE OF THE ENZYME

The functionality of an enzyme as a biocatalyst lies in its ability to catalyze chemical reaction. The activity and selectivity of a catalyst is most sensitive at those sites where the catalyst and the reactants physically contact each other. Therefore, mutations and/or cross-links are least desirable in the active site, and residues in or proximal to the active site are excluded.

His224 is in the active site, and was therefore excluded. Because Tyr183 is in close proximity to His224, the selected residues below should be mutated to generate polypeptides with tyrosine pairs, with and without the mutation of Tyr183 to Phe183. Furthermore, because His224 is also in close proximity to Trp104, and because Trp104 is in close proximity to Phe48, residue pairs containing the above residues were also excluded. The remaining residue pairs are list in Table 12.

**Table 12.** List of remaining residue pairs with relevant distance measurements.

	CALB residue pair		Alpha carbon	C $\alpha$ -C $\beta$ Distance	Epsilon carbon
			distance	Difference	distance*
5	Phe117	Tyr300	7.7	2.07	4.59
	Trp52	Tyr234	8.71	0.02	7.00
	Tyr135	Tyr203	7.58	0.10	9.08
	Phe9	Tyr82	9.29	-0.20	9.31

### 7.8. ANALYSIS OF EPSILON CARBON DISTANCES

Because the most likely isomer of the di-tyrosine bond is thought to be the epsilon-epsilon bond, and because coordinate data for an epsilon position atom of all of the amino acids selected is available, the distances between the epsilon positions of the above selected residue pairs in Table 12 were analyzed.

The pairs in Table 12 were ranked according to their epsilon carbon distances. However, since in three of the four pairs a point-mutation is required to generate a tyrosine pair, these distances may be altered, and all of the pairs are generated and examined.

### 7.9 POINT MUTATIONS AND EXPRESSION SYSTEM

See Section 6, *supra*, for a description of the substitution of residues of the selected pairs with tyrosine, expression vector and system, and bacterial expression and purification.

### 7.10. INTRODUCTION OF THE

#### OXIDATIVE TYROSYL-TYROSYL CROSS-LINK

The polypeptides containing only the mutations of undesired reactive tyrosine residues to phenylalanine, and mutations of the selected residue pair to tyrosine are partially purified and equilibrated by dialysis in phosphate buffered saline (PBS) at 0.1-1000mM. The hydrophobic core of the protein is exposed by denaturation with 6M guanidine. The catalyst, metalloporphyrin 20-tetrakis (4-sulfonatephenyl)-21H,23H-porphine manganese (III) chloride (MnTPPS) is then added on ice to a concentration of 1mM, 5mM, 10mM, 50mM and 100mM to the reaction. The guanidine is then diluted to 1:2, 1:5, 1:10, 1:20, 1:50, 1:100, 1:200, 1:500, and 1:1000 to allow the protein to refold, and the reaction is initiated by the addition of the oxidant potassium mono-persulfate. The oxidant is added to a concentration of 1-100mM, at room

temperature or otherwise, for each of the concentrations of the catalyst, and at several protein concentrations. After 45 seconds the reaction is quenched by the addition of TrisCl pH 7.9 to 50 mM and b-mercaptoethanol to 10 mM, and the solution is again dialyzed against PBS to remove remaining guanidine, the catalyst, oxidizing and reducing agents. Cross-linked and not cross-linked biocatalysts and monomers are isolated by gelfiltration FPLC. The efficiency of the cross-link reaction is tested by PAGE and Coomassie blue staining.

## 7.11 ASSAYING CALB STABILITY, ACTIVITY, AND SPECIFICITY

---

By any of the methods known in the art, the resultant, cross-linked CALB is analyzed for its retained activity and specificity, and for improvements in its stability under adverse conditions. Lipase activity, e.g., is determined by hydrolysis of p-nitrophenylesters of fatty acids with various chain lengths (>10) and spectrophotometric detection of p-nitrophenol at 410 nm. Alternatively, 1,2-O-dilauryl-rac-glycero-3-glutaric acid resorufin (Boeringer Mannheim Roche GmbH, Germany) can be hydrolyzed, yielding resorufin, which can be detected spectrophotometrically at 572 nm, or fluorometrically at 583 nm. Furthermore, a number of novel, synthesized fluorogenic alkyl diacylglycerols can be hydrolyzed dual wave length of both lipase activity and stereoselectivity (Jaeger K-E. et al. Annu. Rev. Microbiol. vol. 53: pp. 315-51, 1999 and Zandonella G. et al. J. Mol. Catal. B: Enzym., vol. 3: pp. 127-130). Improved stability is determined by standard protocols, that include calorimetric and/or other thermodynamic analyses, and time-course experiments under physiological conditions or more adverse conditions, such as higher temperatures, pressures, more stringent pH conditions, increased or decreased salinity, the presence and absence of reducing and oxidizing reagents, and the inclusion of various concentrations of different organic solvents.

## 8. REFERENCES

- Campbell L.A. *et al.* Protein Cross-linking Mediated by Metalloporphyrins. Bioorganic and Medicinal Chemistry, vol. 6: pp. 1301-1037, 1998
- Brown K.C. *et al.* Highly Specific Oxidative Cross-link of Proteins Mediated by a Nickel-peptide Complex. Biochem.; vol. 34(14): pp. 4733-4739, 1995
- Pollitt S. and Schultz P. Agnew. Chem. Int. Ed.; vol. 37(15): pp. 2104-2107, 1998

- Spangler B.D. and Erman J.E. Cytochrome c Peroxidase Compound I: Formation of Covalent Protein Crosslinks During the Endogenous Reduction of the Active Site. *Biochim. Biophys. Acta*; vol. 872(1-2): pp. 155-7, 1986
- 5 Gmeiner B. and Seelos C. Phosphorylation of Tyrosine Prevents Dityrosine Formation in vitro. *FEBS Lett* ; vol. 255(2): pp. 395-7, 1989
- Kanwar R. and Balasubramanian D. Structure and Stability of the Dityrosine-linked Dimer of GammaB-crystallin. *Exp. Eye Res.*; vol. 68(6): pp. 773-84, 1999
- 10 Fancy D.A. and Kodadek T. Chemistry for the Analysis of Protein-protein Interactions: Rapid and Efficient Cross-linking Triggered by Long Wavelength Light. *Proc. Natl. Acad. Sci., U.S.A.*; vol. 96: pp. 6020-24, 1999
- Klinman J.P. (ed.). Redox-active Amino Acids in Biology. *Methods in Enzymology*; vol. 258, 1995
- 15 Richards, F.M. The Interpretation of Protein Structures: Total Volume, Group Volume Distributions and Packing Density. *J. Mol. Biol.*; vol. 82: pp. 1-14, 1974
- Eisenberg, D. Three-dimensional Structure of Membrane and Surface Proteins. *Ann. Rev. Biochem.*; vol. 53: pp. 595-623, 1984
- 20 National Brookhaven Laboratory Protein Database (on-line at [www.nbl.pdb.gov](http://www.nbl.pdb.gov))
- Pastan *et al.* Recombinant Disulfide Stabilized Polypeptide Fragments Having Binding-specificity. United States Patent No. 5,747,654, issued May 5, 1998
- 25 Hofmann K. The Modular Nature of Apoptotic Signaling Proteins. *Cell Mol. Life Sci.*; vol. 55(8-9): pp. 1113-28, 1999
- Johnson, G. *et al.* Weir's Handbook of Experimental Immunology I. Immunochemistry and Molecular Immunology, Fifth Edition, Ed. L. A. Herzenberg, W. M. Weir, and C. Blackwell, Blackwell Science Inc., Cambridge, MA, Chapter 6.1-6.21, 1996
- 30 Wickelgren I. Mining the genome for drugs. *Science*; vol. 285(5430): pp. 998-1001, 1999
- Leong S.R. *et al.* IL-8 single-chain homodimers and heterodimers: interactions with chemokine receptors CXCR1, CXCR2, and DARC. *Protein Sci.*; vol. 6(3): pp. 609-17, 1997
- 35 Pawson T. Tyrosine Kinase Signalling Pathways. *Princess Takamatsu Symp.*; vol. 24: pp. 303-22, 1994



- Cowburn D. Peptide Recognition by PTB and PDZ Domains. *Curr. Opin. Struct. Biol.*; vol. 7(6): pp. 835-8, 1997
- Bockaert J. and Pin J.P. Molecular Tinkering of G Protein-coupled  
5 Receptors: an Evolutionary Success. *EMBO J.*; vol. 18(7): pp. 1723-9, 1999
- Royet J. *et al.* Notchless Encodes a Novel WD40-repeat-containing Protein that Modulates Notch Signaling Activity. *EMBO J.*; vol. 17(24): pp. 7351-60, 1998
- Chou J.J. *et al.* Solution Structure of the RAIDD CARD and Model for CARD/CARD Interaction in Caspase-2 and Caspase-9 Recruitment. *Cell*; vol. 94(2): pp.  
10 171-80, 1998
- Black R.A. and White J.M. ADAMs: Focus on the Protease Domain. *Curr Opin Cell Biol.*; vol. 10(5): pp. 654-9, 1998
- Strasser A. and Newton K. FADD/MORT1, a Signal Transducer that Can  
15 Promote Cell Death or Cell Growth. *Int. J. Biochem. Cell. Biol.*; vol. 31(5): pp. 533-7, 1999
- McInnes C. and Sykes B.D. Growth Factor Receptors: Structure, Mechanism, and Drug Discovery. *Biopolymers*; vol. 43(5): pp. 339-66, 1997
- Lotz M. *et al.* The Nerve Growth Factor/Tumor Necrosis Factor Receptor  
20 Family. *J. Leukoc. Biol.*; vol. 60(1): pp. 1-7, 1996
- Casaccia-Bonnel P. *et al.* p75 Neurotrophin Receptor as a Modulator of Survival and Death Decisions. *Microsc Res Tech.*; vol. 45(4-5): pp. 217-24, 1999
- Natoli G. *et al.* Apoptotic, Non-apoptotic, and Anti-apoptotic Pathways of  
25 Tumor Necrosis Factor Signalling. *Biochem. Pharmacol.*; vol. 56(8): pp. 915-20, 1998
- Alber T. Structure of the Leucine Zipper. *Curr. Opin. Genet. Dev.*; vol. 2(2): pp. 205-10, 1992
- Griffith T.S. *et al.* Functional Analysis of TRAIL Receptors Using Monoclonal Antibodies. *J. Immunol.*; vol. 162(5): pp. 2597-605, 1999
- 30 Yasuda H. *et al.* Identity of Osteoclastogenesis Inhibitory Factor (OCIF) and Osteoprotegerin (OPG): a Mechanism by which OPG/OCIF Inhibits Osteoclastogenesis in vitro. *Endocrinology*; vol. 139(3): pp. 1329-37, 1998
- Ortiz A. *et al.* New Kids in the Block: the Role of FasL and Fas in Kidney Damage. *J. Nephrol.*; vol. 12(3): pp. 150-8, 1999  
35

Price Waterhouse: Survey of Biopharmaceutical Industry, 1998 Boston Consulting Group: The Contribution of Pharmaceutical Companies: What's at stake for America, 1993

- 5                   Pharmaceutical Research and Manufacturers of America. New Medicines in Development, Survey. [www.phrma.org/publications/industry/profile99/chap2.html](http://www.phrma.org/publications/industry/profile99/chap2.html), 1998

Penuche M.L. *et al.* Antibody-IL-2 Fusion Proteins: a Novel Strategy for Immune Protection. *Hum Antibodies*; vol. 8(3): pp. 106-18, 1997

- 10                   Sensel M.G. *et al.* Engineering Novel Antibody Molecules. *Chem. Immunol.*; vol. 65: pp. 129-58, 1997

Reiter Y. and Pastan I. Recombinant Fv Immunotoxins and Fv Fragments as Novel Agents for Cancer Therapy and Diagnosis. *TIBTECH*; vol. 16(12): pp. 513-520, 1998

- 15                   Reiter Y. *et al.* Engineering Antibody Fv Fragments for Cancer Detection and Therapy: Disulfide-stabilized Fv Fragments. *Nat Biotech.*; vol. 14: pp. 1239-1245, 1996

- 20                   Pluckthun A. and P. Pack. New Protein Engineering Approaches to Multi-valent and Bi-specific Antibody Fragments. *Immunotechnology*; vol. 3(2): pp. 83-105, 1997

Wright A. and Morrison S.L. Effect of Glycosylation on Antibody Function: Implications for Genetic Engineering. *Trends Biotechnol.*; vol. 15(1): pp. 26-32, 1997

- 25                   Schwartz M.A. *et al.* Monoclonal Antibody Therapy. *Cancer Chemother. Biol. Response Modif.*; vol. 13: pp. 156-74, 1992

Houghton A.N. and Scheinberg D.A. Monoclonal Antibodies: Potential Applications to the Treatment of Cancer. *Semin Oncol.*; vol. 13(2): pp. 165-79, 1986

Cao Y. and Suresh M.R. Bi-specific Antibodies as Novel Bio-conjugates. *Bioconjugate Chemistry*; vol. 9(6): pp. 635-644, 1998

- 30                   Raag R. and Whitlow M. Single-chain Fvs. *FASEB*; vol. 9: pp. 73-80, 1995

Webber K.O. *et al.* Preparation and Characterization of a Disulfide-stabilized Fv Fragment of the Anti-Tac Antibody: Comparison with its Single-chain Analog. *Mol. Immunol.*; vol. 32(4): pp. 249-258, 1995

- 35                   Klinman J.P. (ed.). Redox-active Amino Acids in Biology. *Methods in Enzymology*, vol. 258, 1995

- Bosilevac J.M. *et al.* Inhibition of Activating Transcription Factor 1- and cAMP-responsive Element-binding Protein-activated Transcription by an Intracellular Single-chain Fv fragment. *J. Biol. Chem.*; vol. 273(27): pp. 16874-16879, 1998
- 5 Graus-Porta D. *et al.* Single Chain Mediated Intracellular Retention of ErbB-2 Impairs Neu Differentiation Factor and Epidermal Growth Factor Signaling. *Mol. Cell Biol.*; vol 15: pp. 1182-1191, 1995
- Richardson J.H. *et al.* Phenotypic Knockout of the High-affinity Interleukin 2 Receptor by Intracellular Single Chain Antibodies against the Alpha Subunit of the
- 10 Receptor. *Proc. Nat. Acad. Sci., USA*; vol. 92: pp. 3137-3141, 1995
- Maciejewski J.P. *et al.* Intracellular Expression of Antibody Fragments Directed against Human Immunodeficiency Virus Reverse Transcriptase Prevents HIV Infection in vitro. *Nat. Med.*; vol. 1: pp. 667-673, 1995
- Marasco W.A. *et al.* Design, Intracellular Expression, and Activity of a
- 15 Human Anti-human Immunodeficiency Virus Type I gp120 Single Chain Antibody. *Proc. Nat. Acad. Sci., USA*; vol. 90: pp. 7889-7893, 1993
- Levy Mintz P. *et al.* Intracellular Expression of Single Chain Variable Fragment to Inhibit Early Stages of the Virla Life Cycle by Targeting Human
- 20 Immunodeficiency Virus Type 1 Integrase. *J. Virol.*; vol. 70: pp. 8821-8832, 1996
- Duan L. *et al.* Intracellular Immunization Against Human Immunodeficiency Virus Type I Infection of Human T Lymphocytes: Utility of Anti-rev Single Chain Variable Fragment. *Hum. Gene Ther.*; vol. 6(12): pp. 1561-1573, 1995
- Kim S.H. *et al.* Expression and Characterization of Recombinant
- 25 Single-chain Fv and Fv Fragments Derived from a Set of Catalytic Antibodies. *Mol. Immunol.*; vol. 34(12-13): pp. 891-906, 1997
- Choi C.W. *et al.* Biodistribution of 18F- and 125I-labelled Anti-Tac Disulfide-stabilized Fv Fragments in Nude Mice with Interleukin 2 a Receptor-positive Tumor Xenografts. *Cancer Research*; vol. 55: pp. 5323-5329, 1995
- 30 Colcher D. *et al.* Pharmacokinetics and Biodistribution of Genetically-engineered Antibodies. *Q J Nucl Med.*; vol. 42(4): pp. 225-41, 1998
- Pavlinkova G. *et al.* Pharmacokinetics and Biodistribution of Engineered Single-chain Antibody Constructs of MAb CC49 in Colon Carcinoma Xenografts. *J. Nucl. Med.*; vol. 40(9): pp. 1536-46, 1999
- 35

Antibody Engineering Page, IMT, University of Marburg, FRG:  
[http://aximt1.imt.uni-marburg.de/\\_rek/indexfenster.html](http://aximt1.imt.uni-marburg.de/_rek/indexfenster.html)

Hunkapiller M. *et al.* A Microchemical Facility for the Analysis and  
5 Synthesis of Genes and Proteins. *Nature*; vol. 310(5973): pp. 105-11, 1984

Xia X and Li WH. What Amino Acid Properties Affect Protein Evolution, *J.*  
*Mol. Evol.*; vol. 47(5): pp. 557-64, 1998

Sandberg M, *et al.* New Chemical Descriptors Relevant for the Design of  
Biologically Active Peptides. A Multivariate Characterization of 87 Amino Acids. *J. Med.*  
10 *Chem.*; vol. 41(14): pp. 2481-91, 1998

Hopp T.P. and Woods K.R. Prediction of Protein Antigenic Determinants  
from Amino Acid Sequences. *Proc. Natl. Acad. Sci., U.S.A.*; vol. 78: pp. 3824, 1981

Bradford, M. A Rapid and Sensitive Method for the Quantitation of  
15 Microgram Quantities of Protein Utilizing the Principle of Protein-dye Binding. *Anal.*  
*Biochem.*; vol. 72: pp. 248-54, 1976

Lowry, O. *J. Biol. Chem.*; vol. 193, pp. 265, 1951

Lei S.P. *et al.* Characterization of the *Erwinia Carotovora pelB* Gene and its  
Product Pectate Lyase. *J. Bacteriol.*; vol. 169: pp. 4379-83, 1987

20 Chou P.Y. and Fasman G.D. Prediction of Protein Conformation.  
*Biochemistry*; vol. 13(2): pp. 222-45, 1974

Lang L. and Eckelmann W.C. One-step Synthesis of <sup>18</sup>F labeled  
[<sup>18</sup>F]-N-succinimidyl 4-(fluoromethyl) benzoate for Protein Labeling. *Appl. Radiat. Isot.*;  
25 vol. 45: pp. 1155-63, 1994

Sambrook *et al.*; Glover (ed.). *DNA Cloning: A Practical Approach.* MRL  
Press, Ltd., Oxford, U.K.; vol. I, II, 1985

Benton and Davis. Screening Lambda<sup>+</sup> Recombinant Clones by  
Hybridization to Single Plaques in situ. *Science*; vol. 196(4286): pp. 180-2, 1977

30 Clemmons D.R. IGF Binding Proteins and their Functions. *Mol. Reprod.*  
*Dev.*; vol. 35: pp. 368-374, 1993

Loddick S.A. *et al.* Displacement of Insulin-like Growth Factors from their  
Binding Proteins as a Potential Treatment for Stroke. *Proc. Natl. Acad. Sci., U.S.A.*; vol.  
95: pp. 1894-1898, 1998

35 Swift G.H. *et al.* Tissue-specific expression of the rat pancreatic elastase I  
gene in transgenic mice. *Cell*; vol. 38: pp. 639-646, 1984

- Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. *Nature*; vol. 315: pp. 115-122, 1985
- 5 Grosschedl R. *et al.* Introduction of a mu immunoglobulin gene into the mouse germ line: specific expression in lymphoid cells and synthesis of functional antibody. *Cell*; vol. 38: pp. 647-658, 1984
- Leder A *et al.* Consequences of widespread deregulation of the c-myc gene in transgenic mice: multiple neoplasms and normal development. *Cell*; vol. 45: pp. 10 485-495, 1986
- Pinkert C.A. *et al.* An albumin enhancer located 10 kb upstream functions along with its promoter to direct efficient, liver-specific expression in transgenic mice. *Genes Dev.*; vol. 1: pp. 268-276, 1987
- 15 Krumlauf R. *et al.* Developmental regulation of alpha-fetoprotein genes in transgenic mice. *Mol. Cell. Biol.*; vol. 5: pp. 1639-1648, 1985
- Kelsey G.D. *et al.* Species- and tissue-specific expression of human alpha 1-antitrypsin in transgenic mice. *Genes Dev.*; vol. 1: pp. 161-171, 1987
- 20 Magram J. *et al.* Developmental regulation of a cloned adult beta-globin gene in transgenic mice. *Nature*; vol. 315: pp. 338-340, 1985
- Readhead C. *et al.* Expression of a myelin basic protein gene in transgenic shiverer mice: correction of the dysmyelinating phenotype. *Cell*; vol. 48: pp. 703-712, 1987
- 25 Shani M. Tissue-specific expression of rat myosin light-chain 2 gene in transgenic mice. *Nature*; vol. 314: pp. 283-286, 1985
- Mason A.J. *et al.* The hypogonadal mouse: reproductive functions restored by gene therapy. *Science*; vol. 234: pp. 1372-1378, 1986
- 30 Smith D.B. and Johnson K.S. Single-step purification of polypeptides expressed in *Escherichia coli* as fusions with glutathione S-transferase. *Gene*; vol. 67: pp. 31-40, 1988
- Lei S.P. *et al.* Characterization of the *Erwinia carotovora* pelB gene and its product pectate lyase. *J. Bacteriol.*, vol. 169: pp. 4379, 1987
- 35 Kim S.H. *et al.* Expression and characterization of recombinant single-chain Fv and Fv fragments derived from a set of catalytic antibodies. *Mol. Immunol.*, vol. 34: pp. 891-906, 1997

- Cale J.M. *et al.* Optimization of a reverse transcription-polymerase chain reaction (RT-PCR) mass assay for low-abundance mRNA. *Methods Mol. Biol.*; vol. 105: pp. 351-71, 1998
- 5                   Weis J.H. *et al.* Detection of rare mRNAs via quantitative RT-PCR. *Trends Genet.*; vol. 8(8): pp. 263-4, 1992
- Frohman M.A. On beyond classic RACE (rapid amplification of cDNA ends). *PCR Methods Appl.*; vol. 4(1): pp. S40-58, 1994
- Adams P.D. *et al.* Extending the limits of molecular replacement through  
10 combined simulated annealing and maximum-likelihood refinement. *Acta Crystallogr. D. Biol. Crystallogr.*; vol. 55 ( Pt 1): pp. 181-90, 1999
- Schwarze S.R. *et al.* In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse. *Science*; vol. 285: pp. 1565-72, 1999
- 15                   Hoffman R.M. Topical liposome targeting of dyes, melanins, genes, and proteins selectively to hair follicles. *J. Drug Target.*; vol. 5(2): pp. 67-74, 1998
- Pluckthun A. *et al.* Catalytic antibodies: contributions from engineering and expression in *Escherichia coli*. *Ciba Found. Symp.*; vol. 159: pp. 103-12; discussion 112-7, 1991
- 20                   Guogiang J. *et al.* Dimerization Inhibits the Activity of Receptor-like Protein-tyrosine Phosphatase alpha. *Nature*; vol. 401: pp.606-610, 1999
- BIC, Explorer, Business Opportunities in Technology Commercialization.
- Illanes A. Stability of biocatalysts. *Elec.J.Biotech.*, vol. 2(1): pp. 7-15, 1999
- 25                   DeSantis G. and Jones J.B. Chemical modification of enzymes for enhanced functionality. *Curr. Op. Biotech.*, vol. 10(4): pp. 324-340, 1999
- Govardhan C.P. Crosslinking of enzymes for improved stability and performance. *Curr Opin Biotechnol.* Aug; vol 10(4):331-5, 1999
- Beguin P. Hybrid enzymes. *Curr. Op. Biotech.*, vol. 10(4): pp. 336-340,  
30 1999
- Haring D. and Schreier P. Cross-linked enzyme crystals. *Curr Opin Chem Biol.*; vol. 3(1): pp. 35-8, 1999
- Moreno-Hagelsieb G. and Soberon X. Protein engineering as a powerful  
35 tool for the chemical modification of enzymes. *Biol Res.*; vol. 29(1): pp. 127-40, 1996

Jaeger K-E. *et al.* Bacterial Biocatalysts: Molecular Biology, Three-Dimensional Structures, and Biotechnological Applications of Lipases. *Annu. Rev. Microbiol.* vol. 53: pp. 315-51, 1999

5           The invention claimed and described herein is not to be limited in scope by the specific embodiments, including but not limited to the deposited microorganism embodiments, herein disclosed since these embodiments are intended as illustrations of several aspects of the invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from  
10 the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.

A number of references are cited herein, the entire disclosures of which are incorporated herein, in their entirety, by reference.

15

20

25

30

35

## WHAT IS CLAIMED IS:

1. A method for making a stabilized protein or fragment thereof comprising:
  - (a) selecting one or more residue pairs in a polypeptide chain or chains for cross-linking using one or more statistical criteria; and
  - (b) cross-linking the residue pairs.
2. The method of claim 1, wherein the stabilized protein or fragment is selected from the group consisting of a hormone, a receptor, a growth factor, an enzyme and an antibody.
3. The method of claim 2, wherein the enzyme is a lipase or the antibody fragment is an Fv fragment.
4. The method of claim 1, wherein the one or more statistical criteria used for selection of residue pairs in step (a) are selected from the group consisting of statistical filter one through statistical filter six.
5. The method of claim 1, wherein tyrosine residues are cross-linked.
6. The method of claim 6, wherein cross-linking is catalyzed by a catalyst selected from the group consisting of polyhistidine, Gly-Gly-His and metalloporphyrin.
7. The method of claim 6, wherein the cross-linked tyrosine residues are introduced into the stabilized protein complex prior to cross-linking by recombinant nucleic acid methods.
8. A method for identifying a residue pair in a polypeptide chain or chains that, following substitution with tyrosine and cross-linking, is least likely to be disruptive of overall protein structure, comprising applying one or more statistical criteria selected from the group consisting of statistical filter one through statistical filter six.



9. A protein cross-linked by the method of claim 1.
10. A protein comprising at least one di-tyrosine cross-link, which protein  
5 retains at least one function displayed by the protein in the absence of di-tyrosine cross-linking.
11. The protein of claim 10, further comprising at least one amino acid which  
10 was substituted for a tyrosine residue such that the residue substituted for the tyrosine residue is not cross-linked under cross-linking conditions.
12. The protein of claim 10, wherein the function retained is selected from the  
group consisting of catalytic activity and binding specificity.  
15
13. The protein of claim 10 which is selected from the group consisting of an  
enzyme and an antibody or fragment thereof.
14. A pharmaceutical composition comprising the protein of any one of claims 9  
20 to 13.
15. The pharmaceutical composition of claim 14, further comprising a  
pharmaceutically acceptable carrier.  
25
16. The pharmaceutical composition of claim 14 which is suitable for *in vivo* use  
in humans.
17. A kit comprising in one or more containers the protein of any one of claims 9  
30 to 13.
18. A method for making a stabilized protein comprising:  
35 (a) selecting one or more residue pairs in a polypeptide chain or chains  
for cross-linking, wherein the selected residues are tyrosine when  
cross-linked; and

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/28595

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) : C12P 21/06; C12N 9/00; C12N 15/00; C07H 21/02, 21/04

US CL : 435/69.1, 183, 252.2, 320.1; 536/23.1, 23.2

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/69.1, 183, 252.2, 320.1; 536/23.1, 23.2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 4,904,592 A (FREEMAN et al.) 27 February 1990, see the entire document.	1-20
Y	US 5,538,876 A (MUTSAERS et al.) 23 June 1996, see the entire document.	1-20
Y	US 4,650,758 A (SHAKED et al.) 17 March 1987, see the entire document.	1-20



Further documents are listed in the continuation of Box C.



See patent family annex.

* "A"	Special categories of cited documents: document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E"	earlier document published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	
"P"	document published prior to the international filing date but later than the priority date claimed	"A" document member of the same patent family

Date of the actual completion of the international search

15 DECEMBER 2000

Date of mailing of the international search report

05 FEB 2001

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

TERCHAND SAIDHA

Telephone No. (703) 308-0196

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/28595

## B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

West; STN files including medline, caplus, biosis, embase, uspatfull, scisearch. Search terms included - stabilized enzyme, stabilized and (protein or antibodies); statistical tests or filters in combination with stabilized protein (or enzyme).

(b) cross-linking the residue pairs.

19. The method of claim 18, wherein the cross-link reaction occurs in the  
5 presence of an oxidant selected from the group consisting of hydrogen peroxide, oxone,  
magnesium monoperoxypthalic acid hexahydrate (MMPP), a photogenerated oxidant, and  
ammonium persulfate.

20. The method of claim 19, wherein cross-linking is catalyzed by a catalyst  
10 selected from the group consisting of polyhistidine, Gly-Gly-His and metalloporphyrin.

15

20

25

30

35

1/20




FIG.1A





FIG.1B

3/20



**FIG. 1C**

4/20




FIG.1D






FIG.2A




FIG.2B




FIG.2C

6/20




FIG.3A




FIG.3B

7/20




FIG. 4A




FIG. 4B

8/20

## LIGHT CHAIN (L)

CHAIN	K&W	ATOM	AMINO ACID	x COORDINATE	y COORDINATE	z COORDINATE
L	1	N	ASP	2.37	-5.00	-27.24
L	1	C $\alpha$	ASP	2.98	-3.78	-26.64
L	1	C	ASP	1.91	-2.70	-26.52
L	1	O	ASP	1.33	-2.29	-27.53
L	1	C $\beta$	ASP	4.14	-3.29	-27.53
L	1	C $\gamma$	ASP	5.18	-2.49	-26.76
L	1	O $\delta$ 1	ASP	4.86	-1.38	-26.27
L	1	O $\delta$ 2	ASP	6.34	-2.97	-26.65
L	2	N	ILE	1.63	-2.26	-25.30
L	2	C $\alpha$	ILE	0.60	-1.24	-25.07
L	2	C	ILE	1.19	0.15	-24.94
L	2	O	ILE	2.14	0.35	-24.94
L	2	C $\beta$	ILE	-0.21	-1.52	-23.78
L	2	C $\gamma$ 1	ILE	-0.90	-2.88	-23.86
L	2	C $\gamma$ 2	ILE	-1.24	-0.43	-23.58
L	2	C $\delta$ 1	ILE	-1.66	-3.26	-22.59
L	3	.	.	.	.	.
.	.	.	.	.	.	.
.	.	.	.	.	.	.

FIG.5A

9/20

## HEAVY CHAIN (H)

CHAIN	K&W	ATOM	AMINO ACID	x COORDINATE	y COORDINATE	z COORDINATE
H	1	N	GLU	11.12	-2.19	9.00
H	1	C $\alpha$	GLU	11.43	-1.08	8.05
H	1	C	GLU	11.93	-1.63	6.71
H	1	O	GLU	13.10	-1.98	6.56
H	1	C $\beta$	GLU	12.47	-0.12	8.66
H	1	C $\gamma$	GLU	13.82	-0.75	9.05
H	1	C $\delta$	GLU	13.70	-1.77	10.17
H	1	O $\epsilon$ 1	GLU	13.38	-1.36	11.31
H	1	O $\epsilon$ 2	GLU	13.94	-2.97	9.92
H	2	N	ILE	11.02	-1.70	5.74
H	2	C $\alpha$	ILE	11.36	-2.24	4.42
H	2	C	ILE	12.10	-1.22	3.59
H	2	O	ILE	11.77	-0.04	3.64
H	2	C $\beta$	ILE	10.11	-2.68	3.62
H	2	C $\gamma$ 1	ILE	9.31	-3.73	4.39
H	2	C $\gamma$ 2	ILE	10.52	-3.22	2.28
H	3	C $\delta$ 1	ILE	8.49	-3.17	5.55
H	3	.	.	.	.	.
.	.	.	.	.	.	.
.	.	.	.	.	.	.

FIG.5B

10/20

## Fv FRAGMENT 1

							Ch	L	L	L	L	L
							K&W	1	2	3	4	5
							At	C $\alpha$	C $\alpha$	C $\alpha$	C $\alpha$	C $\alpha$
							AA	Asp	Ile	.	.	.
							x	2.98	0.60	.	.	.
							y	-3.78	-1.24	.	.	.
							z	-26.64	-25.07	.	.	.
Ch	K&W	At	AA	x	y	z						
H	1	C $\alpha$	Glu	11.43	-1.08	8.05	35.80	34.84	.	.	.	.
H	2	C $\alpha$	Ile	11.36	-2.24	4.42	32.21	31.42	.	.	.	.
H	3	C $\alpha$	.	.	.	.	.	.	.	.	.	.
H	4	C $\alpha$	.	.	.	.	.	.	.	.	.	.
H	5	C $\alpha$	.	.	.	.	.	.	.	.	.	.

FIG.6A

## Fv FRAGMENT 2

							Ch	L	L	L	L	L
							K&W	1	2	3	4	5
							At	C $\alpha$	C $\alpha$	C $\alpha$	C $\alpha$	C $\alpha$
							AA	Glu	Ser	.	.	.
							x	35.61	31.94	.	.	.
							y	83.10	83.89	.	.	.
							z	56.99	56.85	.	.	.
Ch	K&W	At	AA	x	y	z						
H	1	C $\alpha$	Glu	10.23	61.09	64.74	34.48	32.46	.	.	.	.
H	2	C $\alpha$	Val	13.63	62.72	65.19	31.07	29.20	.	.	.	.
H	3	C $\alpha$	.	.	.	.	.	.	.	.	.	.
H	4	C $\alpha$	.	.	.	.	.	.	.	.	.	.
H	5	C $\alpha$	.	.	.	.	.	.	.	.	.	.

FIG.6B

11/20

Fv FRAGMENT 3

							Ch	L	L	L	L	L
							K&W	1	2	3	4	5
							At	C $\alpha$	C $\alpha$	C $\alpha$	C $\alpha$	C $\alpha$
							AA	Glu	Ser	.	.	.
							x	19.56	19.09	.	.	.
							y	-13.02	-15.06	.	.	.
							z	-15.86	-12.67	.	.	.
Ch	K&W	At	AA	x	y	z						
H	1	C $\alpha$	GLN	26.71	9.76	10.88	35.84	35.05	.	.	.	.
H	2	C $\alpha$	Val	27.45	8.61	7.34	32.69	32.11	.	.	.	.
H	3	C $\alpha$	.	.	.	.	.	.	.	.	.	.
H	4	C $\alpha$	.	.	.	.	.	.	.	.	.	.
H	5	C $\alpha$	.	.	.	.	.	.	.	.	.	.

FIG.6C

12/20

RESIDUE PAIRS		AVERAGE	St.DEV.	MAX	MIN	MEDIAN
H1	L1	35.38	0.78	35.84	34.48	35.80
H1	L2	34.12	1.44	35.05	32.46	34.84
H1	L3	.	.	.	.	.
H1	L4	.	.	.	.	.
.	.	.	.	.	.	.
H1	L106	.	.	.	.	.
H2	L1	31.99	0.83	32.69	31.07	32.21
H2	L2	30.91	1.52	32.11	29.20	31.41
H2	L3	.	.	.	.	.
H2	L4	.	.	.	.	.
.	.	.	.	.	.	.
H2	L106	.	.	.	.	.
H3	L1	.	.	.	.	.

FIG.7A

RESIDUE PAIRS		AVERAGE	St.DEV.	MAX	MIN	MEDIAN
H1	L1	35.09	1.56	37.37	31.23	35.54
H1	L2	34.00	1.87	37.36	29.92	34.38
H1	L3	.	.	.	.	.
H1	L4	.	.	.	.	.
.	.	.	.	.	.	.
H1	L106	.	.	.	.	.
H2	L1	32.26	1.57	36.71	30.34	32.14
H2	L2	31.32	1.99	36.77	29.20	31.11
H2	L3	.	.	.	.	.
H2	L4	.	.	.	.	.
.	.	.	.	.	.	.
H2	L106	.	.	.	.	.
H3	L1	.	.	.	.	.

FIG.7B



13/20

							Ch	L	L	L	L	L
							K&W	1	2	3	4	5
							At	C $\beta$	C $\beta$	C $\beta$	C $\beta$	C $\beta$
							AA	ASP	ILE	.	.	.
							x	4.14	-0.21	.	.	.
							y	-3.29	-1.52	.	.	.
							z	-27.53	-23.78	.	.	.
Ch	K&W	At	AA	x	y	z						
H	1	C $\beta$	GLU	12.47	-0.12	8.66		37.27	34.85	.	.	.
H	2	C $\beta$	ILE	10.11	-2.68	3.62		31.73	29.30	.	.	.
H	3	C $\beta$	.	.	.	.		.	.	.	.	.
H	4	C $\beta$	.	.	.	.		.	.	.	.	.
H	5	C $\beta$	.	.	.	.		.	.	.	.	.

FIG.8

14/20

ALPHA DISTANCES							Ch	L	L	L	L	L
							K&W	1	2	3	4	5
							At	C $\alpha$	C $\alpha$	C $\alpha$	C $\alpha$	C $\alpha$
							AA	ASP	ILE	.	.	.
							x	2.98	0.60	.	.	.
							y	-3.78	-1.24	.	.	.
							z	-26.64	-25.07	.	.	.
Ch	K&W	At	AA	x	y	z						
H	1	C $\alpha$	GLU	11.43	-1.08	8.05	35.80	34.84	.	.	.	.
H	2	C $\alpha$	ILE	11.36	-2.24	4.42	32.21	31.42	.	.	.	.
H	3	C $\alpha$	.	.	.	.	.	.	.	.	.	.
H	4	C $\alpha$	.	.	.	.	.	.	.	.	.	.
H	5	C $\alpha$	.	.	.	.	.	.	.	.	.	.

FIG.9A

BETA DISTANCES							Ch	L	L	L	L	L
							K&W	1	2	3	4	5
							At	C $\beta$	C $\beta$	C $\beta$	C $\beta$	C $\beta$
							AA	ASP	ILE	.	.	.
							x	4.14	-0.21	.	.	.
							y	-3.29	-1.52	.	.	.
							z	-27.53	-23.78	.	.	.
Ch	K&W	At	AA	x	y	z						
H	1	C $\beta$	GLU	12.47	-0.12	8.66	37.27	34.85	.	.	.	.
H	2	C $\beta$	ILE	10.11	-2.68	3.62	31.73	29.30	.	.	.	.
H	3	C $\beta$	.	.	.	.	.	.	.	.	.	.
H	4	C $\beta$	.	.	.	.	.	.	.	.	.	.
H	5	C $\beta$	.	.	.	.	.	.	.	.	.	.

FIG.9B

15/20

DIFFERENCE			Ch	L	L	L	L	L
			K&W	1	2	3	4	5
DIFFERENCES BETWEEN RESIDUE PAIR			AA	ASP	ILE	.	.	.
ALPHA- AND BETA CARBON DISTANCES						.	.	.
						.	.	.
						.	.	.
Ch	K&W	AA						
H	1	GLU		-1.47	-0.01	.	.	.
H	2	ILE		0.48	2.10	.	.	.
H	3	.	.	.	.	.	.	.
H	4	.	.	.	.	.	.	.
H	5	.	.	.	.	.	.	.

FIG.9C

16/20

		L1	L2	L3	L4	L5	.	.
Fv FRAGMENT 1	H1	-1.47	-0.01	.	.	.	.	.
	H2	0.48	2.10	.	.	.	.	.
	H3	.	.	.	.	.	.	.
	H4	.	.	.	.	.	.	.
	.	.	.	.	.	.	.	.
	.	L1	L2	L3	L4	L5	.	.
Fv FRAGMENT 2	H1	-1.61	0.46	.	.	.	.	.
	H2	0.18	2.04	.	.	.	.	.
	H3	.	.	.	.	.	.	.
	H3	.	.	.	.	.	.	.
	.	.	.	.	.	.	.	.
	.	L1	L2	L3	L4	L5	.	.
Fv FRAGMENT 3	H1	0.92	1.59	.	.	.	.	.
	H2	0.69	1.31	.	.	.	.	.
	H3	.	.	.	.	.	.	.
	H3	.	.	.	.	.	.	.
	.	.	.	.	.	.	.	.
	.	L1	L2	L3	L4	L5	.	.
Fv FRAGMENT 4	H1	.	.	.	.	.	.	.

FIG.10

17/20

RESIDUE PAIRS		AVERAGE	Strd.DEV.	MAX	MIN	MEDIAN
H1	L1	-0.72	1.42	0.92	-1.61	-1.47
H1	L2	0.68	0.82	1.59	-0.01	0.46
H1	L3	.	.	.	.	.
H1	L4	.	.	.	.	.
.	.	.	.	.	.	.
H1	L106	.	.	.	.	.
H2	L1	0.45	0.26	0.69	0.18	0.48
H2	L2	0.68	0.82	1.59	-0.01	0.46
H2	L3	.	.	.	.	.
H2	L4	.	.	.	.	.
.	.	.	.	.	.	.
H2	L106	.	.	.	.	.
H3	L1	.	.	.	.	.

FIG.11A

RESIDUE PAIRS		AVERAGE	Strd.DEV.	MAX	MIN	MEDIAN
H1	L1	-0.68	1.04	0.92	-2.20	0.83
H1	L2	0.34	0.82	2.37	-0.54	0.09
H1	L3	.	.	.	.	.
H1	L4	.	.	.	.	.
.	.	.	.	.	.	.
H1	L106	.	.	.	.	.
H2	L1	0.74	0.69	1.83	-0.18	0.59
H2	L2	1.78	0.50	2.55	0.75	1.94
H2	L3	.	.	.	.	.
H2	L4	.	.	.	.	.
.	.	.	.	.	.	.
H2	L106	.	.	.	.	.
H3	L1	.	.	.	.	.

FIG.11B

18/20

Res.	AA	F	AA	F	AA	F	AA	F	AA	F	AA	F
1	Glu	58	Glu	24	Asp	3	Glu	3	Gly	2	Ala	1
2	Val	99	Ile	2	Ala	1	Glu	1	Met	1	-	-
3	Gln	90	Thr	5	Glu	3	His	2	Leu	2	Lys	2
4	Leu	101	Val	3	-	-	-	-	-	-	-	-

FIG.12A

Amino Acid	van der Waals volumes [A <sup>3</sup> ]	Hydrophobicity
Ala	67	0.62
Arg	148	-2.50
Asn	96	-0.78
Asp	91	-0.90
Cys	86	0.29
Gln	114	-0.85
Glu	109	-0.79
Gly	48	0.30
His	118	-0.40
Ile	124	1.40
Leu	124	1.10
Lys	135	-1.50
Met	124	0.64
Phe	135	1.20
Pro	90	0.12
Ser	73	-0.18
Thr	93	-0.05
Trp	163	0.81
Tyr	141	0.26
Val	105	1.10

FIG.12B

Res.	AA	F	AA	F	AA	F	AA	F	AA	F	AA	F
1	109	61	109	24	91	3	48	2	67	1	-	-
2	105	99	124	2	67	1	109	1	124	1	-	-
3	114	90	93	5	109	3	118	2	124	2	135	2
4	124	101	105	3	-	-	-	-	-	-	-	-

FIG.12C

19/20

## VAN DER WAALS VOLUMES

CHAIN	K&W	CONS.	WEIGHTED		UNWEIGHTED	
			AVERAGE	StDev.	AVERAGE	StDev.
H	1	Glu	108	11	90	27
H	2	Val	105	5	106	23
H	3	Gln	114	6	116	14
H	4	Leu	123	3	115	13

FIG.13A

## HYDROPHOBICITY

CHAIN	K&W	CONS.	WEIGHTED		UNWEIGHTED	
			AVERAGE	StDev.	AVERAGE	StDev.
H	1	Glu	-0.77	0.24	-0.37	0.72
H	2	Val	1.08	0.20	0.59	0.84
H	3	Gln	-0.78	0.33	-0.42	0.89
H	4	Leu	1.10	0.00	1.10	0.00

FIG.13B




FIG.14



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**